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1  Introduction 
 
The World Health Organisation of the United Nations prognoses the development 
of world-wide diabetes cases over the next decades in actual studies. Accordingly, 
the number of type II patients will more than double until 20301.  
Next to the disease itself, moreover, 25% of diabetes patients frequently develop 
chronic wounds with about half of them requiring elaborate inpatient treatment. 
Therefore, the diabetic foot causes more hospitalisation than does any other 
complication associated with diabetes and represents approximately 2.5% of all 
hospital admissions2.  
Not least driven by this need wound treatment has gone through great revolution 
during the last decades. The paradigm shift from dry dressings based on woven 
fabrics towards a moist environment caused whole lots of new developments in 
this field.  
Nevertheless, the pathological cases of chronic wounds are still difficult to handle. 
Even with the moist concept they require very patient and persistent treatment. 
Therefore, there still is strong desire for improved methods of therapy. And, due to 
the prognosed rise of the diabetes, this desire is likely to largely increase over the 
next decades.  
One resort out of this situation could be revealed by biotechnology. Especially in 
the year 2000, the even greater revolutions in this field mostly occurring in typical 
scientific laboratories but praised and supported by highest authorities raised great 
expectations for new drug candidates. Hence for example, on international level 
United States President Bill Clinton announced the completion of the first survey 
of the entire human genome and nationally the government of the free state of 
Bavaria launched its high-tech-offensive endowed with investments of 1.35 billion 
Euros in local life science research. In this environment several small new biotech 
companies were founded. A considerable number of those established in 
Martinsried near Munich and began their research work. One of those companies is 
the SWITCH BIOTECH AG focusing its research on wound treatment based on 
peptides. One outcome of this work was the identification of α1-antichymotrypsin 
(ACT) as potential therapeutic for chronic wounds. 
Hence, to take the next step in development of α1-antichymotrypsin (ACT) as drug 
candidate a collaboration between SWITCH BIOTECH AG and the Department 
Pharmaceutical Technology and Biopharmaceutics of the LMU Munich was 
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contracted in terms of a Ph. D. study at the Department under the supervision of 
Prof. Dr. Winter.  
The aim of this study is to create formulations and drug carriers that stabilise and 
deliver ACT in bioactive state into the wound site. This thesis addresses 
introductory remarks about wound healing and protein delivery from hydrogels 
followed by the results of the research on the ACT formulation and concomitant 
carrier development. 
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1.1  Wound healing 
In this section an overview over the physiology and pathophysiology of wound 
healing is described. This represents the medicinal context of this work and 
highlights the scientific rational behind the delivery of ACT in chronic wounds. 
Moreover, the established methods for treatment of wounds including dressings 
and carriers are discussed. Hereby, the methodical context of a treatment with ACT 
as drug product with the indication wound treatment is given.  
 
1.1.1  Physiology of wound healing 
The following paragraph describes the physiology of wound healing. It starts with 
the process of healing itself. Next, a selection of growth factors involved in the 
process is outlined in detail. The role of growth factors is essential for the present 
understanding of wound healing. Moreover, growth factors are important starting 
points for drug based wound treatment having led to approval of platelet-derived 
growth factor (PDGF), the main competitor of a maybe future product based on 
ACT. Consequently, proteases and their inhibitors relevant in wound healing are 
highlighted. As well as growth factors, proteases play important roles in wounds. 
And, together with their inhibitors proteases are also starting points for wound 
therapy. Thereby, the discussion focuses on the inhibitor ACT and its target 
cathepsin G because ACT and its delivery represents the main topic of this thesis.  
 
1.1.1.1  Wound healing process 
The physiological wound healing process in the present understanding is usually 
divided into four steps – coagulation, inflammation, followed by migration and 
proliferation and finally the remodelling phase. These phases are not exactly 
distinguishable from each other, because occasionally they overlap or proceed 
concurrently. 
In the damaged vessel wall platelets - stimulated by mediators - immediately adhere 
to the exposed collagen of the vessel wall. The clustered platelets partially coalesce 
with each other and release the platelet factors that initiate the actual clotting 
process. During the clotting a network of fibrin forms around the platelet plug 
finally filling the entire wound gap. The purpose of this fibrin network or first 
extracellular matrix is to retain cellular components of the blood, e.g. erythrocytes, 
Chapter 1 - Introduction 
- 4 - 
and thereby form a clot for the purpose of haemostasis, wound closure and 
provision of a matrix for the later collagen mounting3. 
 
Coagulation – this part is started by the platelet factors released by degranulating 
thrombocytes and by substances liberated from damaged tissue cells, for example 
PDGF, IGF-I, EGF and TGF-β. Following, the coagulation cascade, the well 
known complex chain reaction, which is initiated by injury4 leading to the 
conversion of prothrombin into the enzyme thrombin is activated. Thrombin now 
converts fibrinogen into fibrin monomers. 
Flowing blood only contains fibrinogen, the water-soluble precursor of fibrin. The 
conversion is solely catalyzed by thrombin located at the wound surface. Thrombin 
is also present in the blood as its inactive precursor prothrombin. Prothrombin and 
fibrinogen are coagulation or clotting factors and part of the coagulation cascade. 
Fibrinogen polymerises to fibrin chains, which are finally interlinked by coagulation 
factor XIII to form the stable fibrin network5. A variety of inhibitors of the 
coagulation factors present in the blood, for example antithrombin III, ensure that 
clotting is confined to the wound site. They inactivate thrombin entering the 
circulating blood stream. Moreover, the members of the cascade are at much lower 
concentration levels in the blood stream which decreases the presumption that the 
necessary partners meet to interact. This contributes to the confinement of the 
coagulation to the wound area.  
 
Inflammation - once haemostasis is achieved inflammation is initiated a few hours 
after injury. The inflammatory phase of wound healing is characterised by 
recruitment and activation of granulocytes, macrophages and lymphocytes that 
clean the wound by phagocytosis of damaged tissue and bacteria and wound 
debridement by enzymatically degrading foreign matter and damaged tissue. The 
substances released from the cell debris resulting from tissue destruction are 
responsible for causing the characteristic inflammatory reactions. Vascular changes 
also contribute to this reaction. A fresh wound usually bleeds due to vessels rupture 
effecting cleansing the wound. To prevent further blood loss, the affected vessels 
narrow within the first minutes. This vasoconstriction is followed by vasodilation 
that increases the blood circulation in the wound area. Consequently, a rise in the 
temperature of the wound and the surrounding skin is caused. Moreover, the 
permeability of the capillary walls is increased by vasodilatory agents – such as 
histamine and serotonin – and as a result blood plasma, erythrocytes, leucocytes 
and platelets enter the wound. The outcome of these processes is wound oedema. 
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This creates the classic signs of the inflammatory process i.e. redness, swelling, 
functional disturbance, heat, and pain. Pain results from the wound oedema 
exerting increased pressure on the small nerves and nerve endings. The 
inflammatory reaction is induced independently of invasion by foreign organisms, 
and therefore inflammation can also develop in closed injuries where the skin 
remains intact6. 
Mediated by the chemotactic effects of cytokines and growth factors infiltrating 
white cells, such as neutrophils and macrophages, are attracted and activated (Fig. 
1-1).  
 
 
Fig. 1-1 A cutaneous wound three days after injury with growth factors thought to be 
necessary for cell movement into the wound – adapted from 7 
 
The defence cells migrate from the blood vessels that have become permeable into 
the wound area7. First to appear at the site of inflammation are neutrophils. These 
have the capacity to phagocytose bacteria and extracellular matrix. They also release 
enzymes that break down degenerating connective tissue8. Consequently, 
monocytes infiltrate attracted by chemotaxins, e.g. PDGF and TGF-β, released by 
aggregating platelets. Monocytes are white blood cells and precursors to 
macrophages. So, they are also capable of phagocytosis and once they have 
ingested foreign bodies they transform into macrophages9.  
Macrophages produce a large number of mediators, e.g. growth factors, of other 
wound healing processes and attract further phagocytic cells to the wound area10. 
Moreover, prostaglandins that sustain the inflammatory process and influence 
vascular dilation and IL-1 which induces fever and attracts further neutrophil 
granulocytes are secernated. Macrophages also release enzymes destroying tissue. 
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IL-1β also draws fibroblasts into the wound and up-regulates enzyme levels. 
Importantly, there is a balance between levels of enzymes and tissue inhibitors of 
these enzymes. 
Inflammation physiologically last for several days. Neutrophil infiltration reaches a 
maximum after approximately 24 hours and declines over the next few days. These 
cells, once present, survive for about a further 24 hours11.  
 
Migration and proliferation - a few days after injury the migration and proliferation 
phase begins. Whereas catabolic processes predominate in inflammation, this phase 
of wound healing is characterised mainly by anabolic reactions, i.e. angiogenesis, 
epithelisation, and fibroplasia (Fig. 1-2). It can last for up to 24 days from the 
moment the wound develops.  
 
 
Fig. 1-2 A cutaneous wound five days after injury; blood vessels sprout into the fibrin clot as 
epidermal cells resurface the wound. Proteinases thought to be necessary for cell movement 
are shown. – adapted from 7 
 
The formation of blood vessels, angiogenesis, starts with an endothelial cell bud 
formed by existing intact vessels. Thereby, the angiogenic stimuli in the first place 
emanate from macrophages by secession of growth factors and cytokines. But, also 
keratinocytes as well as fibroblasts provide chemoattractants. So stimulated, the 
endothelial cells in the venules begin to produce enzymes that break down the basal 
membrane in the area of the stimulus12. Soon, endothelial cells migrate through the 
resulting gap in the direction of the wound following the oxygen gradient. They 
divide and form tubular structures that connect with other buds. As a result, during 
the maturation process a new basal membrane develops from the extracellular 
matrix components. The newly formed vascular loops then connect with intact 
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vessels and differentiate accordingly into capillaries, arterioles, and venules, 
respectively3. 
For epithelisation, proceeding in parallel to angiogenesis, keratinocytes migrate 
across the wound and as a result reconstitute epidermal covering from the wound 
margin and hair follicle remnants13. In addition, migration essentially requires the 
presence of a moist substrate, well perfused with blood, as is the case with 
granulation tissue. In contrast, epithelial cells are not able to migrate in a 
dehydrated layer. This is supposed to be a reason for the success of moist wound 
dressings. 
Fibroplasia is determined by the chemotactically attracted migration of fibroblasts 
along the fibrin network into the wound site and their replicative activity there to 
form the new loose extracellular matrix consisting of proteoglycans as well as the 
water-soluble collagen fibres essential for tissue stability. Thus, especially at wound 
edges fibroblasts are the predominant cell type14.  
Concurrently, the provisional fibrin network, the first extracellular matrix, is broken 
down by fibrinolysis. This breakdown process is caused by the enzyme plasmin. 
Mainly, t-PA activates plasmin from its inactive precursor plasminogen7. 
Collagen is crucial to the process of wound healing as it has been identified as the 
most abundant connective tissue protein. Collagen is a fibrous protein synthesised 
in several stages. Its precursors are assembled from amino acids in the fibroblast. 
These protocollagen chains are twisted together in triple helical formation and get 
interlinked. Finally, vesicles transport the collagen to the cell membrane where they 
are released as soluble tropocollagen into the interstitium. Beyond, the 
tropocollagen molecules accumulate to form protofibrils consequently polymerising 
into microfibrils. Several microfibrils unite to form a collagen fibril, several of 
which, in turn, arrange themselves into bundles. In healthy tissue the collagen fibres 
are aligned in basketweave patterns. This organised structure is not achieved in 
wound healing as the collagen fibres at the wound site will fashion themselves in an 
alignment parallel to the stress lines of the wound15. Collagen synthesis depends on 
the presence of ascorbic acid as a coenzyme and further on iron and copper as 
cofactors. Type I and type III are the collagens most commonly found in healing 
wounds, although at least 19 different types of collagen have been identified and 
characterised16,17. During the process of wound healing, type III collagen and 
fibronectin are deposited – type III collagen later in the remodelling phase being 
replaced by type I. 
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Remodelling - at last, the remodelling or maturation phase finalises the wound healing 
process. Generally, it can take up to two years and means changes in the matrix 
composition over the healing time. The wound is contracted and the tensile 
strength of the wound cover is enhanced. The synthesis of matrix material is, as 
mentioned, provided by fibroblasts and regulated by growth factors, cytokines, 
enzymes, and prostaglandin mostly derived from macrophages and fibroblasts. The 
granulation tissue of the first extracellular matrix mostly consisting of keratinocytes 
gradually matures into scar tissue. With the formation of new fibres, the mitotic 
activity of the fibroblasts is concluded. They then may transform into 
myofibroblasts18. Myofibroblasts, like the muscle cells, contain contractile elements, 
which allow them to draw together. The collagen fibres become taut and, as far as 
possible, aligned to the main contours of tension in the tissue. As a result, the scar 
tissue shrinks and the functional cutaneous tissue at the wound margin contracts 
leaving only a small defect19. 
As outlined above, early collagen fibrils are laid down randomly resulting in a 
tensile strength of only 5 per cent of normal undamaged skin at two weeks post-
injury. Over time these type III fibrils are replaced by type I collagen fibres, 
improving the tensile strength of the scar tissue to that of 80 per cent of normal 
skin. Nonetheless, scar tissue still appears different to original tissue, the former 
being weaker than unwounded skin. One reason for this distinction is as already 
mentioned that the final assembly of the collagen in granulation tissue does not 
resemble that of normal unwounded dermis. Moreover, since the pigment 
producing cells, the melanocytes, cannot be regenerated, the scar tissue does not 
turn brown but remains white. Besides, this tissue contains no hairs, sebaceous or 
sweat glands. 
 
1.1.1.2  Growth factors in physiological wounds 
As described above the process of wound repair is characterised by a series of 
complex cellular and molecular events with a great degree of overlap and 
interdependence. Growth factors play fundamental roles in this process, by 
stimulating chemotaxis and cellular proliferation, by providing signalling among 
cells of the same and different type, by controlling extracellular matrix formation 
and angiogenesis, by regulating the process of contraction, and by re-establishing 
tissue integrity (Fig. 1-1). They work by binding to specific cell surface receptors 
and can target cells in a number of recognised modes. Release of these substances 
into the blood stream allows them to get to distant targets (endocrine mode). From 
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the cell of origin, growth factors can diffuse over short distances to affect other 
cells (juxtacrine mode), and to influence neighbouring cells (paracrine mode). 
Growth factors can also act on the cell in which they are produced (autocrine 
mode)10,20.  
In the following, the growth factors with greatest importance in the wound healing 
process are described in detail.  
 
PDGF (platelet-derived growth factor) mainly is synthesised by macrophages, 
endothelial cells, fibroblasts, smooth muscle cells, and platelets. Beyond, it can be 
stored in platelets until cell activation for example by thrombin. The synthesis of 
PDGF can be induced by IL-1, IL-6, TNF-α, TGF-β and EGF. PDGF 
physiologically is not released into the blood stream. However, by binding to 
several proteins, e.g. of the extracellular matrix (ECM), local concentrations can 
reach increased levels. PDGF is a hydrophilic protein of 30kDa molecular weight. 
It is composed of two distinct polypeptide chains A and B, that form homodimers 
(AA or BB) or heterodimers (AB). The subunits are linked by disulfide bonds. 
Recently, additional C and D subunits have been described acting similarly to the A 
and B species 21-23. Platelets synthesise a mixture of the three possible isoforms 
while fibroblasts stimulated with EGF synthesise AA homodimers. Activated 
macrophages produce the BB homodimer. The dimeric form of PDGF is mainly 
mitogenic for smooth muscle cells and vascular endothelium cells. Although, 
monomeric forms of PDGF are mainly chemotactic. So, PDGF is a 
chemoattractant for fibroblasts, monocytes and neutrophils. In addition, PDGF is a 
potent vasoconstrictor. However, it does not act on epithelial and endothelial cells 
because these cells do not express PDGF receptors24.  
 
B-FGF (basic fibroblast growth factor) is the prototype of the FGF family. 
Thereby, b-FGF shows a homology to a-FGF. Many cells, first of all endothelial 
cells, express b-FGF and partly store it in an inactive form. It is released after tissue 
injuries and during inflammatory processes. Binding of b-FGF to its receptors 
requires the interaction with proteoglycans of the ECM before full functional 
activity is obtained.  
Additionally, heparin is a protectant for b-FGF, especially from the impact of 
proteases, acids, and heat. It also improves receptor binding and hence potentiates 
the biological activity of b-FGF. B-FGF stimulates the growth of fibroblasts, 
endothelial cells, and keratinocytes potentiated in the presence of thrombin. 
Additionally, b-FGF reduces the expression of the receptor for TGF-β, thus 
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effectively modulating the inhibitory action of TGF-β on endothelial cells. Also, 
FGFs control proliferation and migration of vascular endothelial cells important 
for angiogenesis. As well, the expression of plasminogen activator and collagenase 
by these cells is enhanced by b-FGF and is antagonised by TGF-β. A special 
member of the FGF family is FGF-7, also known as KGF, with the mentioned 
effects solely concentrated on keratinocytes10,25. 
 
EGF (epidermal growth factor) is a globular protein and is produced by cells in 
various organs. Following, it is present in most body fluids. It is synthesised as a 
larger pre-protein from which the factor itself is released by proteolytic cleavage. In 
addition, EGF is the prototype of a large family of EGF-like proteins (EGF-F). 
Particularly, TGF-α shows a strong homology to EGF. However, antibodies for 
EGF do not bind to TGF-α. Both factors are functionally analogous, they bind to 
the same receptor, and they have similar biological activities. So, EGF stimulates 
the proliferation of epidermal and epithelial cells, including fibroblasts and 
keratinocytes. This can be inhibited by the EGF inhibitor. Moreover, EGF strongly 
influences the synthesis of proteins of the ECM, including fibronectin, collagens, 
laminin, and glycosaminoglycans. Indirectly, EGF also supports angiogenesis 
because of its mitogenicity for endothelial cells which can be potentiated by 
thrombin. Besides, EGF is a chemoattractant for fibroblasts and epithelial cells26. 
 
TGF-α and TGF-β (transforming growth factors) are distinguished both chemically 
by their unique amino acid sequences and biologically by their different activities on 
cells. The interactions of TGF-α and TGF-β can be either synergistic or 
antagonistic.  
TGF-α consists of a single chain peptide and is produced by keratinocytes, 
macrophages, and platelets. It has strong homology to EGF resulting in 
competition for receptor binding. The biological activities of TGF-α as well 
resemble those of EGF. However, some biological activities of TGF-α are stronger 
than those of EGF. Especially, TGF-α is mitogenic for fibroblasts and inhibits the 
synthesis of collagen.  
 
TGF-β is not related to TGF-α. The biologically active form of TGF-β is a 
disulfide-linked homodimer. Still, TGF-β is released as the inactive complex latent-
TGF with proteoglycans from the ECM. This complex should represent TGF-β 
molecules released by platelets after tissue injuries. This allows the factor to be 
stored in an inactive form. In fact, platelets contain very high amounts of TGF-β. It 
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is also produced for example by macrophages, lymphocytes, endothelial cells, and 
keratinocytes27. Depending upon cell type and concentration secretion of TGF-β 
can be induced or inhibited by a number of different stimuli. So, induction can be 
achieved by, for example, EGF, NGF, and IL-1. On the contrary, the synthesis can 
be inhibited by e.g. EGF, FGF, and calcium ions28. Generally, TGF-β has 
bifunctional effects and can either stimulate or inhibit growth of the same cells, 
depending on conditions. It is a potent growth inhibitor for epithelial cells, 
endothelial cells, fibroblasts, keratinocytes, and smooth muscle cells. It also 
deactivates macrophages. In many cell types TGF-β antagonises the biological 
activities of EGF, PDGF, and FGFs. Besides, the factor stimulates the synthesis of 
the major matrix proteins, including collagen, proteoglycans, glycosaminoglycans, 
and fibronectin. On the other hand, it inhibits their degradation mainly by 
inhibiting the synthesis and secretion of proteinases and by increasing their 
proteinase inhibitor levels. Furthermore, in monocytes TGF-β stimulates the 
expression of IL-1, PDGF, and FGF and inhibits the synthesis of TNF-α, TNF-β 
and IFN-γ. Moreover, TGF-β is a chemoattractant for neutrophils10. 
 
For IGF (insulin-like growth factor) two different isoforms, IGF-1 and IGF-2 of 7 
kDa molecular weight, have been described. They display broad homology with 
insulin but can not be neutralised by antibodies directed against insulin. Both types 
of IGF are synthesised in many organs throughout the body finally obtained by 
processing of precursors. Solely IGF-1 is produced also by fibroblasts. Cell types 
responding to IGF-1 also include epithelial cells and fibroblasts. The factors 
regulating concentrations of IGF are somatotropin as well as PDGF and FGF. 
Thus, IGF-1 stimulates collagen and matrix synthesis. In fact, IGF-1 is considered 
to be one of the major anabolic factors regulating the metabolism of joint cartilage. 
Besides, it is also involved in angiogenesis. Like insulin, free IGF-1 causes 
hypoglycaemia. Therefore, binding of IGF-1 to carrier proteins prevents the 
establishment of a permanent hypoglycaemia in spite of high serum IGF-1 
concentrations. These carrier proteins also increase plasma half life of IGF-1 and 
prevent the release from the blood stream into interstitial spaces. It also effects 
neurons and has been demonstrated to reduces neuronal loss after injury29. 
 
VEGF (vascular endothelial growth factor) is a homodimeric and glycosylated 
protein. The subunits are linked by disulphide bonds. The factor exists in several 
isoforms that are produced via precursors in many cells including endothelial types 
and macrophages. The isoforms differ in biological properties such as recognising 
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receptor types and interaction with proteoglycans. Consequently, shorter forms are 
soluble while the heavier forms are mostly bound to heparin containing 
proteoglycans of the ECM. VEGF is a strong angiogenic protein, especially a 
mitogen for vascular endothelial cells. Thereby, b-FGF and VEGF act 
synergistically in the induction of angiogenesis. Moreover, VEGF influences 
vascular permeability and is a chemoattractant for monocytes. It also induces the 
synthesis of clotting factors and collagenase30,31. 
 
1.1.1.3  Proteases in physiological wounds 
Proteolytic enzymes are present in all wound exudates and play an essential role in 
the healing of acute and chronic wounds. For wounds, proteases are mainly 
produced by granulocytes, keratinocytes and fibroblasts. Proteases contribute to the 
regulation of the balance between tissue synthesis and tissue degradation. Thus, 
proteolytic activity is tightly regulated with control at the transcriptional level and 
control by extracellular enzyme activation and inhibition. A defect in one or more 
of these control mechanisms would result in an increase in proteolytic activity, a 
trait of chronic wounds, and considered one of the primary causes of wound 
healing disorders. Therefore, protease control is a major goal of wound treatment. 
Proteases comprise endopeptidases and exopeptidases which cleave peptide bonds 
at points within the protein and remove amino acids sequentially from either N or 
C-terminus, respectively. Endopeptidases are further classified according to the 
structure of their active site in cysteine proteinases, aspartic proteinases, metallo 
proteinases and serine proteinases. In this chapter discussion focuses on serine 
proteases and serpins with regard to the main topic of this thesis being ACT. 
 
Cysteine proteases - the cysteine proteinases family includes the lysosomal enzymes 
cathepsins B, K and L. Like with serine proteinases outlined below catalysis 
proceeds through the formation of a covalent intermediate and involves a cysteine 
and a histidine residue.  
 
Aspartic proteinases - aspartic proteinases include lysosomal cathepsin D and other 
proteases of the pepsin family. A second family comprises viral proteinases such as 
retropepsin from HIV. In contrast to serine and cysteine proteases, catalysis by 
aspartic proteinases do not involve a covalent intermediate though a tetrahedral 
intermediate exists. 
 
Chapter 1 - Introduction 
- 13 - 
Metalloproteinases - the known metalloproteinases (MMP) differ widely in their 
sequences and their structures. However, the great majority of enzymes contains 
conserved regions of homology and a zinc atom which is catalytically active. Zinc is 
in most cases bound by three amino acids, the fourth coordination site is occupied 
by a water molecule. The catalytic mechanism leads to the formation of a non 
covalent tetrahedral intermediate after the attack of the zinc-bound water molecule 
on the carbonyl group of the scissile bond. This intermediate is further 
decomposed by transfer of the glutamic acid proton to the leaving group. MMPs 
are mostly stored in leukocytes, keratinocytes and dermis cells. They are activated 
by removing a small peptide fragment, with the active enzyme exhibiting optimal 
activity around the physiologic pH. The collagenases are very specific in their 
function in that they split the triple helix of fibrillar collagens. The resultant 
denatured collagen molecule is then susceptible to attack from other proteases, in 
particular the gelatinases. In fact, though their substrate specifity is very different, 
in combination they can degrade all matrix molecules and each one deactivates 
inhibitors for serine proteases, mostly α1-PI32.  
In detail, the interstitial collagenase (MMP-1) degrades the collagen types 1, 2, 7, 8 
and 10, gelatine, proteoglycans and entactin. The neutrophil collagenase (MMP-8), 
works very similar, it cleaves collagens 1, 2, 3, 7, and 10, gelatine, proteoglycans, 
bradykinin, and angiotensin I. Unlike the others, the neutrophil collagenase 
deactivates α1-antichymotrypsin. Collagenase 3 (MMP-13) degrades elastin, fibrillin, 
fibronectin and already denatured collagen. 
Gelatinase A (MMP-2), the 72kDa enzyme, and gelatinase B (MMP-9), the 92kDa 
enzyme cleave collagen types 4, 5, 7, 10, and 11, gelatine, elastin, fibronectin, 
laminin and entactin. They also activate pro-IL-1β. 
The stromelysins 1 and 2 (MMP-3 and -10) degrade collagen types 4, 5, 9, 10, and 
11, fibronectin, laminin, proteoglycans and gelatine. In addition, they activate pro-
MMP-1, -8 , -9 and pro-IL-1β.  
Matrilysin (MMP-7) and metalloelastase (MMP-12) degrade elastin, fibronectin, 
laminin, entactin, proteoglycans and collagen IV32,33. 
 
Serine proteases - the serine proteinase class comprises two distinct families. The 
chymotrypsin family which includes enzymes such as cathepsin G, chymotrypsin, 
trypsin, elastase or kallikrein and the subtilisin family which include bacterial 
enzymes. The general structure is different in the two families but they have the 
same active site geometry and then catalysis proceeds via the same mechanism34.  
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The serine proteinases exhibit different substrate specificities which are related to 
amino acid substitutions in the various enzyme subsites interacting with the 
substrate residues. Three residues which form the catalytic triad are essential in the 
catalytic process, i.e. His 57, Asp 102 and Ser 195 after chymotrypsinogen 
numbering (Fig. 1-3A)34.  
 
 
 
Fig. 1-3 chemical and kinetic mechanisms of catalysis for serine proteases. The catalytic 
groups of trypsin (A) are shown interacting with an oligopeptide substrate. C: Common 
kinetic mechanism of catalysis for serine proteases; adapted from34 
 
The first step in the catalysis is the formation of an acyl enzyme intermediate 
between the substrate and the essential Serine. Formation of this covalent 
intermediate proceeds through a negatively charged tetrahedral transition state 
intermediate and then the peptide bond is cleaved. During the second step or 
deacylation, the acyl-enzyme intermediate is hydrolysed by a water molecule to 
release the peptide and to restore the Ser-hydroxyl of the enzyme. The deacylation 
which also involves the formation of a tetrahedral transition state intermediate, 
proceeds through the reverse reaction pathway of acylation. A water molecule is 
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the attacking nucleophile instead of the Ser residue. The His residue provides a 
general base and accept the OH group of the reactive Ser (Fig. 1-3C).  
Cathepsin G is a cationic single chain glycoprotein of 29kDa molecular weight and 
is stored in active form within leukocyte granules and proinflammatory 
monocytes35. It provides a broad spectrum of biological activities, whereby around 
pH 7.4 its maximum activity is developed36-38. Cathepsin G activates other enzymes, 
i.e. collagenase (MMP 8) and gelatinase (MMP 9). Besides, Cathepsin G degrades 
macromolecules of the ECM – elastin, fibronectin, laminin, proteoglycans and 
collagen (type 4) – itself. Also, it appears to be necessary for proper elastase activity 
in the latter case. Moreover, the cytokines TNF-α and TNF-β, several lymphocyte 
receptors, and plasma proteins, e.g. immunoglobulins and clotting factors, are 
deactivated by cleavage. Platelets, on the other hand, are activated. Further, the 
conversion of angiotensin I into angiotensin II is catalysed by cathepsin G39. 
As the latter, elastase is a cationic single chain glycoprotein. For storage it is 
embedded in leukocyte granules, proinflammatory monocytes, eosinophiles, 
basophiles, mast cells and lymphocytes. The biological functions are similar to 
those of cathepsin G. Along with platelets, elastase also activates lymphocytes and 
the cytokines pro-IL-1b and IL-8. The secretion of signal molecules from cells is 
also induced by elastase, i.e. GM-CSF, IL-6, and IL-839,40. 
Proteinase 3 is also found in monocytes and mast cells. Function and chemical class 
are also similar to cathepsin G and elastase.  
Urokinase type plasminogen activator (uPA) is stored in monocytes, mononuclear 
phagocytes, T-lymphocytes and natural killer cells. Its main activity is the activation 
of plasmin by converting plasminogen which is present throughout body fluids. 
Plasmin itself degrades fibrin, laminin, fibronectin and proteoglycans activator. 
Besides, it activates some pro-MMPs and TGF-β39,40. 
 
1.1.1.4  Protease inhibitors in physiological wounds 
The entirety of protease inhibitors in the wound healing process is called the 
antiproteolytic shielding. It controls the destructive activity of proteases41. The 
plasma proteinase inhibitors, after albumin and the immunoglobulins, constitute 
with nearly 10% by weight of the total protein the third largest group of functional 
proteins in human plasma.  
 
Serine protease inhibitors (serpins) with ACT - the serine proteinase inhibitors are a 
superfamily of proteins with a size of 350–500 amino acids. They fold into a 
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conserved structure and employ a unique suicide substrate-like inhibitory 
mechanism. Most serpins inhibit serine proteinases of the chymotrypsin family. To 
date around 250 serpin coding sequences are known42. They are divided into 16 
clades and 10 highly diverged orphans. 
Serpins adopt a metastable conformation that is required for their inhibitory 
activity. Serpins in the stable latent conformation are non-inhibitory but can be 
converted back to the active state by denaturation and refolding. 
The conformation of serpins consists of a conserved secondary structure 
comprised of three β-sheets and at least seven, mostly nine, α-helices. In the 
metastable active form the reactive site loop containing the proteinase recognition 
site, is located between the first and third β-sheet. However, serpins can undergo 
intramolecular structural changes e.g. to convert to the more stable latent form. In 
that case the reactive site loop is placed into the first β-sheet while another side 
chain is extracted from the third sheet43. 
The most stable state for inhibitory serpins is a form, in which the loop has fully 
inserted into the first β-sheet, as in the latent conformation, but without the 
extraction of the side chain from the third β-sheet. The Tm for unfolding of such 
conformation is about 120 °C, compared to about 60 °C for the native state44. 
Protein proteinase inhibitors act competitively by allowing their target enzymes to 
bind directly to a substrate-like region contained within the amino acid sequence of 
the inhibitor. This reaction between enzyme and inhibitor is essentially second 
order, and the resultant complex generally is equimolar45.  
Serpins inhibit serine proteinases by an irreversible suicide substrate mechanism. 
The proteinase initially is bound in a non-covalent complex with serpin. Secondly, 
the active site serine of the protease forms a covalent ester with a carbonyl of the 
inhibitor. Following, the peptide bond is cleaved and the reactive site loop is 
inserted into the first β-sheet and transports the covalently bound proteinase with 
it. Upon complete loop insertion the active site catalytic triad of the proteinase is 
distorted and therefore deactivated.  
This conformational rearrangement is driven by the greater stability of the cleaved 
loop-inserted conformation compared with the native-like conformation. Thus, the 
acyl-intermediate is kinetically trapped due to slowing of the deacylation steps of 
the normal substrate reaction. In fact, serpin-proteinase complexes would be 
cleared long before complex decay could occur. 
Though, in the case that the described reactions are somehow impeded, the enzyme 
may successfully complete the deacylation step and escape before entrapment. This 
yields an active proteinase and a cleaved, inactive serpin. The ratio of complex and 
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cleaved serpin products is determined by the competition between the rate of ester 
hydrolysis and that of loop insertion and proteinase distortion. So, chymotrypsin 
and cathepsin G produce a modified inactive, no longer inhibitory form of ACT. A 
negative effect of the need for a metastable conformation in the active state is that 
inappropriate loop insertion can occur mediated by several factors including 
formulation excipients and processes. More precisely, by reaction of the loop of 
one molecule and the beta-sheet of another, aggregation to dimers and higher order 
oligomers can result45,46. Therefore, one major physical instability of ACT during 
formulation studies is estimated to be the dimer formation and perhaps the 
formation of higher order aggregates. 
Α1-antichymotrypsin (ACT) is a plasma glycoprotein first isolated and characterised 
in 196247 (Fig.1-4). The inhibitor is a major acute phase protein, whose 
concentration increases rapidly and dramatically after a variety of events, ACT 
shows the most immediate response as an acute phase protein, doubling in 
concentration from 250µg/ml normal concentration in plasma within eight hours 
of insult.  
 
 
Fig. 1-4 Crystal structure of ACT with partial loop insertion; adapted from48 
 
Three laboratories isolated ACT using a variety of conditions47,49,50. Significantly, 
ACT can be isolated from serum through its ability to bind to DNA 51. In all cases 
the product obtained stoichiometrically inhibited chymotrypsin to produce an 
equimolar complex that was denaturation resistant to dissociation. The molecular 
weight of the native protein was between 58,000 and 68,000; the differences were 
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attributable to the methodology and the high carbohydrate content (about 26%) of 
this glycoprotein. Thus, ACT is a specific inhibitor of chymotrypsin-like 
proteinases, forming stable complexes with chymotrypsin49and neutrophil 
cathepsin G46. No inhibition of either human trypsin or neutrophil elastase has 
been found52. ACT rapidly forms complexes with the mentioned chymotrypsin-like 
serine proteinases; the rate is by far the fastest with cathepsin G (k = 5,1 × 107 M-1 
s-1), and much slower with chymotrypsin53.  
 
Inhibitors of matrix metallo proteases - recently, a number of inhibitors for MMPs have 
been described 54. The best known substances are TIMP-1 and -2 (tissue inhibitor 
of MMPs) and α2-macroglobuline. These inhibitors selectively bind to MMPs and 
deactivate them.  
 
1.1.2  Pathophysiology of chronic wounds 
This paragraph outlines the pathophysiology of chronic wounds both on cellular 
and clinical levels. 
A chronic wound is defined as one in which the normal process of healing is 
disrupted at one or more points in the phases of haemostasis, inflammation, 
proliferation and remodelling55. Chronic wounds, unlike acute wounds, do not 
undergo the ordered molecular and cellular processes of physiological tissue repair 
previously discussed. However, the healing process of chronic wounds is thought 
to be stuck in inflammation. 
Chronic wounds can also be considered to be an imbalance between tissue 
deposition stimulated by growth factors, and tissue destruction mediated by 
proteases56. Hereby, the imbalance favours the destructive process. Thus, the 
molecular and cellular processes are disrupted leading to significant differences in 
the microenvironment of the wound, both in terms of the constituents of the 
exudates and the cellular components of the wound area. In addition, oxidative 
damage by free radicals, condition specific factors of underlying diseases, and 
accumulated necrotic tissue as well contributes to the chronic state. The further 
healing of those wounds results in skin defects of excessive fibrous appearance, for 
instance keloids and scar contractures, or alternatively in insufficient tissue 
replacement, i.e. a non-healing wound. 
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1.1.2.1  Cellular and biochemical imbalance in chronic wounds 
Moreover, the persisting inflammatory phase leads to wound exudate showing - in 
comparison to acute wounds – increased protease concentration and reduced levels 
of growth factor activity.  
During the inflammatory phase chemotactically attracted and activated 
macrophages secrete inflammatory cytokines, which increase protease production 
and reduce the synthesis of inhibitors.  
In a physiologically healing wound there is also a balance of pro-inflammatory 
cytokines and their natural inhibitors. In chronic wounds on the contrary, the levels 
of these cytokines are increased. Mainly, the persistent inflammatory stimulus is 
caused by repetitive trauma, local tissue ischaemia, necrotic tissue, heavy bacterial 
burden, or tissue breakdown57. 
As well, in acute wounds proteases and their inhibitors are in equilibrium, but 
protease concentrations are elevated in chronic wounds. So, levels of collagenase, 
gelatinase A, and gelatinase B (MMP-1, -2, -9) have been shown to be elevated in 
fluid derived from pressure ulcers and venous leg ulcers58,59. Other proteases, such 
as neutrophil elastase, have also been observed to be higher in chronic wounds60. 
Hence, elevated levels of serine proteases cause degradation of extracellular matrix, 
resulting in impaired cell migration and connective tissue deposition. Furthermore, 
they degrade growth factors and their target cell receptors59. Growth factors applied 
externally to the wound are degraded the same way. To sum up, the wound healing 
balance is shifted in favour of destructive processes. 
Emerging from cell membrane lipids break down caused by exaggerated cell 
necrosis associated with impaired wound healing effects higher numbers of cell 
death. Certainly, increased amounts of active oxygen species, for example hydroxyl 
radicals, peroxide anions, hydroperoxyl radicals or nitric oxide (NO) are known to 
be key negative factors in a number of inflammatory conditions61,62. 
Furthermore, in chronic wounds the specific cell populations and processes that are 
essential for wound repair are disrupted. So, epithelial cells fail to migrate across the 
wound tissue. Hence, hyperproliferation of cells occurs at the wound edges and 
interferes with normal cellular migration. As a result, the proliferation rate of 
fibroblasts is reduced and their apoptosis is inhibited63-65. And generally, the 
response of cells to growth factors is reduced because the failure to re-epithelialise, 
the most obvious clinical feature of chronic wounds, is due to a failure in migration 
rather than proliferation of the keratinocytes66. 
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In fact, these processes effectively hold the wound in the inflammatory phase and 
therefore prevent a wound from entering the proliferative phase and a physiological 
ongoing of the healing process. 
 
1.1.2.2  Clinics of chronic wounds 
According to their causale chronic wounds may be categorised as diabetic foot 
ulcers, venous or arterial leg ulcers, pressure ulcers, tumours, burns or even post-
surgical wounds. But, the most common are the venous leg ulcer, the pressure ulcer 
and the diabetic foot ulcer. These types appear different externally, but all share 
common characteristic features. In detail, recurrent trauma, ischaemia, and 
prolonged inflammation are apparent.  
Ulcus cruris disorders are divided into venous and arterial ulcerations. Venous 
ulcerations are the most common type of ulcer affecting the lower extremities. 
Here, a chronic venous reflux disorder occurs because of inherited or 
postthrombotic varicosis. With vein valves becoming incompetent the resulting 
backflow of blood causes venous congestion. The lymphatic system compensates 
the oedema in the first part, but soon it as well suffers damage from the overload. 
This results in oedema and a decreased oxygen supply in the surrounding skin. In 
arterial ulcers a complete or partial arterial blockage mostly resulting from 
arteriosclerosis lead to similar inadequate supply of surrounding tissue. 
Consequently, in both cases tissue necrosis and ulceration will develop. 
The pressure ulcer is a compressive-ischaemic skin lesion predominantly occurring 
above bony prominences such as the sacrum, heel, or ankle. Ulceration is again 
caused by inadequate supply due to ischaemia resulting from abnormal pressure on 
the tissue on a cellular level. The pressure to tissue is usually applied between a 
bony prominence and a hard surface, for example ankles in inappropriate foot 
wear. Beyond, an ischaemic lesion of the skin develops which after a short latent 
period leads to ischaemic skin necrosis. 
Diabetic foot ulcers are a common complication of diabetes mellitus because 
diabetes as underlying disease can cause damage to the nerve and vascular supply in 
the feet and legs. So, diabetics are prone to foot ulcerations due to both 
neuropathic and ischaemic complications. Next to the consequences of vascular 
damage outlined above neuropathy contributes to ulceration. In detail, neural 
damage also leads to lacking supply, and due to the loss of sensation the risk of 
trauma is severely increased67.  
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1.1.2.3  Infection of wounds 
Bacterial bioburden can cause a delayed or impaired healing. In detail, endotoxins 
and proteases stimulate an inflammatory wound environment, further the clotting 
mechanisms, leukocyte function, angiogenesis, and formation of granulation and 
scar tissue are disordered. Defined by extent and necessary treatment bacterial 
burden present in the wound is divided into several degrees68. Contamination is 
defined as the presence of non-replicating bacteria. This is a normal condition in 
chronic wounds and does not contribute to impaired healing. Colonisation is 
defined as the presence of replicating bacteria without a host reaction. Replicating 
bacteria colonise and contaminate all chronic wounds not meaning that these 
wounds are infected. Bacterial colonisation does not contribute to impaired healing. 
Critical colonisation is defined as the presence of replicating microorganisms, 
which are beginning to cause local tissue damage. There may be subtle local 
indications that a change in the equilibrium, or increasing bioburden, could be 
contributing to delayed healing69. Infection occurs when healing is impaired 
because bacteria have invaded tissue, are multiplying, and are causing a host 
reaction. 
Although bacteria are present in all chronic wounds, generally, only critical 
colonisation and infection indicate an antimicrobial treatment. But, additional other 
factors are to be maintained for every case individually, i.e. the balance between 
host resistance and the quantity and virulence of bacteria, second concomitant 
medications including immunosuppression, and any underlying diseases such as 
diabetes. 
Biofilms are an element of wound infection that has recently become apparent. 
Bacteria proliferating in wounds form microcolonies attaching to the wound and 
secreting a biofilm that protects the organisms. So, biofilms are protected areas of 
infection and bacterial resistance within the wound, protecting bacteria from the 
effects of antimicrobial agents such as antibiotics and antiseptics70. 
 
1.1.3  Treatment of chronic wounds 
In this section the methods of treatment of chronic wounds are outlined. Although, 
many older but obsolete methods are still in use in clinical practice solely the 
modern state-of-the-art methods are described. As a first treatment the wound is 
debrided. After that, under a moist dressing depending on the wound type the 
healing process is allowed to proceed in moist environment. Where necessary, an 
infection controlling treatment is conducted. For further support of the healing 
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process skin substitutes are available as well as vacuum treatment devices. And, for 
the correction of the above described imbalance phenomena products for the 
control of growth factors and protease levels in the wound can be applied. An ACT 
delivering device would also belong to this last group of products and thus, in that 
section also the scientific rational behind the delivery of ACT into wounds is 
discussed.  
 
1.1.3.1  Debridement 
Debridement – the removal of devitalised tissue - is facilitated by natural 
mechanisms in every wound, but accelerating this process makes healing more 
efficient. It may be necessary because devitalised tissue in the wound bed supports 
bacterial growth and is a physical barrier to healing. Devitalised tissue may also 
cause excessive amounts of proteases to be released. The methods of debridement 
in today’s clinical practice are surgical, enzymatic, autolytic, mechanical and 
biologic. 
Sharp surgical debridement is a very fast and efficient way to remove necrotic tissue 
from the wound bed. It is performed where there is an extensive amount of 
necrotic tissue or there is a widespread infection requiring infected material to be 
removed.  
Enzymatic debridement means the use of manufactured proteolytic enzymes, i.e. 
collagenases. These support naturally occurring enzymes to degrade necrotic tissue. 
Autolytic debridement is a process performed by phagocytic cells and proteolytic 
enzymes in the wound site liquefying and separating necrotic tissue from healthy 
tissue. Wound dressings, which maintain a moist wound bed, can provide an 
optimal environment for debridement, as they allow migration of the phagocytic 
cells. Unsurprisingly, the process of autolytic debridement can result in increased 
wound fluid requiring appropriate dressing. 
Mechanical debridement is a method that physically removes debris from the 
wound. Examples of mechanical debridement include conventional dressings 
causing mechanical separation of necrotic tissue from the wound bed once the 
dressing is removed and wound irrigation using a pressurised stream of water to 
remove necrotic tissue. 
Biologic larval therapy is an alternative method using sterile maggots that break 
down, liquefy and remove dead tissue secreting powerful proteolytic enzymes 
followed by eating of the digested tissue71. 
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1.1.3.2  Moist wound treatment 
1.1.3.2.1  History of moist wound treatment 
Prior to late 20th century, wounds were felt to heal better if exposed under a scab. 
This process produced surface desiccation and eschar formation now known to 
deepen the wound, but was felt to protect the wound from outside influence. The 
thinking is understandable given the fact that the most severe effect of wounding at 
that time was infection and no antibacterial agents were available for treatment. 
This concept remained popular until the mid-20th century. 
Between 1948 and 1958 several articles were published describing accelerated 
healing of acute wounds under occlusion. But, the primary death from wounds, 
especially burns, was still infection and therefore standard care returned to 
exposure, especially with the advent of a topical antibiotic silver sulfadiazine cream 
to be applied twice daily. This and following topical antibiotics could control 
infection in exposure but also retarded healing, especially epithelialisation, which 
nevertheless was considered as secondary. 
A landmark study in 1962 by George Winter, from Smith &Nephew Inc. and 
considered the father of moist wound healing, demonstrated that wounds 
epithelialised more rapidly under occlusive dressings with the reason being that 
occlusive dressings maintained a moist wound surface. This study was conducted 
on pigs showing that the moist environment accelerated the epithelialisation 
process about 30% compared to air dried wounds72. Numerous studies followed 
which demonstrated that wound occlusion and moisture increased all phases of 
healing. Wound bacterial colonisation which was demonstrated to be higher in a 
case study in a moist healing environment did not appear to retard healing or cause 
sepsis73. However, the risk of severe burden and infection decreasing the healing 
process was proven to be lower in occluded wounds74. In 1994, U.S. authorities 
published a guideline for treatment of pressure ulcers comprising occlusion for the 
purpose of autolytic debridement and provision of a moist environment. Following 
until present, wet treatment has been established in clinical practice as standard 
care. 
 
1.1.3.2.2  Effects of moist wound treatment 
In general, during a moist treatment the likelihood of scarring is reduced because 
there is no scab formation. In addition, moisture is essentially required for the 
already described activity of growth factors and proteolytic enzymes (section 
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1.1.1.2, 1.1.1.3 ). It is as well necessary for surface oxygen delivery and an efficient 
nutrient delivery. As a result, moisture improves the processes of the migration and 
proliferation phase by providing the ability of cells to migrate across the wound 
surface. So, an increased rate of epithelisation and angiogenesis is reached and 
further, fibroblast proliferation and thus collagen synthesis is improved.  
Next to an improvement of the healing by biochemical means there is also an 
improvement for direct patients’ concern. Pain is a major complication for wound 
treatment because in open wounds, the nerve endings are exposed and the wound 
can feel painful. With a moist environment the nerve endings are cushioned and 
protected which gives relief from pain.  
On the contrary, any surface desiccation decreases all phases of healing. In fact, 
surface drying was shown to lead to an increase in wound depth and a higher risk 
of infection75. 
1.1.3.2.3  Products for moist wound treatment 
The topical wound management product chosen will depend on wound 
characteristics, including amount of exudate, wound size, the presence of infection, 
and the characteristics of the surrounding skin. Especially the amount of exudate is 
important because low levels of moisture may lead to the discussed disadvantages 
but exaggerated levels of moisture lead to unwanted counterproductive maceration 
of tissue including intact skin. Hence, moisture-retentive dressings like okklusive 
films, hydrogels, and hydrocolloids are preferably selected for wounds with light to 
moderate drainage. Absorbent dressings like foams and alginates tend to be 
selected for wounds with moderate to heavy exudate.  
Film dressings – occlusive films are semi-permeable polyurethane dressings that are 
coated with an adhesive. They are used for minor exudating wounds. Their purpose 
is to prevent bacterial infection by shielding, to absorb low amounts of exudate and 
to maintain a moist wound environment for fresh epithelial tissue. The dressings 
insure a gaseous exchange for vaporising superfluous liquid. 
Hydrogels - hydrogels and hydrogel dressings are used to treat wounds with low 
exudate levels. With these products only low amounts of exudate are necessary to 
provide a moist milieu, since they contain high amounts of water themselves. Most 
products contain sodium carboxymethyl cellulose or polyacrylates swollen to an 
amorphous gel in a propylenglycol water mixture. Hydrogel dressings are used to 
hydrate necrotic tissue, facilitating autolytic debridement, while being able to 
absorb exudate. They can also be used to provide a moist wound environment 
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during the later stages of wound closure. In clinical practice, hydrogels are often 
additionally covered by a film dressing.  
Hydrocolloids - for moderate exudation hydrocolloid dressings can be used. They 
contain a layer of hydrocolloid. This is defined as liquid absorbing particles in an 
elastic, self-adhesive mass. The particles mostly consist of sodium carboxymethyl 
cellulose, calcium alginate, pectine, and gelatine, respectively. The elastic mass 
contains different synthetic polymers. The wound exudate binds to the absorbing 
particles of the hydrocolloid matrix to form a cohesive gel maintaining a moist 
wound environment. Most products as well are covered on the upper side by a 
semi-permeable polyurethane film.  
Foams - foam or hydrocellular dressings are double-layer dressings consisting of a 
polyurethane film carrier and a polyurethane foam layer on the wound side. They 
are used for moderate to heavily exuding wounds. The foam may be combined 
with polyacrylate particles supporting the liquid absorption. The foam core binds 
high amounts of debris and exudate. The film again provides gaseous exchange, but 
provides shielding against bacteria. So, a balance of absorbed and vaporising liquid 
establishes a moist milieu. Speciality absorbent dressings can be used as secondary 
dressings. 
Alginates - alginate dressings are used to cover heavily exuding wounds. They mostly 
contain a combination of calcium and sodium alginate fibres. Alginate dressings are 
highly absorbent and can incorporate high amounts of exudate by forming a 
hydrogel. Thereby, the calcium alginate polymers are soaked with exudate. After 
that, due to the high amounts of sodium in the exudate there is a diffusional 
exchange of calcium and sodium enabling the resulting sodium alginate to swell and 
form a hydrogel. Moreover, alginates support healing by binding bacteria and 
debris inside the gel structure and by providing a moist environment75. 
 
1.1.3.3  Infection control in wounds 
The most frequently used topical antimicrobials in modern wound care practice 
include octenidine, iodine, and silver containing products. Chlorhexidine, hydrogen 
peroxide, and honey as well are in discussion but seem to be used more rarely. In 
the past acetic acid, sodium hypochlorite, potassium permanganate and proflavine 
have been used.  
Iodine – iodine as element was used in treating wounds mainly in the 19th century. 
Due to its heavy adverse effects it is obsolete today. Therefore, the safer 
formulations povidone iodine and cadexomer iodine have been developed. 
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Povidone iodine is a polyvinylpyrrolidone - iodine complex; cadexomer iodine is 
composed of beads of dextrin and epichlorhydrin that carry iodine. Whereas its 
efficacy as a skin disinfectant is undisputed, numerous publications describe the use 
of iodine in cleansing wounds, and as a topical agent to prevent or treat localised 
wound infections, but controversy surrounds its safety and efficacy76.  
Silver - silver also has a long history as an antimicrobial agent, especially since the 
late 19th century77. Metallic silver is not active, but in aqueous environments silver 
ions are released and antimicrobial activity depends on the intracellular 
accumulation of low concentrations of silver ions. These bind to negatively charged 
components in proteins and nucleic acids, thereby effecting structural changes in 
bacterial cell walls, membranes and nucleic acids that affect viability78. The complex 
issues concerning the toxicity of silver to mammalian systems, and its effects on the 
healing process are not completely discussed. Skin discolouration and irritation 
associated with the use of silver nitrate is well documented; absorption of silver, 
systemic distribution and excretion in urine has also been reported79. In wound care 
silver has been utilised in several formulations. Silver nitrate application is rare, but 
silver sulphadiazine, colloidal and nanocrystalline elemental silver dressings have 
recently been developed and are widely used. These function by the sustained 
release of low concentrations of silver ions over time, and generally appear to 
stimulate healing, as well as inhibiting micro-organisms80. 
 
1.1.3.4  Skin substitutes for wound healing 
Tissue engineering has added several skin substitutes to the variety of dressings 
available for wound treatment. These products for example consist of fibroblasts 
and keratinocytes grown on collagen matrices. In clinical evaluation the application 
of Apligraf® has been shown to accelerate wound closure compared to control81. 
 
1.1.3.5  Growth factors control in chronic wounds 
For the described inductive effects of growth factors on cell migration the potency 
of these substances has been evaluated in numerous experiments. Convincing 
results of these efforts have been published in an unmanageable amount of 
publications. Following the results of research, many clinical trials with growth 
factors externally applied on wounds have been conducted. But, various degrees of 
success have been reported. For example, Richard et al conducted a trial with b-
FGF on diabetic foot ulcers with no seen advantage of verum over the placebo 
control82. Also, EGF was exogenously applied to patients with diabetic foot 
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ulcers83. There, a significant enhancement of healing and a reduction of healing 
time was reported. But, Falanga et al84 treated patients with venous ulcers in a study 
with EGF. Although they showed EGF was safe and significantly reduced the size 
of the ulcers, it failed to enhance epithelialisation. Robson et al applied KGF-2 or 
repifermin on chronic venous ulcers during clinical trial. Thereby, a significant 
acceleration of wound closure was achieved85. 
For PDGF-BB (platelet-derived growth factor consisting of BB-homodimer) or 
becaplermin several clinical trials finally leading to the approval of Regranex® in 
1999 for the treatment of diabetic foot ulcers have also been published. Efficacy 
and safety in diabetic foot ulcers have been proofed86-88. So, the application of 
Regranex® achieved a 43% increase of incidents of wound closure and a 32% 
decrease of time until wound closure. Similar trials, e.g. concerning pressure ulcers, 
acute, and open surgical wounds have also been conducted with promising results 
but not yet leading to an approval89-91. In Regranex® PDGF is formulated in an 
aqueous carboxymethyl cellulose hydrogel. Further, the formulation contains an 
acetate buffer, lysine hydrochloride, and sodium chloride. 
Another new technology for augmenting levels of growth factors in wounds is by 
gene transfer. Andree et al used particle-mediated and microseeding gene transfer 
to deliver human EGF to porcine wounds92,93. A high expression of EGF, as well 
as a significant acceleration of healing, was shown in the transfected wounds. For 
PDGF a clinical trial using a viral vector is planned94. 
In summary, there are several growth factors being evaluated in clinical trials, but 
given by the very diverse results, the type of the individual wound is an essential 
criteria for the choices of growth factors. Therefore, the approval of Regranex® 
only for diabetic foot ulcers is feasible.  
To overcome this problem and to make allowance to the thought of growth factors 
acting in concert, methods of autologous growth factor application have been 
developed. Thereby, a sample of the patient’s blood is taken and separated by 
centrifugation. The necessary fraction, e.g. platelets, is isolated and applied to the 
wound area as appropriate. However, effects are not well proven and 
questionable95,96. 
 
1.1.3.6  Protease control in chronic wounds 
Next to the delivery of growth factors the protease levels in chronic wounds have 
been identified as efficient starting point for treatment. Generally, as described in 
section 1.1.2.1 protease levels in chronic wounds are increased. Therefore, a 
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decrease of these levels is a goal of treatment. For that purpose, so-called active 
dressings are available that modulate these protease levels unspecifically. Moreover, 
the delivery of a protease inhibitor represents a potent possibility to balance the 
exaggerated lytic activity in chronic wounds in a very distinctive way. Despite many 
small chemical entities being protease inhibitors have been patented none of those 
has led to approval97. But, a physiological inhibitor could be an alternative to these 
substances due to a bandwidth of effects outlined below. Therefore, the topic of 
this thesis is the delivery of ACT, a physiological protease inhibitor, into wound 
sites. 
 
1.1.3.6.1  Active dressings for chronic wounds 
Some polymers, i.e. collagen and oxidative regenerated cellulose, proved to 
modulate the wound environment at the biochemical level. In detail, the levels of 
proteolytic enzymes in wound fluid are reduced by physically entrapping and 
mechanically inhibiting their activity. This is thought to originate the described 
decrease of tissue destruction and prevention of growth factor degradation, leading 
to an overall increase in granulation tissue formation and faster wound repair. 
Therefore, wound dressings consisting of collagen or oxidative regenerated 
cellulose were developed98,99. 
 
1.1.3.6.2  Delivery of ACT in chronic wounds 
It has been shown by works of SWITCH BIOTECH AG that chronic, diabetic 
ulcera in humans have strongly reduced capability for up-regulation of the level of 
expression of ACT. In healthy humans, the expression of ACT increases drastically 
in the wound tissue following wounding. Further, it has been established that 
besides the reduced levels of ACT transcripts, the activity of the ACT polypeptides 
is also selectively decreased in poorly-healing diabetic wounds compared to the 
oberserved increase in activity in normally healing wounds as well as in venous 
ulcers. Thus, it is the increase of both expression and function, particularly the 
activity, which leads to a strengthening of the antiprotease shield, and which in turn 
allows an increased neosynthesis of collagen and consequently supports rapid 
wound healing in normally healing wounds. Furthermore, the results show that this 
disturbance in the ACT protease inhibitor equilibrium is specific for the poorly 
healing diabetic wounds97,100.  
As a consequence, application of ACT into chronic wounds should support the 
wound healing process in a variety of ways. It can protect the extracellular matrix 
Chapter 1 - Introduction 
- 29 - 
via inhibition of mast cell chymase and cathepsin G. Cathepsin G itself is capable 
of activation of MMP 8 and MMP 9. So, delivery of ACT can at least partly 
decrease the enzymatic activity of this group of proteases. In similar way, elastase 
activity was shown to be dependent on the presence of cathepsin G. Furthermore, 
ACT has been reported to inhibit the neutrophil chemotaxis and superoxide 
generation. Both factors contribute to the inflammation at the wound site. For this 
multitude of effects the protein protease inhibitor ACT is likely to be superior over 
small chemical entities designed to inhibit one enzyme39.  
Therefore, the delivery of ACT into the wound area promises improvement of the 
disturbed healing of particularly diabetic wounds. 
 
Chapter 1 - Introduction 
- 30 - 
1.2  Protein delivery from hydrogel formulations 
“Hydrogels are three-dimensional, hydrophilic, polymeric networks capable of 
imbibing large amounts of water or biological fluids. The networks are composed 
of homopolymers or copolymers, and are insoluble due to the presence of chemical 
crosslinks (tie-points, junctions), or physical crosslinks, such as entanglements or 
crystallites. The latter provide the network structure and physical integrity. These 
hydrogels exhibit a thermodynamic compatibility with water which allows them to 
swell in aqueous media”101.  
Hydrogels have been in use in the pharmaceutical, medicinal, and cosmetic field for 
many years. Mainly, they have been applicated topically with or without a drug 
substance for local treatment. An exception of course are the matrix based 
transdermal therapeutic systems for e.g. systemic delivery of hormones. But, with 
the availability of large molecular weight protein drugs and the grown demands for 
a controlled release of drugs in modern medicine, hydrogels have earned further 
increasing attention as drug delivery systems for the systemic delivery of both 
peptide and small chemical compounds101.  
For the desired controlled delivery of drugs by gel matrices the release mechanism 
is a decisive parameter. Generally, for the release from polymeric drug delivery 
devices three main mechanisms are described and reviewed102. 
Diffusion control - in a diffusion controlled system the drug is distributed 
homogeneously in the gel matrix. For release, the protein drug permeates through 
the continuum of the carrier to the release site. Hence, diffusion of the protein 
through the matrix is the rate-limiting step.  
Chemical control - in the case of chemical control, the polymer is degraded resulting 
in an erosion of the matrix and release of the drug.  
Figure 1-5 displays the different types of polymer degradation mechanisms. In (1) a 
biodegradable bond is incorporated into the polymer backbone. Chemical or 
enzymatic cleavage of the bond converts a water-insoluble polymer into water-
soluble, low molecular weight polymer fragments. In (2) the gel exists as a 
covalently or ionically cross-linked matrix. Therefore, cleavage of unstable linkages 
in the crosslinks leads to a breakdown of the network structure. Covalently 
crosslinked hydrogels and ionically cross-linked polymers degrade by this 
mechanism. For these two mechanisms a further differentiation can be made 
concerning physical terms. Hydrolysis can occur at an even rate throughout the 
whole polymer matrix indicating a bulk erosion phenomenon. Contrarily, in surface 
erosion the delivery system degrades only at its surface because the degradation is 
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blocked inside the matrix e.g. by excipients changing the pH to value unfavourable 
for hydrolysis. Besides, in some systems the drug can be attached to the polymer by 
a covalent bond that is degraded chemically triggering the release of the drug.  
Example (3) of Fig. 1-5 describes polymer solubilisation as degradation mechanism 
which is not actually related to a chemical reaction. Rather, the system dissolves 
and liquefies as water diffuses into the network leading to swelling and simple 
dilution of the polymers (Fig. 1-5).  
 
 
 
Fig. 1-5 Polymer degradation mechanisms in hydrogels and related devices; (1) hydrolysis of 
the backbone; (2) hydrolysis of the crosslinked polymer network; (3) hydration and 
solubilisation of a polymer matrix;102 
 
Solvent activation - a third mechanism is solvent activation. The drug can be released 
either by swelling of the polymer in which the drug was previously locked into 
place within the polymer matrix in a glassy state or by an osmotic effect, which can 
be accomplished by external water entering the drug delivery system because of an 
osmotic driving force and subsequently driving the drug out of the system.  
 
1.2.1  Suitability of hydrogels for protein delivery 
Protein drugs place stringent demands on their delivery systems due to their 
structure, physicochemical properties, stability, pharmacodynamics, and 
pharmacokinetics. More specifically, peptides and proteins must retain their 
structural integrity until they reach their delivery site and must not be degraded 
upon enzymatic interactions. In addition, the physiological barriers, e.g. skin and 
cell membranes, are obstacles for the successful penetration of such drugs to their 
site of action.  
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Thus, next to protein integrity, a delivery device is required to deal satisfactorily 
with technological factors such as protein loading efficiency and desired release 
characteristics.  
 
Due to their high water content, hydrogels are generally considered as 
biocompatible materials. So, they provide minimal mechanical irritation upon in-
vivo implantation mainly due to their soft and rubbery nature which is similar to 
natural tissue101.  
Generally, the mostly aqueous environment of hydrogels appears very similar to the 
physiological environment for proteins and peptides in the body and therefore is 
supposed to be favourable for stability and activity of these substances. Moreover, 
due to the low interfacial tension between water and hydrogels, tendencies to 
protein adsorption and cell adhesion are very low. Furthermore, hydrogels offer a 
broad acceptability for individual drugs with different hydrophilicities and 
molecular sizes. Also, maximum drug load is expected to be uncritical for proteins 
in most cases because the high water content provides a high solubility for 
hydrophilic protein substances101. Therefore, hydrogel carriers are favourable for 
the delivery of peptide and protein drugs. 
 
1.2.2  Protein delivery from hydrogels 
In the following an overview over protein delivering hydrogel formulations 
published during the last decades is outlined in dependence of the application site. 
Thereby, the application of hydrogels in wounds, on skin for transdermal delivery, 
in the gastrointestinal tract via oral administration, and for injection is highlighted.  
 
1.2.2.1  Application in wounds 
For the application of protein drug loaded hydrogels in wounds, a multitude of 
reports has been published. These mainly deal with the delivery of growth factors 
aiming towards an acceleration and improvement in wound closure. Also, a whole 
variety of gelling agents has been used for the various approaches. A series of 
examples is given that report improving or accelerating impact of growth factors on 
wound healing. 
Hydroxyethyl cellulose was used to incorporate a-FGF in a gel formulation103. A 
preparation of 1mg/ml a-FGF stabilised by heparin was evaluated in vitro and in 
vivo. In release studies in a special apparatus in vitro indicated that 90% of total a-
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FGF content were liberated and recovered in the acceptor consisting of 
PBS/heparin. Moreover, in a diabetic mouse model an improvement of wound 
healing was found. 
B-FGF further was delivered from crosslinked chitosan gels104. Thereby, in vitro 
release from a 1mg/ml b-FGF containing gel into PBS solely under non-degrading 
conditions was studied in a well plate without a membrane. Thereby, a maximum 
of 20% was released within 24 hours in PBS as acceptor. It was concluded that the 
remaining substance was locked in the matrix, while in vivo degradation was 
expected to liberate the whole dosis. Besides, in a diabetic mouse model an 
improvement of wound healing was found. 
Further, collagen gels have been reported to effectively deliver EGF and TGF-β105. 
As well, collagen was used as carrier for delivery of PDGF, TGF-β, and FGF106. 
Furthermore, gelatine was tested on the delivery of FGF107. Besides, a gelatine gel 
crosslinked with dextran dialdehydes was used on EGF108. KGF was administered 
in a fibrin gel carrier109. Moreover, TGF-β was administered in a Poloxamer® gel as 
well as a polyethylene glycol gel110.  Furthermore, a PEG-PLGA-PEG 
blockcopolymer was used on a TGF-β plasmid111. And, the thrombin receptor 
agonist peptide was embedded in a polyvinyl caprolactam - calcium alginate film112. 
Also, methylcellulose gels delivered TGF-β113. EGF further was delivered from 
chitosan gels114. 
The research on the delivery of PDGF in a carboxymethyl cellulose hydrogel has 
finally led to approval of Regranex® (see section 1.1.3.5). 
The variety of combinations of proteins and gellant types researched for wound 
treatment indicates a broad compatibility of proteins and hydrogels. Nevertheless, 
data given in these publications mostly are written from the medical point of view 
and therefore focus on in vivo effects. Stability and release concerns of the 
proteins, however, are not always investigated thoroughly.  
 
1.2.2.2  Transdermal delivery 
Recently, research on transdermal delivery of proteins is focusing on electrically-
assisted mechanisms, using iontophoresis and electroporation115. Polyacrylamide 
hydrogel formulations are being investigated as vehicles for transdermal 
iontophoresis to obtain the enhanced permeation of luteinising hormone releasing 
hormone into hairless rat skin116.  
Moreover, a methyl cellulose hydrogel was used as a viscous ultrasonic coupling 
medium for transdermal sonophoresis. It was concluded that an enhanced 
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permeation of insulin and vasopressin out of a gel vehicle across human skin driven 
by sonophoresis is possible117. 
 
1.2.2.3  Oral delivery 
Orally administered peptides and proteins are usually prone to hydrolysis and 
digestion in the harsh, acidic, and enzymatically active environment of the stomach. 
To overcome this obstacle various approaches have been made to protect the drug 
from degradation by pH sensitive polymers in form of matrices or coatings.  
For example, a protection mechanism for oral delivery of insulin was investigated 
using a pH-responsive complexation hydrogel matrix118. The hydrogels used to 
protect insulin were crosslinked matrices consisting of a copolymer of 
polymethacrylic acid and polyethylene glycol. Complexation of the polymeric 
carrier occurs via the hydrogen bonding between the carboxyl group of the 
methacrylic acid and the oxygen of the PEG chains, which protects the drug in the 
low pH environment of the stomach. As the environmentally sensitive polymeric 
carrier passes into the small intestine, the pH is shifted to neutral, causing 
deprotonation of the carboxyl group on the acrylic acid and thus creating repulsion 
between the polymer chains. The increased mesh size, due to the ionic repulsion 
and the uptake of water in the decomplexed state, allows for release of the drug at 
the targeted site of absorption. 
In vivo experiments with microparticles in oral administration studies using both 
healthy and diabetic rats indicated that insulin was released in the neutral and basic 
regions of the intestine. Moreover, a strong dose-dependent hypoglycaemic effect 
was demonstrated.  
Besides the intestine, the colon is considered as promising absorption site for oral 
administration of proteins and peptide drugs as well. In contrast to the upper 
gastrointestinal tract, the colon as delivery site offers very low proteolytic enzyme 
activities. Therefore, the route of oral administration of proteins to target the 
release of the drug to colon is under research. Early approaches used polymer 
coatings with azo aromatic crosslinks that are degraded by specific microflora, e.g. 
Bifidobacteria, in the colon. With this system the peptide hormones vasopressin 
and insulin could be delivered to the colon of rats after oral administration119.  
Later approaches aim towards embedding of the proteins in biodegradable matrices 
and hydrogels120. Thereby, polymers are preferred that are degraded by colon 
specific microflora, such as inulin. Till date, in vitro studies on the release of bovine 
serum albumin from methacrylated inulin hydrogels have been published121. To 
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further improve the shielding against degradation in the upper gastrointestinal tract 
these gel systems may be combined with coatings of pH-sensitive, biodegradable, 
or bioadhesive polymers. 
 
1.2.2.4  Ophthalmic delivery 
Maleic anhydride-alkyl vinyl ether copolymers have been used to fabricate 
polymeric films containing α-interferon122. The interferon was coincorporated with 
human serum albumin as a suspension into gels. Albumin was used both as a 
diluent for the interferon and as an intermolecular binder for the polymer matrix. 
The gels were processed as ophthalmic implants. It was reported that the erosion 
of the polymer matrix next to diffusion of interferon contributes to the release 
profile. 
 
1.2.2.5  Delivery by injection and general approaches 
The development of protein drug loaded hydrogels applicated by injection aims 
towards a parenteral depot form for these substances desirably with a controlled 
release behaviour. Therefore, most reports deal with the liberation characteristics of 
the peptides from hydrogels preferably with a prolonged release period with little or 
no burst effects.  
In general, for subcutaneous or intraperitoneal delivery of proteins in gel matrices, 
the basic semi-solid hydrogel formulation seems inappropriate. Therefore, rather 
than semi-solid gels, other hydrogel-related application forms are in the focus of 
delivery research. These are e.g. stimuli-sensitive hydrogels that are injectable at 
room temperature but form a gel when heated to body temperature. Another 
approach is the in situ photopolymerisation of the polymers leading to gel 
formation. Examples are given below followed by reports about more general 
approaches on protein delivery from hydrogels. 
 
A very well investigated thermoresponsive hydrogel is formed by Poloxamer® 407. 
In general, Poloxamers® are block copolymers of polyethylene oxide and 
polypropylene oxide. Aqueous solutions at concentrations of 20% Poloxamer® 407 
are injectable liquids that rapidly gel when exposed to body temperature after 
subcutaneous or intraperitoneal injection. There, they are not metabolised by the 
body, but the gels dissolve over time getting cleared finally. A formulation of 
interleukin-2 in Poloxamer® 407 gels has shown good effects and biocompatibility 
in vivo. Hereby, interleukin-2 lost 15% of activity over a 3 days storage at 37°C, but 
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could be stabilised over that period by human serum albumin. However, in vitro 
studies indicated a release of greater 80% within 8 hours123.  
Moreover, the release of human growth hormone from Poloxamer® 407 gels was 
investigated in vitro and in vivo. A release of close to zero order kinetics was found 
over three days. After subcutaneous administration in rats the formulation was 
reported to liberate the protein over one week124.  
 
Another group of polymers exhibiting reverse thermal gelation properties are low 
molecular weight PLGA-PEG-PLGA copolymers. This system, known as ReGel®, 
was evaluated as a pharmaceutical vehicle by Zentner et al.125. In vivo 
biodegradation studies in rats revealed that the formulation was completely 
resorbed from the injection site within 4–6 weeks. The ReGel® system has also 
been tested for the parenteral delivery of peptides. Thereby, formulations consisted 
of the peptide in an appropriate buffer system with the gellant but no further 
stabilisers. Zn-insulin release from ReGel® occurred over approximately one week 
and even longer depending on the basic triblock copolymer composition. 
Moreover, the in vitro studies on porcine growth hormone (pGH) and Zn-pGH 
indicated a continuous liberation over two weeks with no initial burst and mass 
balance recovery of drug. In vivo results support these results. Furthermore, G-
CSF was released from ReGel® to 85% over 12 days. Thereby, no degradation of 
G-CSF was detected during the release period. Again, this was supported by in vivo 
data.  
 
Moreover, Hubbell et al. introduced block copolymers of lactic acid and 
polyethylene glycol as protein delivery vehicles126. The polymers are terminally 
diacrylated and are photopolymerised in an aqueous precursor solution forming a 
hydrogel. From that preparation insulin, lysozyme, lactate dehydrogenase, 
ovalbumin, and bovine serum albumin were liberated in vitro. But, release of all 
substances was finished within 2 to 5 days depending on their molecular weight.  
A later report by Hubbell et al. focuses on formation of a bilayer hydrogel depot on 
polyethylene glycol basis. In detail, it consists of a higher permeability intimally-
adherent layer, containing the drug, and a lower permeability luminal layer. Both 
layers are formed by photopolymerisation of polyethylene glycol diacrylate 
precursors of different molecular weight. In this system, horseradish peroxidase 
was used as a model protein, and delivery to the arterial media was measured in rat 
carotid arteries ex vivo. Thereby, the lower permeability luminal layer served to 
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enhance delivery of the model protein into the arterial media for delivery periods of 
three days.  
 
As a more general approach, Hennink and coworkers reported on degradable 
dextran hydrogels127. There, the release of interleukin-2 from non-biodegradable 
methacrylated dextran and biodegradable lactate-hydroxyethyl methacrylated 
dextran hydrogels was investigated in vitro. The latter are crosslinked via 
hydrolysable ester bonds. Interestingly, from non-degradable hydrogels with an 
initial water content above 70%, the protein release followed Fickian diffusion, 
whereas from gels with an initial water content of 70% or lower the protein was 
fully entrapped in the hydrogel meshes. The release from the biodegradable system 
lasted over 5 to 15 days depending on the crosslinking density. Thereby, the 
liberation is determined by degradation and diffusion resulting in a nearly zero 
order profile. Further, interleukin-2 was recovered as monomer in all cases.  
Later the group around Hennink reported on degradable dextran hydrogels based 
on stereocomplex formation between enantiomeric oligomeric lactic acid chains. 
Release of lysozyme and immunoglobulin G in vitro were finished after six days. 
Thereby, the proteins were quantitatively released from the gels and with full 
preservation of lysozyme activity128. 
 
1.2.3  Summary 
To conclude, there is a broad variety of publications dealing with the delivery of 
proteins out of hydrogel matrices. But, research on that topic seems mainly 
motivated by the goal to create a controlled and sustained releasing drug delivery 
system. An exception might be the application on wounds. Because, these are 
widely based on in vivo experiments leading to results that a clinical effect is seen 
after administration of the preparation or not.  
However, the release from hydrogels is mainly diffusion controlled in most cases. 
According to Fick’s law the release rate in this mechanism solely depends on the 
diffusion coefficient which is closely related to the molecular weight of the 
diffusing substance. Hence, the liberation rate of these systems is not very 
sustained but hard to be influenced129. Though there are certain possible 
manipulations reported, e.g. concerning the crosslinking density of the network and 
swelling behaviour of the gel, to prolong the release, most of the aqueous gel 
preparations outlined offer a maximum releasing period from days to weeks for 
protein drugs (see references above).  
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Thus, to provide a further sustained release profile, for example to reach a 
continuous release over three months, other delivery devices that release the drug 
load by different mechanisms, e.g. non-aqueous systems being prone to chemical 
degradation, have to be evaluated130,131.  
 
As mentioned the major part of publications concentrate on the release 
characteristics of the protein drug - hydrogel system. However, if at all, the 
stabilisation of proteins in the particular hydrogels is addressed only concerning the 
release period. Longer term stability of proteins embedded in the hydrogels like it is 
necessary for the further development of a commercial formulation seems to be 
investigated only to a minor degree.  
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1.3  Aim of the thesis 
The major aim of this work was to formulate ACT in suitable carriers that provide 
proper stability and delivery of this protein drugs into wound sites. The studies are 
to be performed in vitro. 
 
The application form for the delivery of ACT should be based on hydrogels. 
Because as outlined in the first introductory parts, hydrogels are the state of the art 
application form in wound healing. Besides, as presented in the later part of the 
introduction chapter, they are also known to be suitable for protein drug delivery. 
 
In addition, several key data have been specified by the collaboration partners 
based on the company medicinal research prior to this work. So, the concentration 
level of ACT is set to 60µg/ml in the hydrated state. The shelf life of the protein 
delivering product should be 18 months or greater to ensure proper marketing and 
logistics for a future commercialised product. Thereby, a water containing product 
can be stored in a refrigerated state, but a dry product should enable a storage at 
room temperature to limit costs of product shipping and distribution. Moreover, 
the preparations should release ACT in considerable amount within one to five 
days in concordance with common change of dressing intervals in clinical practice. 
For the selection of ingredients and manufacturing methods after the concerns of 
protein stability and suitability for wound treatment also the regulatory status 
should be considered to not unnecessarily hamper a later approval process.  
The research work is finished with the presentation and recommendation of 
formulations for ACT meeting the requirements given above. Subsequently to this 
collaboration, the formulations are to be introduced in animal experiments with 
prospect to clinical trials by the collaboration partner.  
 
This thesis is divided into three main chapters. The theoretical introductory 
remarks about wound healing and protein delivery from hydrogels are outlined 
before. This is followed by chapter 2 describing materials and methods used in this 
work. Consequently, chapter 3 with results and discussion is presented. There, the 
structure follows the milestones of development, i.e. stabilisation of ACT in 
solution, development of semisolid hydrogel carriers and stabilisation of ACT 
therein, development of dried gel forms – xerogels and films – and stabilisation of 
ACT therein, and finally the release of ACT from the reconstituted dry systems.  
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Chapter 4 summarises the experimental outcome, aims for appropriate conclusions 
and puts the results into perspective. Chapter 5 is addressed to listen special and 
continuative literature referred to in the thesis. 
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2  Materials and Methods 
2.1  Materials 
2.1.1  α1-Antichymotrypsin (ACT) 
α1-antichymotrypsin (ACT) is a human protein proteinase inhibitor. It is isolated 
from human plasma and is purchased from Calbiochem, Darmstadt, Germany as 
lyophilisate (from 188µl solution consisting of 1mg ACT, 150mM NaCl, 20mM 
Tris, pH 7.4) to be stored at –20°C.  
 
Met Glu Arg Met Leu Pro Leu Leu Thr Leu Gly Leu Leu Ala Ala Gly 
1               5                   10                  15       
Phe Cys Pro Ala Val Leu Cys His Pro Asn Ser Pro Leu Asp Glu Glu  
            20                  25                  30           
Asn Leu Thr Gln Glu Asn Gln Asp Arg Gly Thr His Val Asp Leu Gly  
        35                  40                  45               
Leu Ala Ser Ala Asn Val Asp Phe Ala Phe Ser Leu Tyr Lys Gln Leu  
    50                  55                  60                   
Val Leu Lys Ala Pro Asp Lys Asn Val Ile Phe Ser Pro Leu Ser Ile  
65                  70                  75                  80   
Ser Thr Ala Leu Ala Phe Leu Ser Leu Gly Ala His Asn Thr Thr Leu  
                85                  90                  95       
Thr Glu Ile Leu Lys Gly Leu Lys Phe Asn Leu Thr Glu Thr Ser Glu  
            100                 105                 110          
Ala Glu Ile His Gln Ser Phe Gln His Leu Leu Arg Thr Leu Asn Gln  
        115                 120                 125              
Ser Ser Asp Glu Leu Gln Leu Ser Met Gly Asn Ala Met Phe Val Lys  
    130                 135                 140                  
Glu Gln Leu Ser Leu Leu Asp Arg Phe Thr Glu Asp Ala Lys Arg Leu  
145                 150                 155                 160  
Tyr Gly Ser Glu Ala Phe Ala Thr Asp Phe Gln Asp Ser Ala Ala Ala  
                165                 170                 175      
Lys Lys Leu Ile Asn Asp Tyr Val Lys Asn Gly Thr Arg Gly Lys Ile  
            180                 185                 190          
Thr Asp Leu Ile Lys Asp Leu Asp Ser Gln Thr Met Met Val Leu Val  
        195                 200                 205              
Asn Tyr Ile Phe Phe Lys Ala Lys Trp Glu Met Pro Phe Asp Pro Gln  
    210                 215                 220                  
Asp Thr His Gln Ser Arg Phe Tyr Leu Ser Lys Lys Lys Trp Val Met  
225                 230                 235                 240  
Val Pro Met Met Ser Leu His His Leu Thr Ile Pro Tyr Phe Arg Asp  
                245                 250                 255      
Glu Glu Leu Ser Cys Thr Val Val Glu Leu Lys Tyr Thr Gly Asn Ala  
            260                 265                 270          
Ser Ala Leu Phe Ile Leu Pro Asp Gln Asp Lys Met Glu Glu Val Glu  
        275                 280                 285              
Ala Met Leu Leu Pro Glu Thr Leu Lys Arg Trp Arg Asp Ser Leu Glu  
    290                 295                 300                  
Phe Arg Glu Ile Gly Glu Leu Tyr Leu Pro Lys Phe Ser Ile Ser Arg  
305                 310                 315                 320  
Asp Tyr Asn Leu Asn Asp Ile Leu Leu Gln Leu Gly Ile Glu Glu Ala  
                325                 330                 335      
Phe Thr Ser Lys Ala Asp Leu Ser Gly Ile Thr Gly Ala Arg Asn Leu  
            340                 345                 350          
Ala Val Ser Gln Val Val His Lys Ala Val Leu Asp Val Phe Glu Glu  
        355                 360                 365              
Gly Thr Glu Ala Ser Ala Ala Thr Ala Val Lys Ile Thr Leu Leu Ser  
    370                 375                 380                  
Ala Leu Val Glu Thr Arg Thr Ile Val Arg Phe Asn Arg Pro Phe Leu  
385                 390                 395                 400  
Met Ile Ile Val Pro Thr Asp Thr Gln Asn Ile Phe Phe Met Ser Lys  
                405                 410                 415      
Val Thr Asn Pro Lys Gln Ala  
            420               
Fig. 2-1 Amino acid sequence of human ACT with numbering;  
 
ACT has a molecular weight of 68kDa and consists of 423 amino acids (Fig. 2-1). 
Moreover, it is heavily glycosylated with 40 neutral sugar residues, 35 
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acetylglucosamine residues, and 14 acetylneuraminic acid residues per molecule 
adding up to about 25% sugar content of the total molecular weight.  
 
2.1.2  Excipients and chemicals 
 
 
Substance Quality Supplier 
   
Sodium chloride, Potassium chloride, 
Magnesium chloride, Ethylenediamine 
tetra acetate, Sodium sulphate, 
Ammonium chloride, 
Tetramethylammonium chloride, 
Potassium bromide, Phosphoric acid, 
Potassium hydroxide 
p.a. Merck KGaA, Darmstadt, Germany 
Polysorbate (Tween®) 20 Ph. Eur. 2004 Serva, Heidelberg, Germany 
Poloxamer® 188 Ph. Eur. 2004 BASF, Ludwigshafen, Germany 
Solutol® HS15 Purest BASF, Ludwigshafen, Germany 
Sucrose Ph. Eur. 2004 Merck KGaA, Darmstadt, Germany 
Trehalose Purest British sugar, Peterborough, UK 
Glycerol Ph. Eur. 2004 Merck KGaA, Darmstadt, Germany 
Propylenglycol Ph. Eur. 2004 Merck KGaA, Darmstadt, Germany 
Mannitol Ph. Eur. 2004 Merck KGaA, Darmstadt, Germany 
Sorbitol Purest Merck KGaA, Darmstadt, Germany 
α-cyclodextrin, β-cyclodextrin, 
Hydroxypropyl-β-cyclodextrin; γ-
cyclodextrin 
Purest Wacker, Burghausen, Germany 
Urea Ph. Eur. 2004 Merck KGaA, Darmstadt, Germany 
Glyine, Alanine, Phenylalanine, 
Arginine, Methionine, Lysine, Cysteine 
Ph. Eur. 2004 Merck KGaA, Darmstadt, Germany 
Benzylalcohol Ph. Eur. 2004 Sigma, Taufkirchen, Germany 
Chlorokresol Ph. Eur. 2004 Sigma, Taufkirchen, Germany 
Parabene Purest Sigma, Taufkirchen, Germany 
Phenol Ph. Eur. 2004 Sigma, Taufkirchen, Germany 
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2.1.3  Polymers 
All polymers were purchased as Ph. Eur. 2004 grade where available. Else, pharma 
grade was ordered. 
 
2.1.3.1  Cellulose ethers 
Polymer Brand name Supplier 
   
Hydroxyethyl cellulose 100.000 Natrosol® 250 HHX Aqualon, Düsseldorf, Germany 
Hydroxyethyl cellulose 30.000 Tylose® H 30.000  Clariant, Wiesbaden, Germany 
Hydroxyethyl cellulose 10.000 Tylose® H 10.000  Clariant, Wiesbaden, Germany 
Hydroxyethyl cellulose 4.000 Tylose® H 4.000  Clariant, Wiesbaden, Germany 
Hydroxyethyl cellulose 1.000 Tylose® H 1.000  Clariant, Wiesbaden, Germany 
Hydroxyethyl cellulose 300 Tylose® H 300  Clariant, Wiesbaden, Germany 
Carboxymethyl cellulose Na 30.000 Tylopur® C 30.000 Clariant, Wiesbaden, Germany 
Carboxymethyl cellulose Na 10.000 Blanose® 7HF Aqualon, Düsseldorf, Germany 
Carboxymethyl cellulose Na 1.000 Tylopur® C 1.000 Clariant, Wiesbaden, Germany 
Carboxymethyl cellulose Na crosslinked AcDiSol® FMC, Newark, USA 
Methyl cellulose 1.000 Tylose® MH 1.000 Clariant, Wiesbaden, Germany 
Hydroxypropyl cellulose 100.000 Klucel® HF  Aqualon, Düsseldorf, Germany 
Hydroxypropylmethyl cellulose 100.000 Methocel® K100M Colorcon, Kent, UK 
Hydroxypropylmethyl cellulose 15.000 Methocel® K15M Colorcon, Kent, UK 
 
 
2.1.3.2  Gellan gum 
Gellan gum is produced by Pseudomonas elodea. It is an anionic polysaccharide 
consisting of a repeating linear tetrasaccharide unit. The latter is a sugar sequence 
of β-D-glucose, β-D-glucuronic acid, β-D-glucose, and α-L-rhamnose. Native 
gellan gum - Kelcogel LT100 – is partly acetylated at the C6-atom of the first 
glucose unit. Moreover, there is a glyceryl at the same glucose unit (Fig. 2-2). The 
acetylated polymers form soft and very elastic gels because the acetyl groups 
disturb and therefore reduce the intermolecular forces. The deacetylated 
polysaccharides – Kelcogel® F – form harder but more brittle gels (Fig. 2-3). Both 
gellan types form thermoreversible gels. Therefore, gel manufacture is described as 
cooling of a warm gellan solution. In our case this step is replaced by steam 
sterilisation. 
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Fig. 2-2 native gellan gum;    Fig. 2-3 deacetylated gellan gum; 
 
Gellan gum molecules are parallel double helices. For gelation, moreover, cations 
like sodium, potassium or calcium are used for their support of interlinking gellan 
gum polymers. In detail, the helices are linked via electrostatic interactions between 
monovalent cations, water molecules and a carboxyl group132: 
 
double helix - K+  - water - K+ - double helix 
 
Bivalent cations form direct complexes with two carboxyl groups.  
 
2.1.3.3  Other polymers 
 
Polymer Brand name Supplier 
   
Polyethylene glycol (PEG) 
400, 2000, 6000, 20.000 
 Clariant, Wiesbaden, Germany 
Alginate Na Protanal® HF120 RBS  FMC, Newark, USA 
Xanthan gum Xanthural® 11k CP Kelco, Lille, Denmark 
Gellan gum F Kelcogel® F CP Kelco, Lille, Denmark 
Gellan gum LT 100 Kelcogel® LT100 CP Kelco, Lille, Denmark 
Gelatine A  Sigma, Taufkirchen, Germany 
Polyacrylate Carbopol® 940 BF Goodrich, Cleveland, USA 
Eudragit® Eudragit® L100 Röhm, Darmstadt, Germany 
Polyvinyl pyrrolidone 17 Kollidon® 17PF BASF, Ludwigshafen, Germany 
Polyvinyl pyrrolidone 90 Kollidon® 90 BASF, Ludwigshafen, Germany 
Polyvinyl alcohol 100.000  Sigma, Taufkirchen, Germany 
Lutrol® F127  BASF, Ludwigshafen, Germany 
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2.2  Methods 
2.2.1  Characterisation of ACT 
2.2.1.1  ACT activity assay 
In order to determine the ACT activity, an activity assay based on Cathepsin G 
binding is performed. During the reaction a complex is formed: 
Cathepsin G/ACT/Antibody 1/Antibody 2 
The antibody 2 is linked to horseradish peroxidase catalysing the detectable colour 
reaction.  
96-well plates are coated with BSA and subsequently with Cathepsin G 
(Calbiochem, Darmstadt, Germany). After washing, ACT samples are added and 
incubated for 30min at 37°C. After three times washing with PBS-T (phosphate 
buffered saline with 0.05% Tween®) buffer , a rabbit anti human ACT antibody 
(DAKO, Glostrup, Denmark) is added to the wells and is incubated for 30min at 
37°C. After washing three times with PBS-T buffer, a goat anti rabbit IgG antibody 
conjugated with horseradish peroxidase (DAKO, Glostrup, Denmark) is added and 
is again incubated for 30 min at 37°C. The wells are again washed three times with 
PBS-T buffer. Subsequently, OPD (1,2-Diaminobenzene, Sigma, Taufkirchen, 
Germany) substrate solution is prepared according to the manufacturer’s protocol 
with hydrogen peroxide (Sigma, Taufkirchen, Germany), added to the wells and 
incubated at room temperature in the dark. After 10 minutes the reaction is 
stopped by adding 100µl 0.5M sulphuric acid per well. Immediately after stopping 
the reaction the absorption at 490 nm is determined. 
 
2.2.1.2  ACT ELISA 
In order to determine the ACT content, an ELISA is performed. During the 
reaction a complex is formed: Antibody1/ACT/Antibody2 
The antibody2 is linked to horseradish peroxidase catalysing the detectable colour 
reaction.  
96-well plates are coated with rabbit anti human ACT antibody (DAKO, Glostrup, 
Denmark) over night at 6°C. After washing and blocking with PBS-T/BSA, ACT 
samples are added and incubated for 120min at 37°C. After three times washing 
with PBS-T/BSA, a anti human ACT antibody conjugated with horseradish 
peroxidase (Biotrend, Cologne, Germany) is added to the wells and is incubated for 
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120min at 25°C. Subsequently, OPD (1,2-Diaminobenzene) substrate solution is 
prepared according to the manufacturer’s protocol (Sigma, Taufkirchen, Germany), 
added to the wells and incubated at 25°C in the dark. After 15 minutes the reaction 
is stopped by adding 100µl 0,5M H2SO4 per well. Immediately after stopping the 
reaction the absorption at 490 nm is determined. 
 
2.2.1.3  Gel electrophoresis 
Protein integrity was analysed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) under non-reducing conditions using an XCell II 
Mini cell system (Novex, San Diego, USA). Samples were diluted in a pH 6.8 Tris-
buffer, containing 2% SDS and 2% glycerin for 30 min at 90°C and subsequently 
loaded into gel wells (NuPAGER Novex 10% Bis-Tris Pre-cast Gel 1.0 mm from 
Invitrogen, Groningen, Netherlands). Electrophoresis was performed in a constant 
current mode of 60 mA in a Tris-glycine/SDS running buffer. After staining with 
coomassie blue staining kit (Novex Colloidal blue stain kit), the gels were dried 
using a DryEaseR Gel Drying System (Invitrogen). 
 
2.2.2 Manufacture of matrices 
2.2.2.1  Wet film manufacture with the scraper 
For the casting of wet films a scraper is used (Erichsen, Hemer, Germany, Model 
360, 03216). It is 6cm wide and provided with defined four gaps of 500µm, 
1000µm , 1500µm, and 2000µm height, respectively. After loading the scraper with 
approx. 10 ml of gel the apparatus is drawn over a glass surface (retail window glass 
prepared by float-technique) with a slow constant speed. 
 
2.2.2.2 Freeze-drying 
Lyophilisation is operated in a two chamber freeze-dryer ε12G (Christ, Osterode, 
Germany). Primary packaging material for production of placebo xerogels are petri 
dishes, whereas ACT loaded matrices are produced in 2R glass vials, glass type I 
with Teflon® coated chlorobutyl rubber stoppers.  
 
Chapter 2 – Materials and Methods 
- 47 - 
2.2.2.3 Warm air drying 
For manufacture of polymer films the warm air dryer reported earlier165 is used 
(Barkey GmbH & Co. KG, Leopoldshöhe, Germany) (Fig. 2-4). 
 
 
Fig. 2-4 Warm air drier for vials and eppendorf caps;  
 
Drying is performed with dry and tempered nitrogen gas injected through nozzles 
into heated vials. All temperatures are set to 25°C. Nitrogen flow rate is 1.0 l/min 
at a pressure of 0.5 bar. 
 
2.2.3 Characterisation of matrices 
2.2.3.1  Viscometry 
Viscometric measurements on hydrogels with pseudoplastic behaviour are 
conducted on a rotating cylinder viscometer DV-II+ (Brookfield, Middleboro, 
USA). Complex rheology is measured with a MCR 100 cone plate viscometer 
(PaarPhysika, Ostfildern, Germany). Therefore, a cone (50mm in diameter, 1° 
angle; CP 50-1) is used at an oscillation frequency of 10 1/s. 
 
2.2.3.2 Mechanical tests  
The mechanical properties of the matrices are evaluated using a Texture Analyser 
model TA.Xtplus (Stable Microsystems, Godalming, UK). 
Compression test method - For compression tests on xerogels a cylindrical probe of 
0.5” in diameter is used. The compression strain is set to 50% deformation, 
crosshead speed is 1mm/min.  
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Tensile test method - The test apparatus for measuring the tensile strength of films 
consists of two mechanic grips and the test procedure is based on the ASTM 
D822-75 method. The extension speed is 1mm/min. Film specimens which break 
directly at the grips are discarded.  
Puncture test method – Films are punctured by a driving ball probe of 0.5” in diameter. 
Fixation of the specimen is provided by a film holder. The dry rectangular film 
specimens are positioned between two mounting plates and are fixed with four 
screws. The plates contain a hole of 22mm in the centre. The ball probe is driven 
downwards through the mounted film at a crosshead speed of 1mm/min. The 
calculation of the nominal puncture strength and the elongation at rupture is 
comparable to the tensile test method. However, the elongation is based on the 
displacement of the radius instead of the length. 
 
2.2.3.3 In vitro Release tests 
Release tests are performed in vitro by using a modified Loth chamber134. The 
chamber body consists of Plexiglas®. Associated material is an IPC 12 channel hose 
pump (Ismatec, Wertheim, Germany), tubing material (Tygon R3603), cellulose 
acetate membrane filters 0.45µm (Sartorius, Göttingen, Germany), and 2ml syringes 
(HSW, Tuttlingen, Germany). 
 
2.2.3.4 Karl Fischer Titration 
Residual moisture is determined via coulorimetric Karl Fischer titration with 
generating the iodine electrolytically to keep the reaction ongoing. Therefore, a 
coulorimetric Karl Fischer titrator with a head space oven is used (Analytik Jena 
AG, Jena, Germany). Sealed samples are heated to 80°C in the oven chamber. For 
measurement the vaporised water is transported into the coulorimetric cell filled 
with Hydranal® Coulomat AG (Riedel-de Haen) via a needle system. 
 
2.2.3.5 Differential scanning calorimetry (DSC) 
Measurements (DSC 204, Netzsch, Selb, Germany) are performed using 5mg to 
10mg of sample. Heating and cooling were conducted at a scan rate of 5 K/min 
from 25°C to 100°C. 
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2.2.3.6 X-ray diffraction 
Wide-angle X-ray scattering (WAXS) was performed by an X-ray Diffractometer 
XRD 3000TT, (Seifert, Ahrensburg, Germany) equipped with a copper anode 
(40kV, 30mA, wavelength 0.154178 nm). Experiments were conducted at a scan 
rate of 2 theta = 0.05° in a 5° to 40° range. 
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3  Results and Discussion 
The development of ACT for topical delivery into wound sites is mainly diverted 
into stabilisation studies on ACT and the development of the (placebo) carrier 
systems. Thereby, the application forms of solution, hydrogel, xerogel, and polymer 
film are run through. During all these stages on the one hand the aspects of the 
delivery vehicle, namely its suitability for protein stabilisation, as its suitability for 
wound treatment, are investigated. And, on the other hand the aspects of ACT 
stabilisation and later the release of ACT are researched. 
In detail, after a discussion of analytical tools the stabilisation of ACT in solutions 
is described in a first section. Secondly, the development of particular hydrogels for 
wound treatment and the stabilisation of ACT within these hydrogels is discussed. 
A third section outlines the xerogel formation by lyophilisation of the named 
hydrogels. Moreover, again the suitability of xerogels for application on wounds 
and their ability to stabilise ACT is researched. The fourth section discusses 
polymer films as alternative to xerogels with similar aspects. Further, the release of 
ACT from the preparations is summarised in a fifth section.  
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3.1  Analytical tools for the characterisation of ACT 
during formulation development 
This section describes evaluations for the characterisation of ACT during 
formulation development.  
Due to its unique mode of action described in chapter 1 and the fact that its native 
and active state represents only a state with a relative minimum of free energy, ACT 
is likely to be prone to deactivation by refolding to the non-active energy minimum 
state and dimerisation or formation of higher order aggregates by entanglement of 
the loops of two ACT molecules during loop movement. 
Analytical tools therefore have to be chosen to mainly detect inhibitory activity and 
aggregate formation of ACT. Furthermore, it is desirable to characterise the tertiary 
structure especially the folding behaviour of ACT during experiments. 
Unfortunately, the low concentration of ACT in measurable samples (1µg/ml to 
60µg/ml) and low sample amounts resulting from high drug prices lead to 
unsuitability of many standard methods for these tasks due to inappropriate 
detection limits and minimal sample volumes135.  
These methods include separation methods with UV-detection, i.e. reversed phase 
liquid chromatography, size exclusion chromatography, capillary electrophoresis, 
and asymmetric flow field-flow fractionation. Further, several analytical methods 
describing protein structure, such as fourier transform infrared spectroscopy, 
circular dichroism, and differential scanning calorimetry are not able to generate 
sensible signals for ACT in the required concentration. So is the case with turbidity 
and particulate matter detection. 
Thus, the immunochemical methods outlined in chapter 2 are used for routine 
detection because of their high specificity and lowest detection limits. However, 
these methods hold high error and standard deviation compared to e.g. established 
chromatographic methods. The activity assay based on a cathepsin 
G/ACT/antibody sandwich and a linked colour reaction is used to determine in 
vitro inhibitory activity of ACT. Further, the ELISA is used for determination of 
total ACT content during release experiments. Moreover, a SDS-PAGE method 
with coomassie blue detection is used for quantitative detection of aggregation and 
fragmentation in selected samples. Hereby, it has to be kept in mind that SDS-
PAGE is suitable for aggregates formed by covalent binding but non-covalently 
bound aggregates may be undiscovered. 
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3.2  Stabilisation of ACT in solution 
As a first step in formulation development, short-term stability studies on ACT in 
aqueous solution are reported. Therefore, the aim of that series of experiments is to 
identify buffer and pH conditions, stabilising additives, and other suitable technical 
ingredients. Hereby, both thermal stress and freeze/thaw (F/T) stress conditions 
are investigated. The outcome is used as an approach to further formulation 
development, but if appropriate the formulations at this stage also can be used as 
early formulation for e.g. animal experiments or toxicology testing itself. 
Samples are prepared in aliquots of 0.1ml with 60µg/ml ACT content in eppendorf 
caps and are stressed either at 40°C in an air bath or by freeze/thawing in liquid 
nitrogen and room temperature, respectively. Readout is done by activity assay and 
SDS-PAGE for some samples.  
 
3.2.1  Effects of pH, buffers, and electrolytes on ACT 
solution stability 
The pH is a very powerful tool to control both the physical stability136 and the 
chemical stability of protein drugs by its well known general influence on chemical 
reactions.  
Electrolytes including buffer salts can affect a protein solution by indirect 
mechanisms like changing the solvent properties or a non-specific electrostatic 
shielding effect. Besides, very specific ion binding phenomena between salts and 
protein are known137. These effects can also stabilise, behave inert and destabilise 
the protein in solution, respectively, depending on the definite situation in the 
formulation. Moreover, the content of salts can effect protein stability directly by 
hydrophilic or hydrophobic interactions depending on their position in the 
Hoffmeister lyotropic series138,139. Exceeding the above mentioned, bi- or 
polyvalent ions can bind to charged positions within the protein molecule, but may 
also catalyse oxidative reactions or bind catalysers, e.g. by chelation, which can 
result in both stabilisation and destabilisation, respectively. 
 
3.2.1.1  Effect of pH on ACT solution stability 
For the investigation of the effect of pH on its stability ACT is formulated in a 
buffer solution containing 50mM potassium phosphate. The pH is adjusted with 
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potassium hydroxide to prevent the known pH shift phenomena of sodium 
phosphate buffered systems during freezing in later experiments140,141. For the 
temperature studies each sample is kept on an elevated stress level of 40°C for 5 
days. As described, analysis is carried out by activity assay and SDS-PAGE.  
The results of recovered activity after stressing show a strong dependency of ACT 
activity on the pH of the solution. In the acidic region up to a pH value of 5.5 
almost no activity can be measured. But there is activity between 50 to 60 % 
recovered around the neutral point peaking between pH 7.0 and 7.6 (Fig. 3-1).  
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Fig. 3-1 pH stability profile of ACT in 50mM potassium phosphate buffer after a 5 days 
storage at 40°C measured by activity assay; 
 
Gel electrophoresis also detects pH dependent degradation. In acidic buffer 
samples the fragment bands are striking. Lane 2 of Fig. 3-2 show the main fraction 
of 85% at the monomer band at around 60kDa, an aggregate band at about 
100kDa to 120kDa representing 9.7% of total content, and two fragment bands 
with 4.7% of total content each at approx. 40kDa and 20kDa molecular weight. 
Similar fragmentation is seen in lane 1. In neutral and basic pHs, lane 3 to 6 of Fig. 
3-2, solely the aggregate band can be seen. 
 
Taking results together it can be concluded that in acidic pHs fragmentation as well 
as aggregation leads to inactivation of ACT. In the neutral and basic regions mainly 
aggregation is responsible for loss of activity.  
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Fig. 3-2 pH dependent stability of ACT in 50mM potassium phosphate buffer after a 5 days 
storage at 40°C measured by SDS-PAGE:  
lane 1: pH 2.2 with 0.5% 100kDa aggregate, 3.2% 40kDa, 0.7% 20kDa fragments; lane 2: pH 
4.5 with 9.7% 100kDa aggregate, 3.8% 40kDa, 0.9% 20kDa fragments; lane 3: pH 6.5 with 
8.5% 100kDa aggregate; lane 4: pH 7.4 with 4.7% 100kDa aggregate; lane 5: pH 8.0 with 
2.5% 100kDa aggregate; lane 6: pH 11.0 with 1.7% 100kDa aggregate; lane 7: marker;  
control without degradation is visualised in Fig. 3-4; 
 
But, one may recognise that although practically no activity is determined in the 
acidic, the main fraction of ACT is still detected as monomer in gel electrophoresis. 
This might be due to the fact that SDS-PAGE is solely sensitive to aggregates with 
covalently bound monomers because non-covalent aggregates are dissociated by 
the preparation with SDS. The latter thus are also detected as monomers. Granted 
that ACT forms inactive, non-covalent aggregates in the first part the given results 
could be explained. And, this is very likely due to the mode of action of ACT 
described in chapter 1. Another explanation instead could be the formation of 
monomeric inactive forms of ACT during stressing by refolding to the inactive 
state of minimum energy which unfortunately can not be further detected due to 
the described analytical problems (section 3.1). This interpretation is also feasible 
for the neutral and basic pHs because the detected amount of aggregates of around 
10% is by far lower than the inactive ACT amount calculated from activity assay 
being about 40 to 50%. 
 
For exact determination of the pH-optimum between pH 7.0 and 7.6 a kinetics 
study is done over a period of twelve days in a narrower pH spectrum. Activity 
there decreases according to first order kinetics. Thus, a logarithmic curve can be 
fitted to the results with its slope indicating the activity loss rate. So, the rate is 
almost constant between pH 7.0 and 7.4 indicated by similar values for the slope of 
the fitted function. But, at pH 7.6 a higher rate is detected by a larger negative slope 
(Tab. 3-1). As a result, the optimum pH for temperature studies is ascertained to 
pH 7.2 representing the centre of a plateau of constant low decrease rate. 
100 kDa 
 
60 kDa 
 
40 kDa 
 
20 kDa 
1            2        3          4          5         6          7
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pH slope of logarithmic curve R2 
7.0 - 38.7 0.979 
7.2 - 42.6 0.994 
7.4 - 44.9 0.996 
7.6 - 55.5 0.993 
 
Tab. 3-1 Slope and correlation coefficient of the fitted logarithmic first order kinetics equation 
on pH stability kinetics of ACT in 50mM potassium phosphate buffer after a 12 days storage 
at 40 °C measured by activity assay; 
 
A similar setting as for the temperature stress study is performed for the F/T tests 
consisting of 5 cycles of freezing in liquid nitrogen and thawing at room 
temperature. The resulting curve of recovered activity like above shows values of 
around 60% between pH 7.2 and 7.6 and a total loss in the acidic region (Fig. 3-3). 
Again, gel electrophoresis indicates dimer formation during the F/T stressing (Fig. 
3-4). 
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Fig. 3-3 pH stability profile of ACT in 50mM potassium phosphate buffer after 5 F/T cycles 
in liquid nitrogen and 25°C, resp. measured by activity assay; 
 
As a matter of fact, the working pH for further studies is determined at pH 7.2. It 
is located in the centre of an area of low decrease rate for both stress types. That is 
why not only the stabilising effect of the solution is maximised but due to the 
plateau also the best possible robustness against small accidental changes of pH 
within the system is created. 
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Fig. 3-4 SDS-PAGE gel for evaluation of freeze/thaw stress dependent stability of ACT in 
50mM potassium phosphate buffer pH 7.2 after 5 F/T cycles: 
lane 1 F/T stressed sample with 9.8% 100kDa aggregate; lane 2 unstressed control sample 
without fragment and aggregate formation; lane 3 marker; 
 
3.2.1.2  Effect of buffer species on ACT solution stability 
As a consequence of the foregoing section, a choice of buffers with a maximum 
capacity around the neutral point is tested at the pH level of 7.2. The content of 
buffer for the F/T-stress is lowered to 10mM instead of 50mM in the temperature 
treated samples. 
For the temperature stress as well as for the F/T-stress next to the phosphate 
buffer, also TrisHCl and a phosphate/citrate mixture show comparable recovered 
relative activities and therefore comparable stabilisation characteristics (Tab. 3-2). 
As a result, these systems act as alternatives to the standard phosphate buffer for 
future development. 
 
buffer pH 7.2 stress condition rel. activity [%] ±sd 
50mM phosphate 40°C/9 days 78.2±0.5 
50mM TrisHCl 40°C/9 days 68.5±5.1 
25/25mM phosphate/citrate 40°C/9 days 80.2±6.8 
10mM phosphate F/T/5 cycles 42.5±7.2 
10mM TrisHCl F/T/5 cycles 41.0±7.1 
10/10mM phosphate/citrate F/T/5 cycles 46.1±4.5 
 
Tab. 3-2 Recovered relative activities of ACT after temperature and freeze/thaw stress in 
dependence of the buffer system measured by activity assay;  
 
The phosphate/citrate mixture is further investigated concerning the relation of 
concentration of the components. Hence, for temperature stress to a 25mM 
phosphate buffer increasing amounts of citrate resulting in concentrations from 
10mM to 50mM are added. For F/T treatment the contents are lowered to 5mM 
phosphate and 2mM to 20mM citrate. 
100 kDa 
 
60 kDa 
1        2      3 
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Results after temperature stressing at that point do not show remarkable 
differences. However, for the freeze/thaw stress an optimum arises for low, 5 to 
10mM, citrate contents (Fig. 3-5). So, an equimolar buffer appears the best choice 
for the phosphate/citrate mixture. 
To summarise, to date the phosphate buffer pH 7.2 is chosen as standard buffer, 
but the TrisHCl system and the equimolar phosphate/citrate mixture can also be 
considered if advantage or necessity arises during further development. All buffer 
systems are approved by FDA for injection up to a content of 1% at least which 
represents solutions of 70mM to 80mM.  
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Fig. 3-5 Recovered relative activities of ACT after 9 days at 40°C storage in 25mM phosphate 
buffer and varying citrate contents (○) and after 5 F/T cycles in 5mM phosphate buffer and 
varying citrate contents (▲) measured by activity assay; 
 
3.2.1.3  Effect of salts on ACT solution stability 
For the use as osmotic agent during formulation and for general use, e.g. during 
drug substance manufacturing, a variety of salts is tested in temperature stress tests. 
Samples are buffered in 50mM potassium phosphate buffer pH 7.2 and salts are 
added resulting in concentrations of 100mM, except 10mM for magnesium 
chloride and EDTA sodium. Other than before, stressing at 40°C lasts for 6 days 
for technical reasons. 
As a result, none of the samples shows a major change of activity after stressing 
compared to the untreated material and therefore all of them can be used with 
ACT. Besides, generally, all tested salts are compatible with the assay, but the 
differences between some controls could be related to assay interaction or in the 
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case of sodium containing samples to pH changes during freezing for 
transportation (Fig. 3-6).  
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Fig. 3-6 Recovered relative activity of ACT in 50mM potassium phosphate buffer pH 7.2 with 
different salt additives before (above) and after (below) a 6 days storage at 40°C measured by 
activity assay; 
 
3.2.1.4  Effect of buffer content and osmolarity on ACT solution 
stability 
Next, the optimal phosphate buffer content and total osmolarity for an ACT 
stabilising solution is to be determined.  
In order to investigate the influence of these two closely related factors of the 
solution on ACT activity under temperature stress a factorial experimental design is 
created. The first relevant factor is the concentration of the potassium phosphate 
buffer system. It is varied from a minimum of 5mM to a maximum of 100mM. The 
other factor is the concentration of potassium chloride as osmotic agent, hereby 
being 0mM the low value and 100mM the high value. With these two factors a 
simplex-lattice design of 3rd order degree, i.e. on four levels, is calculated by the 
Statistica 6.1 software. For interpretation a 2nd degree multiple regression is carried 
out resulting in a corresponding response surface function (Fig. 3-7). 
For the pure buffer samples (Fig. 3-7 edge behind on left) an increase of activity is 
measured from the minimum to about 25mM of phosphate concentration. To 
higher pure buffer contents more or less a plateau on high level can be seen. 
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Osmolarity there is determined between 150mosm/kg and 200mosm/kg. The 
addition of KCl as osmotic agent works counterproductive in most cases. Only 
with very low buffer contents of 10mM to 20mM an improvement of stability of 
ACT can be obtained by an optimum concentration of KCl which is around 
50mM. For these samples osmolarity is measured as 154mosm/kg. In conclusion, 
the favourable range of osmolarity is supposed to be between 150mosm/kg to 
200mosm/kg. Unless, except for the case of low buffer contents the addition of an 
osmotic agent is not necessary and recommended.  
Recovered activity values in this chart for technical reasons exceed the values from 
former experiments. This arises from the reference to a different control sample 
with a lower measured activity.  
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Fig. 3-7 Response surface calculated from recovered relative activities of ACT in samples 
with potassium phosphate buffer pH 7.2 and salt (KCl) contents according to a simplex-lattice 
design after temperature treatment – 40°C for 9 days;  
 
For F/T-studies on the buffer and electrolyte content solely the buffer 
concentration is altered without further addition of electrolytes. 5 cycles of the 
usual F/T-stressing are performed. From the recovered activity curve against 
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buffer concentration a clear maximum at 10mM can be determined (Fig. 3-8). 
Therefore, in contrast to temperature studies a lower buffer content is to be used.  
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Fig. 3-8 Recovered relative activities of ACT after 5 F/T cycles in varying potassium 
phosphate buffer contents pH 7.2 measured by activity assay; 
 
3.2.1.5  Summary of the effects of pH, buffer, and electrolytes on 
ACT solution stability 
During the experiments of this section buffer systems and electrolyte contents of 
an ACT stabilising solution are investigated. In detail, optimal pHs, buffer species, 
buffer contents, compatible salts and suitable buffer/salt combinations are 
evaluated.  
In fact, for temperature stress a potassium phosphate buffer concentration of 
50mM at a pH of 7.2 and for F/T stress a 10mM phosphate buffer at same pH is 
to be recommended. For temperature stress, alternatively, a solution containing 
20mM phosphate buffer and 50mM potassium chloride is suitable. Despite, for 
further development the pure buffer alternatives are determined as standard buffer 
systems. 
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3.2.2 Effects of stabilisers and excipients on ACT solution 
stability 
In this section protein stabilisers are screened in the same manner as the 
buffer/electrolyte systems. Besides, substances able to stabilise during drying 
processes and substances for other technical purposes are tested in this setting.  
The basis for the samples are 0.1ml solution of 60µg/ml ACT in a 50mM 
potassium phosphate buffer pH 7.2 for temperature stressing and a reduced buffer 
content of 10mM for the freeze/thaw experiments. 
In literature, various stabilisers different in their chemical structure and mode of 
action are described137. In the course of this work, theses substances have to be 
applicable on open wounds next to their ability to stabilise. So additionally, for a 
first consideration the regulatory status of the substances is taken into account.  
The following is dealing with the testing of surfactants, sugars, polyols, 
cyclodextrins, amino acids, and preservatives. Polymeric adjuvants are described in 
a later section (3.3.2.1). 
 
3.2.2.1  Surfactants for the stabilisation of ACT in solution 
Besides their ability to reduce surface tension in liquids surfactants are known to 
bind at hydrophobic surfaces142, gas-liquid interfaces143 and at the protein molecule 
itself mostly at hydrophobic areas144. Therefore, mechanisms of protein protection 
by surfactants based on a competitive situation for adsorption on denaturing 
interfaces between protein and surfactant are discussed145. Further, a mechanism 
relating to a direct binding of the surfactant to the protein, marked by a higher 
necessary concentration of surfactant that depends on the protein content in the 
solution has been reported146. But surfactants are also able to prevent chemical 
degradation in some cases 147. Ionic surfactants are usually avoided because of their 
ability to bind to polar as well as to unpolar groups and therefore denature proteins 
148. For that reason only a choice of non-ionic surfactants is investigated in this 
study.  
Tween® 80, Poloxamer® 188, and Solutol® HS15 are added to the standard 
phosphate buffer to a maximum content of 0.2%.  
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Fig. 3-9 Recovered relative activity of ACT in dependence of the concentration of surfactants 
in ACT samples in 50mM potassium phosphate buffer after a 9 days storage at 40°C 
measured by activity assay; : Poloxamer® 188, : Tween® 80, : Solutol® HS15; 
 
In the temperature stress Solutol HS15 causes a severe decay in ACT activity in all 
tested concentrations. For that reason, Solutol HS15 appears to be completely 
incompatible with ACT and the investigation on that surfactant is stopped here. 
Poloxamer 188 and Tween 80 are compatible with the protein and moreover can 
effectively improve its stability particularly when surfactant content exceeds 0.1% 
(Fig. 3-9). 
 
In the corresponding F/T-stress experiments the effect is even more convincing. 
One may notice that the control is close to zero when the stress level hereby is 
raised to 15 F/T cycles. Indeed, Poloxamer® 188 and Tween® 80 completely 
prevent the ACT activity loss even at 15 F/T cycles. Hereby, Poloxamer® 188 is 
effective from 0.05% and Tween® 80 from 0.1% (Fig. 3-10). 
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Fig. 3-10 Recovered relative activity of ACT in dependence of the concentration of 
surfactants in ACT samples in 10mM phosphate buffer pH 7.2 after 15 F/T cycles measured 
by activity assay; above: Tween® 80; below: Poloxamer® 188; 
 
To sum up, the tested surfactants Poloxamer® 188 and Tween® 80 prove high 
efficiency in stabilising ACT during temperature and even more in F/T stressing. 
Hereby, a concentration of 0.1% is recommended representing a compromise 
between stabilising efficiency and physiological tolerance. The regulatory status of 
these two surfactants is satisfactory. Poloxamer® 188 is approved by FDA to a 
maximum potency of 0.6% for intravenous injection and 0.3% for subcutaneous 
injection149, whereas Tween® 80 is approved also by FDA to a maximum potency 
of 0.2% for intralesional injection and 8% for intravenous injection149. Solutol® 
HS15 destabilises ACT and is therefore unsuitable for further studies. 
 
3.2.2.2 Sugars and polyols for the stabilisation of ACT in solution 
Sugars and the related groups of polyols are very often reported as non-specific 
protein stabilisers. Applied in a concentration of at least 5% their stabilisation 
mechanism is interpreted as a preferential exclusion phenomenon150,151. Though, in 
some cases sugars and polyols can as well inhibit chemical degradation by 
complexation effects in a similar way as polyvalent ions. However, because of the 
well known Maillard reaction between amino groups and reducing sugars only non-
reducing sugars are considered152. For the use as stabilisers in solution and in 
prospect of the use in later manufacturing steps, e.g. as bulking agents in freeze-
drying, a variety of sugars and sugar alcohols is tested in this section.  
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Samples based on 0.1 ml 60µg/ml ACT solutions in standard phosphate buffers 
pH 7.2 are loaded with excipient to a resulting concentration of 5% sugar and 
polyol, respectively. Stressing is done at 40°C for 9 days. 
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Fig. 3-11 Recovered relative activity of ACT in 50mM potassium phosphate buffer pH 7.2 
with sugar/polyol additives before (above) and after (below) a 9 days storage at 40°C 
measured by activity assay; 
 
Despite the well known stabilising effects of sugars, the preservation of ACT 
activity by these additives is quite disappointing. All samples without stressing are 
in comparable range with the control without excipient. Thus, the tested substances 
are compatible with the assay. Therefore, the huge losses of activity during stressing 
at 40°C are proven to be due to a destabilising effect on ACT. Only the sugar 
alcohol samples containing mannitol and sorbitol are in comparable range with the 
control sample in heat stressing and thus can be considered as inert. 
In the corresponding F/T experiments (data not shown) none of the candidates 
shows stabilising effects on ACT.  
Consequently, only mannitol and sorbitol though having no stabilising potential 
can be considered to be added to an ACT formulation for technical reasons. Also, 
the regulatory status of these substances is satisfactory. Mannitol is approved by 
FDA to a maximum potency of 13% for intravenous injection and 10.66% for 
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intralesional injection149. Sorbitol is approved also by FDA to a maximum potency 
of 45% for intralesional injection and 30% for intravenous injection149.  
 
3.2.2.3 Cyclodextrins for the stabilisation of ACT in solution 
Cyclodextrins are cyclic oligosaccharides consisting of six, seven, and eight glucose 
monomers, respectively. Nomenclature corresponds to the molecule size rising 
from α-CD to β-CD to γ-CD. In the ring the polar hydroxyl groups are located on 
the outside, whereas the etherlike oxygen atoms in the inside form a nonpolar 
cavity. The exterior allows cyclodextrins to dissolve in water while the cavity forms 
inclusion complexes with hydrophobic molecules, e.g. the hydrophobic residues in 
proteins. Depending on the number of glucose units the cavity grows from α- to β- 
to γ-CD. So, the size relation of cavity and including molecule also influences 
complex characteristics. This way of complexation can affect the protein in two 
ways. On the one hand, it can stabilise the unfolded state of proteins by 
intercalating the hydrophobic residues in proteins. On the other hand, by 
intercalating these hydrophobic residues it can prevent proteins from 
aggregation153,154. 
In the stability study, α-, β-, Hydroxypropyl-β-, and γ-cyclodextrin are tested. As 
above, samples based on 0.1ml 60µg/ml ACT solutions in standard phosphate 
buffers pH 7.2 are loaded with cyclodextrin to a resulting concentration of 2% 
which means a major excess of cyclodextrin based on molecular numbers. Stressing 
is done at 40°C for 9 days.  
Again, all unstressed samples are in comparable range (Fig. 3-12 above) indicating 
all additives being compatible with the assay. The stressed samples of β-, HP-β-, 
and γ-CD are comparable with the stressed control sample (Fig. 3-12 below). Solely 
in the α-cyclodextrin samples a remarkably reduced recovered activity is measured. 
Therefore, α-CD proves to destabilise ACT, whereas the other derivatives are more 
or less indifferent against ACT activity after temperature stressing.  
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Fig. 3-12 Recovered relative activity of ACT in 50mM potassium phosphate buffer pH 7.2 
with cyclodextrin additives (2%) before (above) and after (below) a 9 days storage at 40°C 
measured by activity assay; 
 
The non-destabilising cyclodextrins are further tested in F/T studies. The testing is 
conducted in 0.1ml ACT solution 60µg/ml in 10mM phosphate buffer at a stress 
level of 15 F/T cycles with 2% cyclodextrin. In this test, β-cyclodextrin and, most 
notably, HP-β-cyclodextrin achieved remarkable stabilising effects. On the 
contrary, γ-CD is not very effective in this stress situation (Fig. 3-13).  
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Fig. 3-13 Recovered relative activity of ACT in dependence of cyclodextrin addition (2%) in 
ACT samples in 10mM potassium phosphate buffer pH 7.2 after 15 F/T cycles measured by 
activity assay; 
 
For HP-β-CD an additional experiment investigating the concentration dependence 
is conducted. Thus, a concentration series from an equimolar ratio to a 100-fold 
excess in molarity of cyclodextrin (0,015%) over ACT is tested in the same F/T 
setting. This shows an increasing protection up to a nearly complete recovery for 
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HP-β-CD detected for the maximum concentration (Fig. 3-14). Therefore, a 
stabilising interaction of HP-β-CD with ACT can be postulated, but an estimation 
of coordination numbers is not possible. Rather, an equilibrium between complex 
and dissociated molecules is to be supposed, whereby the necessary excess of HP-
β-CD pushes the equilibrium towards the stabilising complex. 
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Fig. 3-14 Recovered relative activity of ACT in dependence of HP-β-cyclodextrin 
concentration in ACT samples in 10mM potassium phosphate buffer pH 7.2 after 15 F/T 
cycles measured by activity assay; data points correspond to molecular ratios of ACT : HP-β-
CD being 1:0, 1:1, 1:5, 1:10, 1:20, 1:50, 1:100; 
 
 
 
Fig. 3-15 HP-β-CD concentration dependent stability of ACT in 10mM potassium phosphate 
buffer pH 7.2 after 15 F/T cycles measured by SDS-PAGE:  
Concentration is given in molecular ratio ACT : HP-β-CD; lane 1: 1:1, 11% aggregate; lane 2: 
1:5, 8.5% aggregate; lane 3: 1:10, 5.8% aggregate; lane 4: 1:50, 3.2% aggregate; lane 5: 
1:100, 1.5% aggregate; lane 6: untreated control; lane 7: marker; 
 
From this experimental setup, additionally, readout by SDS-PAGE is operated. It 
indicates a decrease in aggregate detection with rising HP-β-CD content (Fig. 3-15 
lanes 1 to 5) by thinning 100kDa bands. Most remarkable, like in the other read 
1         2         3        4         5        6          7
100 kDa 
 
60 kDa 
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outs, the amount of lost activity in the activity assay and the detected aggregates by 
SDS-PAGE are not in the same magnitude.  
 
Therefore, HP-β-CD can be used as stabiliser mainly for F/T stabilisation. 
Concentration is tested suitable between 0.015% and 2%. But, HP-β-CD is 
approved by FDA for intravenous injection to a maximum potency of 0.4%149. 
 
3.2.2.4 Amino acids for the stabilisation of ACT in solution 
As sugars and sugaralcohols amino acids are supposed to be able to stabilise 
proteins by preferential exclusion. Moreover, in special cases some amino acids 
inhibit chemical degradation, e.g. methionine may work as antioxidant and so 
reduce oxidative degradation of the protein. For these purposes, a selection of 
amino acids already used in protein stabilisation are investigated137. 
The 50mM phosphate buffers are produced with a 2% addition of the particular 
amino acid. The pH of 7.2 then is adjusted with potassium hydroxide. Stressing is 
done on 0.1ml 60µg/ml ACT solutions at 40°C for 9 days.  
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Fig. 3-16 Recovered relative activity of ACT in 50mM potassium phosphate buffer pH 7.2 
with different amino acids before (above) and after (below) a 9 days storage at 40°C 
measured by activity assay;   
 
All tested substances are interoperable with the assay indicated by the untreated 
samples being in the same range as the buffer control (Fig. 3-16 above). Among the 
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stressed samples glycine, alanine, arginine, and lysine allow hardly any damage to 
ACT activity during temperature stressing. On the contrary, the sulphur containing 
amino acids methionine and cysteine drop out as well as phenylalanine (Fig. 3-16 
below).  
From this experiment readout by SDS-PAGE is conducted. In the presence of 
methionine, phenylalanine, and lysine fragments in amounts smaller 10% are 
observed. With methionine, phenylalanine, cysteine, glycine, and alanine dimer 
amounts of 1.4 to 21.6% are detected (Fig. 3-17).  
Although SDS-PAGE again only roughly correlates with activity assay results, it 
can be concluded that arginine, glycine, and alanine perform best in both analytical 
techniques.  
 
 
 
Fig. 3-17 SDS-PAGE gel on influence of amino acids on stability of ACT in 50mM 
potassium phosphate buffer pH 7.2 after thermal treatment (9 days, 40°C): lane 1: methionine 
9.6% dimer, 1.2% fragment; lane 2: arginine only monomer; lane 3: phenylalanine 4.5% 
dimer, 3.6% fragment; lane 4: lysine 6.7% fragment; lane 5: cysteine 21.6% dimer; lane 6: 
glycine 1.4% dimer; lane 7: alanine 3.6% dimer; lane 8: marker; 
 
Unfortunately, during F/T experiments the tested amino acids did not show any 
stabilising effect (data not shown). 
For its proven stabilisation on ACT and its known stabilisation qualities during 
protein drying arginine was chosen to be examined in further concentration 
studies155. This series was studied in the same setting as described above. The 
results curve shows a clear optimum at 10mM (Fig. 3-18), because the measured 
ACT activity after thermal treatment is at its maximum at that point.  
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Fig. 3-18 Recovered relative activity of ACT in 50mM phosphate buffer pH 7.2 with different 
arginine contents after a 9 days storage at 40°C measured by activity assay;   
 
Indeed, arginine can be used for stabilisation of ACT at an optimal concentration 
of 10mM, correspondent to 0.17%. FDA approval is given for up to 88% for 
intravenous injection149. 
 
3.2.2.5 Preservatives for ACT containing solutions 
Finally, a choice of parenterally usable preservatives is tested as excipients in this 
series. In the standard phosphate buffer the following substances are tested: 1% 
benzyl alcohol, 0.1% 4-chloro-m-cresol, and a paraben mixture, i.e. p-
hydroxybenzoic acid methyl ester/ p-hydroxybenzoic acid propyl ester 
0.1%/0.04%.  
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Fig. 3-19 Recovered relative activity of ACT in 50mM potassium phosphate buffer pH 7.2 
with preservatives before and after a 9 days storage at 40 °C measured by activity assay;   
 
Unfortunately, these substances are not interoperable with the assay because 
neither the unstressed samples nor the stressed samples show remarkable activity 
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(Fig. 3-19). So, no information about their behaviour against ACT can de obtained. 
Due to this interference with analysis, these preservatives cannot be used in a 
formulation for ACT. 
 
3.2.3 Summary of ACT solution stability studies 
In the course of this chapter the stabilisation of ACT in solution is evaluated. The 
main degradation pathway for ACT seems to be dimer formation and presumably 
later higher order aggregation. Only in acidic pHs and with some amino acids a 
fragmentation can be seen.  
A pH of 7.2 turned out to be the best choice for a buffered solution. However, the 
optimal range of pH values is very narrow. First of all, low pH levels can harmfully 
damage, fragment and inactivate ACT. So, for application on a wound site which 
can provide an acidic pH a buffer system is recommended in the delivery device to 
guarantee suitable pH for non-liberated protein. Therefore, phosphate, Tris, and 
phosphate/citrate buffers can be used. For phosphate the optimal content and 
relating osmolarity have been examined. Moreover, from a variety of substances 
surfactants, cyclodextrins, and amino acids have proven stabilising potential on 
ACT.  
 
 stabiliser liquid solution frozen solution 
buffer 50mM potassium phosphate pH 7.2  
  
alternative: 20mM potassium phosphate /  
50mM potassium chloride pH 7.2 
 10mM potassium phosphate pH 
7.2 
  alternative: Tris HCl pH 7.2   
  alternative: potassium phosphate/citrate pH 7.2   
surfactant 0.1% Poloxamer® 188 0.1% Poloxamer® 188 
  alternative: 0.1% Tween® 80 alternative: 0.1% Tween® 80 
cyclodextrin possibly: HP-β-CD 0.015-2% HP-β-CD 
amino acid 10mM arginine possibly: arginine 
 
Tab. 3-3 Recipes of stabilising aqueous solutions for 60µg/ml ACT in liquid solution (from 
temperature stress study) and in frozen solution (from F/T stress study); 
 
Indeed, depending on the stress type two recipes for stabilising solutions can be 
formulated relating to solutions to be kept in liquid state and frozen solutions, 
respectively (Tab. 3-3). All ingredients are already approved for parenteral use by 
FDA. 
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3.3  Hydrogels as delivery system for ACT into 
wounds 
 
In this chapter the manufacture of hydrogels as ACT loaded delivery devices for 
wound healing is evaluated. Therefore, the gels are optimised concerning their 
sterilisation and rheologics to meet the requirements of wound dressings. And, in a 
second step stabilisation studies of ACT in dependence of the polymer and in the 
total semi-solid formulation are conducted.  
 
3.3.1  Development as delivery system for wound healing 
From the great variety of pharmaceutically relevant polymers156 a selection is 
assembled according to these criteria: 
 
• The polymer is already in use in medical products for wound 
treatment.  
• The regulatory status of the polymer promises uncomplicated 
approval by regulatory authorities for application on open 
wounds.  
• The polymer is readily available to affordable pricings and does 
not require excipients with toxic or protein destabilising potential 
for gelling.  
• The polymer must not release monomers or oligomers during 
(bio-) degradation with disturbing activity on protein stability157. 
 
The resulting choice is listed in Table 3-5. 
Following, in the course of the development of the hydrogel as wound dressing 
material the parameters concerning sterility and mechanical properties have to be 
evaluated.  
Sterility in general can be produced by several well known techniques, but steam 
sterilisation is the most effective and safe method. Therefore, gelling agents and the 
hydrogels made thereof that enable autoclavation without remarkable change in 
properties are in favour for the choice as formulation ingredient. 
The mechanical properties in the first place are described by the rheological 
behaviour of the gel. In detail, the viscosity of the gel has to be adjusted to provide 
proper manufacture and application, and while on the wound site staying in place 
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and providing intimate contact to the wound ground essential for effective drug 
release. 
 
3.3.1.1  Sterilisation of hydrogels 
A variety of gels (Tab. 3-5) is evaluated concerning possible sterilisation methods. 
As outlined above, the first to choose technique for sterilisation of the hydrogels is 
steam sterilisation. Therefore, standard conditions like they are described in the 
pharmacopoeia are used, i.e. a temperature of 121°C at 2 bar steam pressure is 
applied for 15 min.  
From the cellulose derivatives the hydroxyethyl- and the carboxymethyl cellulose 
sodium species are suitable for autoclavation. Resulting gels are homogeneous, free 
of air bubbles, and completely swollen. Moreover, changes of viscosities are 
negligible. Further, xanthan gum and gellan gum can be autoclaved successfully. In 
addition, autoclavation can replace the heat treatment of these polymers obligatory 
for gel formation. 
Besides, alginate gels are liquefied during autoclavation, while methyl-, 
hydroxypropyl- and hydroxymethylpropyl cellulose precipitate due to their well 
known paradox temperature solubility.  
 
3.3.1.2  Viscosity of hydrogels 
Preparations with low viscosity tend to evaporate fast and cannot provide 
satisfactory contact with the wound surface because their tendency to adhere to the 
wound site is too low. A very high viscosity, in contrast, complicates the 
manufacturing processes and a convenient application. So, a reasonable viscosity 
range of the gels has to be determined which is done by comparison with 
commercially available semisolid products indicated for wound treatment. Thus, in 
a first series of experiments a choice of market products is characterised by 
viscosity measurement. As all the measured gels are pseudoplastic, experiments are 
conducted in a Brookfield rotating cylinder viscometer.  
For interpretation of the measurements the rheograms are considered. In these 
diagrams the shear rate χ is drawn against the shear stress σ which results in the 
typical curves. For these gels the power-law (Ostwald-de Waele) for pseudoplastic 
materials is used (Equ. 3-1). The equation is linearised by the logarithm and is 
written as Equ. 3-2. 
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nk χσ ⋅=   χσ lnlnln ⋅+= nk  
    Equ. 3-1     Equ. 3-2 
 
Equ. 3-1&3-2 Power or Ostwald-de Waele law 3-1, in linearised, logarithmic form 3-2 with 
shear stress σ [dyn/cm2 = 10Pa], shear rate χ [1/s], consistency coefficient k [0,1Pa sn], and 
flow behavior index or Power-law exponent n [-]; n<1 meaning pseudoplastic and n>1 shear 
thickening behaviour158; 
 
For graphic interpretation, the measured curves are charted into double logarithm 
plots. The linearised equation (Equ. 3-2) now can be fitted to the results disclosing 
the slope n and the y-intercept ln k. The correlation coefficient R indicates the 
quality of fitting (Fig. 3-20, Tab. 3-4). 
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Fig. 3-20 Rheograms of market products listed in table 3-4 in double-logarithm plot with 
fitted evens; legend and rheological data from fitted function parameters ln k, n, and R2 from 
power law (Equ. 3-2) are listed in table 3-4 
 
  ln k n R2 
Traumon Gel® ▲ 7.37 0.14 0.994 
Traumasept® 7.49 0.19 0.996 
Tyrosur® 7.12 0.17 0.992 
Decoderm Basiscreme® 6.57 0.32 0.954 
Multilind Heilpaste® 7.88 0.09 0.999 
Suprasorb G®  8.27 0.39 0.995 
Askina Braun®  8.34 0.32 0.999 
 
Tab. 3-4 Legend and rheological data from fitted function parameters ln k (consistency 
coefficient, flow behaviour index n, and correlation coefficient R2 from power law (Equ. 3-2); 
 
The resulting even of the rheograms is parallel to a major extend indicating a 
similar flow behavior index n and therefore a similar pseudoplastic flow behaviour. 
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Therefore, the logarithm of the consistency coefficient k (ln k) can be used as 
characteristic parameter for describing viscosity in this context. Ln k of most 
products developed for application on wounds is between 7.0 and 7.5. The 
products with higher ln k values are gels of high viscosity that are difficult to handle 
for further preparations (Tab. 3-4). 
 
Thus, the viscosity of the hydrogels to be developed are adjusted to the lower ln k 
values of 7.0 to 7.5. For that purpose, a set of gels from several gellants is prepared 
always including a concentration series for every gelling agent. Where possible, 
steam sterilisation was carried out before measurement. The corresponding 
rheograms for every gel are determined as above. It has been found that ln k is 
directly proportional to the concentration of most tested gelling agents (Fig. 3-21). 
From that proportion an equation combining ln k and the gellant concentration 
(Equ. 3-3) is gained from linear regression. 
 
( )agentgellingionconcentratBAk ⋅+=ln  
 
Equ. 3-3 Relation of consistency coefficient k and concentration of gellant in tested gels;  
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Fig. 3-21 Ln k values of carboxymethyl cellulose sodium 10.000 (□), hydroxyethyl cellulose 
100.000 (■), and hydroxyethyl cellulose 10.000 (▲) gels in dependence of the gelling agent 
content measured after steam sterilisation; 
 
Following, in a simple calculation using Equ. 3-3 the concentration resulting from 
the required ln k between 7.0 and 7.5 described above is determined for every 
gelling agent. That is the concentration of the gelling agents to be used in the 
manufacture of the hydrogel as wound dressing and drug carrier in following 
studies (Tab. 3-5). 
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Polymer Quality Intercept A 
Slope 
B 
Correlation 
coefficient R2 
Concentration 
(polymer) [%]
Alginate Sodium SF250 4.53 0.58 0.986 4.5 
Carboxymethyl cellulose 
sodium 1.000 1.62 0.98 0.993 6.0 
Carboxymethyl cellulose 
sodium 10.000 2.24 1.04 0.986 5.0 
Carboxymethyl cellulose 
sodium 30.000 0.56 1.41 0.985 10.5 
Carboxymethyl cellulose 
sodium 
cross-
linked 0.37 0.60 0.973 11.5 
Hydroxyethyl cellulose 300 1.74 0.72 0.982 8.0 
Hydroxyethyl cellulose 4.000 2.16 0.89 0.975 6.0 
Hydroxyethyl cellulose 10.000 1.88 0.93 0.978 5.5 
Hydroxyethyl cellulose 100.000 3.00 1.64 0.988 2.5 
Hydroxypropyl cellulose 100.000 4.19 1.07 0.999 2.5 
Hydroxypropylmethyl 
cellulose 15.000 4.14 0.96 0.989 3.5 
Hydroxypropylmethyl 
cellulose 100.000 4.3 1.28 0.998 2.5 
Methyl cellulose 1.000 1.18 0.82 0.999 7.0 
Carboxymethyl starch sodium  5.82 0.20 0.981 8.5 
Gellan gum LT100 5.31 1.22 0.992 1.5 
Gellan gum F 5.26 1.18 0.985 1.5 
Xanthan gum  0.26 5.35 0.978 7.0 
Polyacrylate Sodium Carbopol 940 6.21 1.04 0.975 1.0 
Polyvinyl pyrrolidone Kollidon 90F -1.04 0.24 0.998 35 
Polyethylen glycol 20000 -6.2 0.19 0.998 72 
 
Tab. 3-5 Gelling agents, regression parameters, and determined concentration to be used in 
wound healing gels; 
 
3.3.1.3  Viscosity of gellan gum/hydroxyethyl cellulose hydrogels 
Since gels are mobile they offer the advantage of intimate contact with the surface 
of a wound, but this advantage is, however, tempered by the conflicting needs of 
making the gel sufficiently mobile for application but viscous enough to prevent 
fast flow out of the wound under the influence of gravity. The latter disadvantage 
of free-flowing gels could be overcome by crosslinking of polymers, but this 
implies major challenges for manufacturing and application.  
Hence, the rheology of gellan gum could be a back door out of this dilemma 
because it is sensitive to monovalent cations, i.e. gellan gum forms non free-flowing 
but very brittle hydrogels in the presence of e.g. sodium and potassium salts.  
This is described by the flow curve of such preparations in comparison to a 
hydroxyethyl cellulose gel (Fig. 3-22). 
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For this purpose the rotating cylinder method in the Brookfield viscometer used till 
date is not sufficient. Rather an oscillating cone plate method is used for these 
evaluations. In detail, an amplitude sweep test with constant oscillation frequency ω 
and controlled shear deformation is performed. That means that the angle of 
deflection φ of the cone and with that the shear rate γ is defined by the method. 
The variable parameters are the corresponding shear stress τ and loss angle δ that 
are obtained from measurement.  
The change of shear rate over time given by the apparatus in this experiment 
follows a sinus curve, whereas the resulting change of shear stress over time 
follows a shifted sinus curve. This phase shift between the two sinus curves is 
described by the loss angle δ. From these values the storage modulus G´ and the 
loss modulus G´´ can be calculated (Equ. 3-4, Equ. 3-5, Equ. 3-6). 
 
δ
γ
τ cos´ ⋅=
A
AG               δγ
τ sin´́ ⋅=
A
AG               `
``tan
G
G
=δ  
Equ. 3-4      Equ. 3-5        Equ. 3-6 
 
Equ. 3-4 & Equ. 3-5 & Equ. 3-6 Storage modulus G`, loss modulus G``, and loss factor tan δ; 
with loss angle δ, amplitude shear stress τA, and shear rate amplitude γA; 
 
Thereby, the storage modulus G´ describes the elastic properties of the sample that 
are responsible for a reversible deformation storing the deformation energy within 
the system. The loss modulus G´´ is a measure for the plastic or viscous behaviour 
of the specimen being responsible for irreversible deformation and a loss of 
deformation energy for the matrix. Furthermore, the loss factor tan δ describes the 
relation of viscous and elastic character in the test sample.  
Thus, these three values are used to describe the rheological behaviour of the gel 
system. The relative positions of moduli in the double logarithm plot against shear 
stress and the value of the loss factor being < 1 indicate that the elastic properties 
prevail over plastic behaviour.  
This domination of the elastic character is seen in both the hydroxyethyl cellulose 
gel and the gellan gum swollen in sodium chloride solution (Fig. 3-22). But for the 
gellan curves with sodium chloride addition this issue is much more pronounced 
due to the higher difference between the curve levels. In fact, the lower loss factor 
marks a rheology tending to be like the behaviour of solids.  
Moreover, the gellan moduli curves cross each other after very abrupt change in 
runs of the curves, describing a break down of the gel structure at a threshold of 
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shear stress. There, a yield value τY gellan can be calculated. Taken together, this 
characterises a very hard but brittle gel with a very distinctive yield point. 
Compared to gellan gum, hydroxyethyl cellulose is characterised by both very low 
pronounced elasticity and yield point describing a soft almost free-flowing gel (Fig. 
3-22). 
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Fig. 3-22 Comparison of gellan gum gel and hydroxyethyl cellulose gel flow curves; 
measurement in amplitude sweep with controlled shear deformation and a constant frequency 
ω=10 1/s of 1.0% gellan gum in 0.9% sodium chloride with storage modulus G’ ( ), loss 
modulus G’’ ( ), loss factor tan δgellan, yield point τY gellan; 2.5% hydroxyethyl cellulose 
100.000 with storage modulus G’ ( ), loss modulus G’’ ( ), loss factor tan δHEC 
 
However, the brittleness of gellan gum gels is inappropriate for a wound dressing 
and so further modifications are necessary. It has been found that a combination of 
the two very different gellants gellan gum and hydroxyethyl cellulose forms suitable 
gels for wound treatment.  
As already mentioned, a higher loss factor expresses a less brittle and softer 
behaviour of the gel. And, the low loss factor of gellan gum alone can be increased 
by partly substitution by hydroxyethyl cellulose in isotonic sodium chloride 
containing gels (Tab. 3-6). 
 
hydroxyethyl cellulose gellan gum loss factor tan δ 
0 % 1.5 % 0.12 
2.0 % 1.0 % 0.18 
2.25 % 0.75 % 0.40 
2.5 % 0 % 0.79 
 
Tab. 3-6 Loss factor tan δ in dependence of hydroxyethyl cellulose and gellan gum content in 
hydrogels containing 0.9% sodium chloride; 
 
tan δgellan gum = 0.12 
τY gellan gum = 195.2 Pa 
tan δHEC = 0.79 
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Although an effective increase of the loss factor values is monitored with contents 
lower 1.0% gellan gum, the 2.0% hydroxyethyl cellulose : 1.0% gellan gum mixture 
is chosen for further development due to its convenient sensory properties, i.e. 
how it is felt on skin. Further, it is observed that the gel system containing the two 
gellants still provides the sensitivity against monovalent cations. Hence, it is 
castable like a liquid without salt content and forms non-free flowing but soft gels 
with salt content. 
 
Moreover, the surrogating of the sodium chloride solution against the potassium 
phosphate buffer used in ACT stabilising formulations is investigated. Therefore, 
the rheological behaviour of the 2.0% hydroxyethyl cellulose : 1.0% gellan gum 
system is examined in water and in 50mM potassium phosphate buffer pH 7.2, 
respectively (Fig. 3-23). Experimental setting of the rheometer method is as above.  
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Fig. 3-23 Flow curves in amplitude sweep of 2.0% hydroxyethyl cellulose / 1.0% gellan gum; 
in 50mM potassium phosphate buffer pH 7.2 with storage modulus G’ ( ), loss modulus G’’ 
( ), loss factor tan δphosphate buffer, yield point τY phosphate buffer; in water with storage modulus G’ 
( ), loss modulus G’’ ( ), loss factor tan δwater ;  
 
For interpretation, again the relative position of moduli is considered. For 
influencing the gel behaviour isotonic sodium chloride solution (tan δ0.9% NaCl = 
0.18) is nearly on a par with 50mM potassium phosphate buffer pH 7.2 (tan 
δphosphate buffer = 0.15) like it is developed for some ACT formulations. The gels also 
provide a yield point τY which is slightly reduced by the hydroxyethyl cellulose 
surrogate (τY 0.9% NaCl = 169.0Pa, τYphosphate buffer = 168.7Pa) compared to gellan gum 
(τY gellan gum = 195.2Pa) alone (Fig. 3-23).  
tan δphosphate buffer = 0.15 
τY phosphate buffer = 168.7 Pa 
tan δwater = 0.75 
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Therefore, the desired plastic behaviour of gellan gum can also be activated in the 
mixture by addition of the usual phosphate buffer. On the contrary, without salt 
content the hydroxyethyl cellulose fraction dominates the viscosity of the gel 
forming a free flowing mass.  
 
To conclude, the 2.0% hydroxyethyl cellulose : 1.0% gellan gum mixture 
conveniently combines the properties of a soft free-flowing gel necessary for 
manufacture, drug loading, and provision of wound contact with the mechanic 
advantages of cross-linked matrices. Thus, this system provides a very attractive 
alternative to pseudoplastic hydrogels made from a single polymer. Unfortunately, 
gellan gum till date is only approved for ophthalmic solutions up to 0.6% by 
FDA149. 
 
3.3.2 Stability of ACT in hydrogel formulations 
Based on the results of the stabilisation studies on ACT in aqueous solution a 
group of polymers is tested in similar manner for short term temperature stress and 
F/T stress. Consequently, these short term studies are followed by mid term 
stability tests in semi-solid hydrogels according to ICH guideline. Prior to these 
tests the manufacture of sterile ACT loaded gels is highlighted. The outcome of the 
stability study is assessed for the purpose of evaluating the possibility of hydrogels 
as application form and as storage form for ACT.  
 
3.3.2.1  Effects of polymers on ACT stability in hydrated formulations 
Polymers are a chemically heterogeneous group of substances. Therefore, their 
effects on proteins can not be outlined in a straight way. Generally, polymer 
interaction with proteins is of great similarity to other discussed substance classes 
depending on their underlying chemical structure. So, for example, surface activity, 
preferential exclusion, steric hindrance, and viscosity limiting structural movement 
are important stabilising interactions with proteins137.  
 
Polymers are tested not only because of their own protein stabilising potency but 
also because of  their necessity for gel forming. In fact, the polymers are tested for 
a non-destabilising effect in the formulation instead of an active stabilising effect. 
That is why the experimental setting is changed concerning sample composition. 
Test samples, thus, basically already consist of an improved phosphate buffered 
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(pH 7.2) and surfactant, 0.1% Poloxamer® 188, containing 60µg/ml ACT solution 
wherein the polymer is added. The polymer content is reduced to 0.5% in these 
experiments to keep the samples in a liquid state. This is done to provide the 
possibility of unchanged liquid handling during sample preparation and analytics 
without further stress factors influencing ACT activity. 
As before, unstressed material is measured first to detect incompatibilities with the 
assay (data not shown). In this set of experiments the polyacrylate polymers, 
Carbopol® and Eudragit®, failed due to complete deactivation of ACT even 
without stressing. Methyl cellulose and Lutrol® F127 were stopped here because of 
their middle-rate stabilising qualities and their unfavourable mechanical 
characteristics in xerogel and film formation (see sections there). The other tested 
polymers showed acceptable compatibility and are tested further on (listed in Fig. 
3-24). 
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Fig. 3-24 Recovered relative activity of ACT in 50mM potassium phosphate buffer pH 7.2 
and 0.1% Poloxamer® 188 with various polymers at 0.5% content after a 9 days storage at 
40°C measured by activity assay; polymers are HEC 10.000, CMC Na 10.000, HPC 100.000, 
HPMC 15.000, gellan gum LT100, PVP 17, PEG 2000, PVA 100.000; 
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With the latter the stressing experiments are carried out. Samples for these 
experiments are prepared in the same improved formulation as above and are 
treated at 40°C for 9 days and 15 F/T cycles, respectively. The control sample 
contains no polymer.  
 
Most of the samples are within the range of the control, where no loss of activity 
can be detected. For xanthan gum and polyvinyl alcohol samples lower values of 
relative activity are obtained (Fig. 3-24).  
 
For the F/T studies a solution is used containing 10mM potassium phosphate 
buffer pH 7.2 and 0.1% Poloxamer® 188 as surfactant. Here, none of the chosen 
polymers caused a destabilisation of ACT activity during 15 F/T cycles (Fig. 3-25).  
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Fig. 3-25 Recovered relative activity of ACT in 10mM potassium phosphate buffer pH 7.2 
and 0.1% Poloxamer® 188 with various polymers at 0.5% content after 15 freeze/thaw cycles 
in liquid nitrogen measured by activity assay; control is formulated in buffer; polymers are 
HEC 10.000, CMC Na 10.000, HPC 100.000, HPMC 15.000, gellan gum LT100, PVP 17, 
PEG 2000, PVA 100.000; 
 
In conclusion, hydroxyethyl cellulose, carboxymethyl cellulose Na, hydroxypropyl 
cellulose, hydroxypropylmethyl cellulose, alginate Na, gellan gum, gelatine A, 
polyvinyl pyrrolidone, and polyethylene glycol are compatible with the analytical 
tool and are not depleting ACT activity in temperature- and F/T stress.  
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The regulatory status of the polymers by the FDA for drug applications is quite 
complex. Gelatine, polyethylene glycol, and carboxymethyl cellulose sodium are 
approved for intramuscular injection up to a content of 16%, 3 to 65% depending 
on PEG species, and 0.9% respectively. Polyvinyl pyrrolidone and hydroxyethyl 
cellulose are approved for use in ophthalmic solutions and transdermal delivery 
systems. Hydroxypropyl cellulose is approved for topical, hydroxypropylmethyl 
cellulose for ophthalmic administration. Alginate is solely approved for oral 
delivery149.  
Although, especially alginate and hydroxyethyl cellulose are used in medical devices 
for wound healing. So, an approval as drug containing material for parenteral use 
with blood contact by authorities should be manageable in spite. 
 
3.3.2.2 Aseptic manufacture of ACT loaded hydrogels 
Obviously, final sterilisation of the gel product is not possible with thermal 
treatment due to protein instability. And, hydrogels are not suitable for sterile 
filtration because of their viscosity. Thus, a separate sterilisation of protein solution 
and hydrogel carrier is needed followed by aseptic manufacturing.  
Where possible, steam sterilisation is conducted on the intermediate drug-free 
hydrogel products. The other polymers are dispersed in 70% ethanol for 15 
minutes. After this disinfection time ethanol evaporates and leaves a dry aseptic 
polymer that gets hydrated with sterile solution to form the hydrogel under aseptic 
conditions.  
 
Polymer screening till date has been performed with reduced polymer contents to 
maintain the liquid state. There, a simple mixing of drug solution with polymer 
solution is appropriate for sample preparation. However, for the manufacture of 
semisolid ACT loaded hydrogels another drug loading procedure has to be 
developed.  
Thus, as first method the homogenisation of a sterile, previously made hydrogel 
with sterile filtered ACT solution using a static mixer is evaluated159(Fig. 3-26).  
The sterile placebo gel is filled into a first syringe. The mixer unit is connected to 
the syringe and the system is filled with gel to remove air. A second syringe 
containing the concentrated ACT solution is connected without trapping air within 
the system. The mass is pumped back and forth 10 times for complete 
homogenisation.  
 
Chapter 3 – Results and Discussion 
- 84 - 
 
 
Fig. 3-26 Static mixer with mounting device between two syringes; gel mass is pumped back 
and forth 10 times for homogenisation; 
 
For validation of this procedure the number of homogenisation steps is evaluated 
with fluorescein sodium. The gel was split into 0.5ml portions which were analysed 
by fluorimetric detection. It turned out that 10 homogenisation steps are 
appropriate for effective drug loading indicated by a relative standard deviation of 
2.7% for the concentration of fluorescein in the measured samples. Moreover, in 
the used setting a minimum of 3ml total amount is shown to be necessary whereby 
1ml is lost in the apparatus.  
Unfortunately, the following experiments for loading of ACT into gels show that 
activity of ACT decreases to a huge extent of over 85% during that loading 
procedure. It can be concluded that not only temperature and freeze/thaw stress 
but also the shear stress in the static mixer device can damage ACT molecules and 
so deactivate them. That is why the method of loading ACT in a gel base with the 
use of the static mixer device is abandoned at that point.  
 
So, another method of loading ACT into a sterile hydrogel preparation with only 
mild stress burden has to be developed. For the reason that a direct drug loading by 
mixing is not possible due to deactivation of ACT by shearing an indirect method 
via a sterile, dry gel intermediate is evaluated. Thereby, the polymer swells into the 
drug solution until homogeneity avoiding shearing in favour of a longer duration of 
the loading process.  
Practically, a steam-sterilised gel is poured into petri dishes or cast out using a 
scraper to a defined thickness of 2mm. Under aseptic conditions, this wet film then 
is dried to a solid film under flowing air. Consequently, the film is cut in shape and 
hydrated in appropriate vases, e.g. petri dishes, glass vials, or well plates, with sterile 
filtered ACT solution. Hereby, one layer film is used for 2mm solution filling 
height and two layers are used for 4mm filling height each resulting in 
correspondent gel thickness. The swelling to homogeneity is finalised after 48 
hours for all polymers at 6°C. Activity measurements indicate that activity of ACT 
is not reduced during this procedure (data not shown). Therefore, for the following 
experiments the described indirect method is used for manufacture of ACT gels. 
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3.3.2.3 Analysis of ACT loaded hydrogels 
Analysis of these gels holds similar difficulties as the manufacture. For reliable and 
reproducible ACT activity determination by the used assay a liquid sample with the 
analyte in solution is necessary. Moreover, only mild shearing should be applied as 
results above indicate. So, to liquefy the gel formulation an enzymatic method and 
a method by simple dilution are evaluated.  
The idea behind the enzymatic method is to degrade the cellulose backbone of 
polymers into shorter fragments being unable to maintain the semi-solid gel 
structure. The tested enzyme, cellulase, is tested in a preliminary series concerning 
its influence on ACT activity in liquid solution. Unfortunately it again has turned 
out that this convenient method is not suitable for ACT because no ACT activity 
could be recovered form test samples incubated over 8 hours at 6°C. The 
molecular impact of cellulase on ACT was not further investigated, but it can be 
speculated that the heavy glycosylation of ACT is a point of attack for the enzyme 
leading to this unwanted complete loss of activity.  
For the reason that a chemical degradation of the polymer is unsuitable a physical 
degradation by dilution was investigated. It was found that a dilution of 1:8 with 
50mM potassium phosphate buffer with 0.1 % Poloxamer® 188 and a repeated 
mild shaking is sufficient to form a liquid with no detectable loss on ACT activity. 
Unless, the dilution of 1:8 which results in concentrations of a maximum of 7.5 
µg/ml can be coped with by the activity assay protocols. As before, most other 
analytical techniques especially with direct UV detection fail because of a higher 
detection limits. Indeed, the described dilution method was used for sample 
preparation prior to activity analysis for all described experiments. 
 
3.3.2.4 Mid term stability of ACT in hydrogel formulations 
Based on the results of the stabilisation in liquids a three months stability test in 
semi-solid gels is launched with a set of formulations. All alternatives for the 
stabilisers are considered. But, for capacity reasons solely for the polymers a 
selection was done, this in prospect of later discussed results for dry forms and 
suitability for steam sterilisation. In fact, only hydroxyethyl cellulose 100.000 and 
mixtures of hydroxyethyl cellulose with acylated and deacylated derivatives of gellan 
gum - quality LT100, and F - are tested. Additionally, soluble polymers are tested 
together with the formulations. These polymers - PVP and PEG - fulfil technical 
purposes outlined in the sections describing the development of xerogels and films. 
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Samples of ACT loaded gels are prepared under aseptic conditions as outlined 
above. Packaging containers are glass vials that are sealed with a Teflon®-coated 
rubber stopper. The concentration of ACT was 60µg/ml, sample volume was 0.4 
ml. So prepared samples are stored at three temperature levels, namely 6°C, 25°C, 
and 40°C. After 1, 4, 8, and 12 weeks storage time samples are drawn and stored at 
–80°C until analysis. But, before analysis by activity assay the samples are 
prediluted 1:8 to form a liquid gel dispensable like a liquid for handling reasons 
according to the evaluated method.  
 
Calculations described in detail below are conducted to estimate reaction kinetics 
and shelf lives under storage conditions; 6°C simulates storage in a refrigerator, 
25°C simulates storage at room temperature, and 32°C simulates temperature 
condition during application on the wound (adapted from160). The data on 32°C 
level is gained from Arrhenius calculations below. 
 
The assessment of samples is done in pursuance with three benchmarks. First is the 
suitability of the hydrogel formulation as future storage form for stocking at room 
temperature. Therefore the 25°C estimation has to exceed 18 months above the 
lower specification limit. Second is the same question for stocking in the 
refrigerator. And, third is the suitability for application of the hydrogel formulation 
into the wound site. For this purpose, the estimated shelf life of the hydrogel at 
32°C should exceed one week. 
 
3.3.2.4.1 Principles of data interpretation 
 
Generally, results are gained as a set of curves of residual activity over time for 
every formulation and temperature level. An example is shown in Fig. 3-27. From a 
starting value of about 100% the activity declines over the 3 months of storage 
time.  
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Fig. 3-27 Recovered relative activities of a hydrogel formulation consisting of 60µg/ml ACT, 
10mM arginine, 0.1% Tween® 80, 0.05% PVP 17, 2.5% hydroxyethyl cellulose in a 50mM 
potassium phosphate buffer pH 7.2 at 6 °C (□) and 40°C ( ) in linear scale measured by 
activity assay;  
 
For an estimation of the reaction kinetics of the loss of ACT activity over time the 
relative activity results are drawn against sample time. Additionally, for higher 
reaction orders mathematical modifications are implemented on the relative activity 
values for linearisation according to the well known time laws:  
 
Equ. 3-7 0. order tkctc ⋅−= 0)0()(  
Equ. 3-8 1st order tkctc ⋅−= 1)0(ln)(ln  
Equ. 3-9 2nd order tkctc
⋅+= 2)0(
1
)(
1
 
Equ. 3-7 & 3-8 & 3-9 Time laws for reaction kinetics for 1st, 2nd, and 3rd order; c(t) is relative 
activity at time t, c(0) starting relative activity, k1/2/3 are velocity constants, and t is time in 
days; 
 
For these three cases functions are fitted over the modified curves and next to the 
equation parameters the correlation coefficient is determined and used for assessing 
the feasibility of the fitted reaction order. Fig. 3-28 shows an example for the fitting 
of the first order time law. 
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Fig. 3-28 Recovered relative activities of a hydrogel formulation consisting of 60µg/ml ACT, 
10mM arginine, 0.1% Tween® 80, 0.05% polyvinyl pyrrolidone 17, 2.5% hydroxyethyl 
cellulose in a 50mM potassium phosphate buffer at 6°C (□) and 40°C ( ) in logarithmic 
concentration scale with fitted logarithmic functions resulting in evens in the one-sided 
logarithmic scale as predicted by first-order time law; measured by activity assay; 
 
As shown in this example the best fitting results given by correlation coefficients 
are gained for the first order equation (Equ. 3-8), i.e. a logarithmic scale for relative 
activity results.  
 
According to the guideline ICH-QA1 the datasets are tested on change-over-time, 
indicated by the p-value of the slope of the fitted line exceeding 0.25 for no 
change-over-time. And, in the case of no change-over-time variability is tested to 
confirm statistical conformity of stability data. Further, for an estimation of the 
shelf life the 95%-confidence intervals are calculated for the curves. The intercept 
of the lower confidence limit with the lower specification limit – in our case 10 % 
loss of relative activity - indicates the end of the shelf life. An example is seen in 
Fig. 3-29. 
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Fig. 3-29 Recovered relative activities of a hydrogel formulation consisting of 60µg/ml ACT, 
10mM arginine, 0.1% Poloxamer® 188, 1.5% polyvinyl pyrrolidone 17, 1.0% PEG 400, 1.0% 
gellan gum, 2.0% hydroxyethyl cellulose in a 50mM potassium phosphate buffer at 6°C 
measured by activity assay; relative activity is in logarithmic scale; fitted logarithmic function 
and 95% confidence intervals are shown; 10% loss line marks the lower specification limit; 
 
Moreover, via the Arrhenius-equation (Equ. 3-10) the reaction constants are linked 
to temperature. 
 
A
TR
Ek A lnln 1 +⋅
−=  
 
Equ. 3-10 Arrhenius equation; k1 is the first order velocity constant, EA is the activation 
energy [J/mol], R is the gas constant [J/(K*mol)], T is the absolute temperature [K], and A is 
the collision factor 
 
By inserting the known values for k and T for the three temperature levels, an even 
can be calculated from where the missing values of EA and A can be determined. In 
detail, the slope is equal to -EA/R and the intercept is equal to ln A (Fig. 3-28). This 
equation can be used to calculate the velocity constant of any temperature lying 
between the data limits. In fact, the calculations are conducted for 6°C, 25°C and 
32°C. Based on that, estimating calculations of shelf lives on these temperature 
levels are conducted. 
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Fig. 3-30 Velocity constants k in logarithmic plot against temperature in reciprocal plot with 
fitted function; slope of the function is equal to -EA/R, intercept is equal to ln A from the 
Arrhenius equation (Equ. 3-10) 
 
3.3.2.4.2 Experimental results and discussion 
The kinetics of the curves follow most likely the first order time law (Fig. 3-26) 
because correlation coefficients are best for the first order kinetics in most cases 
(data not shown).  
 
But, all datasets show change-over-time and additionally many are variable 
according to ICH-QA1 guideline (calculations not shown). Thus, confidence 
intervals of most datasets are too large to allow a sensible, statistically profound 
estimation of shelf life as described above.  
Instead, an estimation is made by simple extrapolation of the fitted curve to the 
intercept with the 10% loss level as lower specification limit. For all formulations, 
consequently, first order reaction constants for every temperature level are 
calculated and corresponding shelf lives are estimated (Tab. 3-7). 
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60µg/ml α1-antichymotrpsin reaction constant k (1°C) 2.99·10-4 1/day 
50mM phosphate buffer reaction constant k (24°C) 1.41·10-3 1/day 
10mM arginine reaction constant k (41°C) 1.05·10-2 1/day 
0.1% Tween® 8o shelf life (6°C) 253.4 days 
0.05% PVP 17 shelf life (25°C) 50.1 days 
2.5% HEC 100.000 shelf life (32°C) 22.1 days 
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 7.19·10-4 1/day 
50mM phosphate buffer reaction constant k (24°C) 1.05·10-3 1/day 
10mM arginine reaction constant k (41°C) 3.63·10-3 1/day 
0.1% Poloxamer® 188 shelf life 6°C 138.0 days 
0.05% PVP 17 shelf life 25°C 67.4 days 
2.5% HEC 100.000 shelf life 32°C 47.0 days 
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 1.58·10-3 1/day 
50/50mM phosphate/citrate buffer reaction constant k (24°C) 2.15·10-3 1/day 
10mM arginine reaction constant k (41°C) 5.29·10-3 1/day 
0.1% Poloxamer® 188 shelf life 6°C 63.3 days 
0.05% PVP 17 shelf life 25°C 37.0 days 
2.5% HEC 100.000 shelf life 32°C 28.3 days 
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 1.70·10-4 1/day 
50mM phosphate buffer reaction constant k (24°C) 8.16·10-41/day 
10mM arginine reaction constant k (41°C) 4.61·10-3 1/day 
0.1% Poloxamer® 188 shelf life 6°C 439.3 days 
0.05% PEG 2000 shelf life 25°C 96.8 days 
2.5% HEC 100.000 shelf life 32°C 45.1 days 
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 9.31·10-4 1/day 
50mM phosphate buffer reaction constant k (24°C) 1.44·10-3 1/day 
10mM arginine reaction constant k (41°C) 6.25·10-3 1/day 
0.1% Poloxamer® 188 shelf life 6°C 105.7 days 
0.05% PVP 17 shelf life 25°C 45.6 days 
2.0% HEC 100.000 shelf life 32°C 29.8 days 
1.0% gellan gum LT100   
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 6.48·10-3 1/day 
50mM phosphate buffer reaction constant k (24°C) 6.62·10-3 1/day 
10mM arginine reaction constant k (41°C) 8.41·10-3 1/day 
0.1% Tween® 8o shelf life 6°C 16.3 days 
0.05% PVP 17 shelf life 25°C 14.5 days 
2.0% HEC 100.000 shelf life 32°C 13.7 days 
1.0% gellan gum LT100   
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 1.36·10-3 1/day 
50mM phosphate buffer reaction constant k (24°C) 3.50·10-3 1/day 
10mM arginine reaction constant k (41°C) 1.05·10-2 1/day 
0.1% Poloxamer® 188 shelf life 6°C 63.1 days 
1.5% PVP 17 shelf life 25°C 24.8 days 
1.0% PEG 400 shelf life 32°C 15.4 days 
2.0% HEC 100.000   
1.0% gellan gum LT100   
 
 
 
(1) 
 
 
 
 
 
(2) 
 
 
 
 
 
 
(3) 
 
 
 
 
 
(4) 
 
 
 
 
 
(5) 
 
 
 
 
 
 
 
(6) 
 
 
 
 
 
 
(7) 
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60µg/ml α1-antichymotrpsin reaction constant k (6°C) 9.95·10-4 1/day 
50mM phosphate buffer reaction constant k (24°C) 2.84·10-3 1/day 
10mM arginine reaction constant k (41°C) - 
0.1% Poloxamer® 188 shelf life 6°C 105.9 days 
0.05% PVP 17 shelf life 25°C 37.1 days 
2.0% HEC 100.000 shelf life 32°C 24.2 days 
1.0% gellan gum F   
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 2.28·10-3 1/day 
50mM Tris buffer reaction constant k (24°C) 5.93·10-3 1/day 
10mM arginine reaction constant k (41°C) 2.50·10-2 1/day 
0.1% Poloxamer® 188 shelf life 6°C 46.3 days 
0.05% PVP 17 shelf life 25°C 17.8 days 
2.5% HEC 100.000 shelf life 32°C 7.7 days 
 
60µg/ml α1-antichymotrpsin reaction constant k (1°C) 2.53·10-3 1/day 
50mM Tris/NaCl buffer reaction constant k (24°C) 9.80·10-3 1/day 
10mM arginine reaction constant k (41°C) 2.08·10-2 1/day 
0.1% Poloxamer® 188 shelf life 6°C 41.6 days 
0.05% PVP 17 shelf life 25°C 10.8 days 
2.0% HEC 100.000 shelf life 32°C 8.3 days 
1.0% gellan gum F   
 
Tab. 3-7 Formulations of the mid term stability testing with ingredients (left column), reaction 
constants k at the experimental stress levels, and estimated shelf lives at the required 
temperature levels (right column); 
 
Unless data show variation according to ICH-QA1 several conclusions can be 
made. For wet state hydrogels stored in glass vials the phosphate buffer has greater 
stabilising potential than the Tris and citrate/phosphate systems. This is manifested 
in shelf lives of formulation (2) in comparison with (3) and (9), as well as 
formulation (8) compared to (10). The surfactant Poloxamer® 188 works better 
than the Tween® 80 alternative. See comparison of formulation (1) with (2), and (6) 
with (7). For the soluble polymers polyethylene glycol is favourable over polyvinyl 
pyrrolidone as shelf lives of formulation (2) and (4) indicate. Moreover, the 
hydroxyethyl cellulose gelling agent is favourable over each tested alternatives. This 
results from comparison of formulation (2) with (5) and (8). However, no 
formulation offers enough stabilising potential to enable a hydrogel as storage form 
at room temperature or in the refrigerator. Because, neither at 6°C nor at 25°C 
storage temperature the estimated shelf life of any formulation reaches the required 
limit of 18 months (550 days). But, for all tested formulations stability is above the 
lower specification limit for over 7 days at 32°C. All formulations, hence, fulfil the 
stability requirements for topical, local application in wounds. Thus, the gained data 
on advantage and disadvantage of excipients do not display knock-out criteria for 
choice of ingredients. Indeed, the spectrum of excipient candidates for further 
development is not narrowed. 
(8) 
 
 
 
 
 
 
(9) 
 
 
 
 
 
 
(10) 
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3.3.2.4.3 Summary 
Results indicate that reaction kinetics of activity loss of ACT is highly likely to 
follow a first order equation. Moreover, a commercial formulation of ACT in a wet 
hydrogel is not possible due to insufficient shelf life. In contrast, all formulations 
can be applicated into the wound site as far as stability of ACT is concerned. As 
well, several formulations are applicative as early refrigerated formulation for the 
purpose of animal experiment or early clinical trial where only limited shelf life is 
required. 
 
3.3.2.5 Freeze/thaw stability of ACT in hydrogel formulations 
For verification of the results of F/T studies on ACT in solution and with polymer 
ingredients similar hydrogel formulations as in the prior section are tested in F/T 
studies. Sample preparation and analysis are performed as described above. 
Stressing is done by repeated freezing in liquid nitrogen and thawing at room 
temperature.  
Samples contain 60µg/ml ACT in 2.5% hydroxyethyl cellulose gels. Other 
ingredients are listed in Tab. 3-8.  
Results indicate a total recovery of ACT after 15 F/T cycles for all excipient 
combinations. In the buffer control without stabilisers activity is completely lost 
after 15 cycles (Fig. 3-31). Therefore, it can be concluded that all hydrogel 
formulations are cryoprotective on ACT.  
This is an important pre-requisite for a successful lyophilisation and enables frozen 
hydrogels for the use as early formulations161 162. 
 
buffer control  formulation 1  formulation 2  formulation 3  formulation 4  
10 mM phosphate 10 mM phosphate 10 mM phosphate 10 mM phosphate 10 mM phosphate
 10 mM arginine  10 mM arginine 10 mM arginine 
 0.1% Poloxamer® 
188 
0.1% Poloxamer® 
188 
0.1% Tween® 80 0.1% Poloxamer® 
188 
 0.05%PVP 17  0.05%PVP 17 0.05%PVP 17 0.05% PEG 2000 
 
Tab. 3-8 Recipes for F/T studies containing 60µg/ml ACT and 2.5% hydroxyethyl cellulose; 
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Fig. 3-31 F/T stability of ACT in hydrogel formulations; kinetics of decay of relative activity 
in formulations listed in Tab. 3-8 during F/T treatment in liquid nitrogen; formulation 1 ( ), 
formulation 2 ( ), formulation 3 ( ), formulation 4 ( ), buffer control ( ); 
 
3.3.3 Summary of hydrogels as ACT delivery systems for 
wound healing 
During these studies hydrogels are developed for both the concerns of a wound 
dressing material and the needs of the drug stability of ACT.  
In a first approach the placebo hydrogel carriers are evaluated with regard to ability 
for sterilisation and rheological properties. Secondly, short term stabilisation studies 
on ACT with suitable polymers are performed. Consequently, ACT stabilising 
hydrogel formulations are created containing excipients being suggested by short 
term stability studies. Following, drug loading procedures into hydrogels are 
evaluated. After that, the named formulations are introduced in mid term stability 
studies and F/T studies. Results indicate that hydrogels are suitable application 
forms for ACT. They also can represent early formulations contingently in frozen 
state. But, hydrogels can not be used as storage form for a future drug product 
based on ACT due to the limited shelf lives of such products. 
 
Chapter 3 – Results and Discussion 
- 95 - 
3.4  Dry delivery systems 
In the last section it has been shown that aqueous carriers are suitable for 
application of ACT on wounds and for early formulations of ACT. In contrast, it 
has been shown that aqueous carriers are not suitable for long term storage. Thus, a 
dry form is to be developed that stabilises ACT during long term storage. 
Moreover, when hydrated just before application a hydrogel is to be formed 
suitable as wound dressing and releasing ACT in suitable period of time. For this 
task, development starts from the gel bases discussed in the hydrogel section. 
 
In Chapter 1 wound dressings that are stored as dry matrices and that form gels 
when put in contact with aqueous solution have been outlined. For the commercial 
production of many of these dressings, e.g. alginate or carboxymethyl cellulose 
dressings, jetting or extrusion of gels or polymers followed by spinning or felting of 
resulting fibres is used163. This forms very fast hydrating fibre matrices due to the 
thin fibres and wide meshed structure. Other products, for example collagen 
sponges, are produced by lyophilisation of hydrogels164.  
 
Although lyophilisation is much more expensive and time consuming, the extrusion 
or jetting techniques are inappropriate for protein drug load due to the extended 
shearing of the material which is very likely to cause damage to the protein 
molecules during fabrication.  
Therefore, the first technique used for drying of ACT loaded hydrogels during this 
formulation study is lyophilisation. The resulting matrices are xerogels. In addition, 
a second technique – the warm air drying - is evaluated. Warm air drying has been 
successfully used for drying of protein solutions165. From this technique swellable, 
self-supportive polymer films are formed.  
In the first part of this chapter the development of xerogels as placebo dressings 
and drug loaded carriers is described. In a second part the development of films 
also in placebo state and as drug loaded matrices is outlined. 
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3.4.1  Xerogels as drug delivery systems for wound healing 
Today, there are several lyophilised and swellable polymer containing products used 
as drug free wound dressings in clinical practice. For example, Suprasorb G® 
consists of collagen, and Promogran® contains a mixture of oxidised regenerated 
cellulose and collagen.  
Besides, many patent applications have been submitted on drugs in xerogel or 
sponge dressing materials. Some of these matrices also contain protein drugs166-176. 
But, despite the large number of patent applications about mainly growth factors in 
lyophilised polymer matrices back in the 1990s none of those has led to approval 
by authorities let alone to market launch, yet. 
In this section, the production of placebo xerogel carriers and investigations of 
their mechanical properties are described. Thereby, influence of the lyophilisation 
process, of the polymer composition, and of further formulation ingredients are 
highlighted.  
The goals of these studies are to ensure the suitability of the xerogel as wound 
dressing and to investigate the compatibility with protein formulation ingredients. 
Xerogels are meant to be reconstituted before or in the moment of application. So, 
the wound will not be confronted with the dry xerogel pad. It rather will get in 
contact with the yet hydrated gel state. Therefore, the swelling behaviour is the 
most important technical feature for xerogels. In fact, a fast and complete swelling 
is essential for such a product. Moreover, a homogeneous appearance, a convenient 
and soft consistency is desirable for compliance reasons. Furthermore, a residual 
moisture of less than 2% is essential for protein drug stability. 
 
3.4.1.1  Lyophilisation process 
For the development of a suitable lyophilisation process for the manufacture of 
xerogels the cryostabilising hydrogel formulations described in the prior section are 
taken as starting points.  
For preliminary studies differential scanning calorimetric experiments are 
conducted on placebo gels from where temperature parameters of the freeze drying 
process are gained. Following, placebo xerogels are examined optically and by x-ray 
analysis. 
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3.4.1.1.1  DSC studies 
For examination of placebo gels by DSC specimen are prepared according to the 
results of the prior ACT stabilisation studies.  
The thermograms solely show a freezing and melting peak (Fig. 3-32). Therefore, a 
standard freeze drying program with a freezing phase leading to temperatures 
below the crystallisation temperature of around –15°C is adequate.  
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Fig. 3-32 DSC thermogram of 2.5% hydroxyethyl cellulose 100.000 gel swollen in 10mM 
phosphate buffer pH7.2, 10mM arginine, 0.1% Poloxamer® 188; freezing curve (below) 
indicates a crystallisation at –14.8°C, melting curve (above) shows a melting peak at –0.9 °C 
 
3.4.1.1.2  Lyophilisation program 
time [h] plate temperature [°C] cabin pressure [mbar] 
0 20 1013 
1 -45 1013 
1.5 -45 1013 
0.1 -45 0.1 
1 -30 0.1 
33 -30 0.1 
5 20 0.1 
0.1 20 0.011 
8 20 0.011 
 
Tab. 3-9 Program of the conventional freeze drying process for xerogels 
 
The first experiments on lyophilisation of hydrogels were conducted with a 
standard freeze drying program according to the preliminary DSC tests. So, the 
samples are filled in petri dishes to a filling height of 4 mm. These are placed in the 
exotherm 
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drying chamber at room temperature and following freezing is done at very fast 
rates of 1.1 K/min. After a retaining phase a conservative main drying step is 
proceeding at –30°C. The subsequent secondary drying is also conservatively 
conducted at 20°C (Tab. 3-9).  
 
Unfortunately, the resulting xerogel pads appear very rough in visible structure 
which may lead to disturbed compliance. The reason for this appearance was found 
in the random crystallisation of the gels during freezing. Indeed, the crystal forming 
in the liquid status starts anywhere in the gel and grows through the gel until 
completeness. And, the way of growth seems to be preserved in the pad (Fig. 3-33).  
 
 
 
Fig. 3-33 Xerogel pads consisting of hydroxyethyl cellulose 100.000 made from 2.5% 
hydrogels by conventional freeze drying process without annealing; left: top, right: bottom 
 
Several attempts aiming to the controlled induction of seed crystals like placing a 
cooled needle into the gel, ultrasonic vibration, and induction by rime formation on 
the surface by opening the dryer chamber door for a short time177, respectively, did 
not succeed.  
But, the introduction of an annealing step into the freezing phase of the 
lyophilisation process led to a more desirable, homogeneous appearance (Fig. 3-
34)178.  
 
 
 
Fig. 3-34 Xerogel pads consisting of hydroxyethyl cellulose 100.000 made from 2.5% 
hydrogels by the freeze drying process with annealing step during freezing; left: top, right: 
bottom 
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This annealing step is carried out as follows: The gels are frozen under the 
crystallisation point until the described random crystal forming process is 
completed. After that, the gels are heated up again close below their freezing point 
(-3°C) to remain there for 90 minutes. Consequently, the gels are cooled again at a 
very slow rate of 7 K per hour to –45°C initialising the primary drying after three 
hours of balancing time. The process is visualised in Tbl. 3-10 and Fig. 3-35. In 
fact, the annealing step at that point is not introduced for the purpose of protein 
stabilisation but only for matrix considerations. 
 
time [h] plate temperature [°C] cabin pressure [mbar] 
0 20 1013 
0.5 -17 1013 
1 -17 1013 
1 -3 1013 
1.5 -3 1013 
0.75 -25 1013 
0.3 -45 1013 
1.5 -45 1013 
0.1 -45 0.1 
1 -30 0.1 
33 -30 0.1 
5 20 0.1 
0.1 20 0.011 
8 20 0.011 
 
Tab. 3-10 Program of the freeze drying process with annealing step for xerogels  
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Fig. 3-35 Temperature/pressure – time diagram of freeze drying process with annealing step 
during freezing; --- plate temperature, --- product temperature, --- cabin pressure 
 
Although there is clearly visible change in optical appearance in the xerogels made 
from lyophilisation with conventional program and program with annealing step, 
respectively, no difference is detected in x-ray analysis. In detail, no remarkable 
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peak formation at all is seen in the x-ray patterns (Fig. 3-36). It can be concluded 
that due to the lack of regular assembly of polymer molecules no reflections of x-
rays can be detected. This indicates an amorphous instead of a crystalline state of 
the molecules in the matrix. 
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Fig. 3-36 X-ray patterns of xerogels consisting of hydroxyethyl cellulose 100.000 made from 
2.5% hydrogels without (above) and with (below) annealing step during lyophilisation; curves 
are shifted on the y-axis for better demonstration; 
 
3.4.1.2   Gel composition for xerogel formation 
For lyophilisation and xerogel formation a variety of polymers is screened for 
eligibility. The concentration of the gellant in the hydrogel was chosen according to 
the results of the rheological studies during hydrogel development. After freeze 
drying with the developed process, the xerogels are examined concerning optical 
appearance, texture analysis, swelling behaviour, and residual moisture.  
As an example for the studies on different gelling agents the studies on 
hydroxyethyl cellulose are described briefly. After an evaluation of parameters 
related to the polymer, excipients for protein stabilisation and for adjustment of 
mechanical properties are incorporated into the matrices and their influence 
investigated. Similarities and differences of the example hydroxyethyl cellulose to 
other gellants are outlined. Moreover, the formation of a xerogel matrix made from 
two gellants – hydroxyethyl cellulose and gellan gum - is described. 
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3.4.1.2.1  Hydroxyethyl cellulose qualities for xerogel formation 
The nomenclature of the different molecular weights of hydroxyethyl cellulose 
qualities is taken over from the Tylose® brand nomenclature where the 
characteristic number expresses the viscosity of a 2% solution measured in [mPa·s]. 
Differences in molecular weight in cellulose derivatives result in different polymer 
contents in the gel needed for attaining the same desired viscosity. After freeze-
drying, the total content of polymer obviously is closely related to the total dry 
mass, the density, and the pore structure of the lyophilisate. It is easy to imagine 
that those factors strongly interact with the mechanical properties of the dry pad 
and the reconstitution behaviour when the pad is hydrated. Both is essential for the 
development of the xerogels as wound dressings. 
In this series xerogels are prepared from gels with the standard viscosity highlighted 
in the hydrogel section but with hydroxyethyl cellulose qualities differing in their 
chain length. In detail, a series of gels from 2.5% of HEC 100.000 to 8.0% of HEC 
300 was manufactured. As before, lyophilisation was carried out with the special 
program with annealing step (see section 3.4.1.1) and analysis was performed by 
swelling studies, texture analysis and residual moisture detection.  
Swelling behaviour is examined by weighing the mass difference between the dry 
xerogel pad and the swollen pad. Therefore, the xerogel pad is soaked in water or 
the particular reconstitution medium. After three minutes swelling time the pad is 
removed from the medium. Consequently, excessive solution adhering to the gel is 
removed by a paper towel and the swollen gel is weighed. Finally, the swelling value 
q is calculated (Equ. 3-11). 
 
( ) ( )
( ) 



 −
=
Xerogelm
XerogelmgelswollenmqSwelling  
 
Equ. 3-11 Swelling value q calculated from dry weight of the pad (m(Xerogel)) and the 
weight after 3 minutes exposure to water (m(swollen gel); 
 
In other words, the swelling value describes how many times the xerogel can take 
up its own dry weight of water within three minutes.  
All samples are acceptable concerning optical appearance measured by sensory 
valuation. The swelling of the tested xerogels instead turned out to be strongly 
dependent on the chain length of the used polymer. So, xerogels with higher chain 
length polymers combined with a lower total polymer content swell faster in the 
given period than xerogels made from polymers with shorter molecules (Fig. 3-37).  
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Fig. 3-37 Swelling of xerogels after 3 minutes exposure to water; matrices are made from 
different hydroxyethyl cellulose qualities in different concentrations but comparable viscosity 
in the hydrated state; 
 
In the same way mechanics are effected. Measurements are conducted by texture 
analysis as compression tests of the matrices with a cylinder probe. This method 
delivers the deformation energy during compression by the probe, restoring energy 
during release of the probe and the elastic modulus calculated as quotient of 
compression stress and strain. The modulus can also be expressed as average slope 
of the force diagram (Fig. 3-38). In fact, matrices from short chain polymers show 
higher elastic moduli and slightly higher restoring energies which delivers a more 
stiff impression (Tab. 3-12).  
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Fig. 3-38 Force diagram of texture analysis of xerogels made form 5% hydroxyethyl cellulose 
4000; xerogel is compressed to 50% of height followed by release to beginning; integrated 
areas are deformation and restoring energy; 
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Polymer Quality Concentration in the hydrogel [%]
Elastic modulus 
[mN/mm2] 
Restoring 
energy [%] 
Hydroxyethyl 
cellulose 100.000 2.5 22.0 28.2 
Hydroxyethyl 
cellulose 30.000 3.0 28.3 29.8 
Hydroxyethyl 
cellulose 10.000 4.0 45.6 29.6 
Hydroxyethyl 
cellulose 4.000 5.0 49.2 30.8 
Hydroxyethyl 
cellulose 300 8.0 59.3 38.2 
 
Tab. 3-12 Mechanical properties of xerogels made of different hydroxyethyl cellulose 
qualities and different concentrations with comparable viscosity gained from texture analysis; 
 
As already pointed out, higher chain length polymers effectuate lower densities of 
the porous freeze-dried material. This results in higher pore sizes which is 
supposed to be the reason for the faster swelling. Indeed, water can penetrate faster 
into the core structure through the wider pores and hydrate the as well lower 
amount of polymer in these xerogels for gelling. Mechanical properties are effected 
for the same reason because a more dense matrix due to a higher dry weight of 
polymer effectuates higher resistibility to compression forces and so higher elastic 
moduli, i.e. increased stiffness. Restoring energy seems to be affected to a minor 
extent.  
Furthermore, residual moisture detection which is a crucial factor for protein 
stabilisation is carried out by Karl-Fischer-Titration. The samples for moisture 
detection were ventilated and stored under in nitrogen atmosphere until analysis. 
Fortunately, moisture content in all samples was measured between 0.55% and 
0.67% which is promising for feasibility of a dry protein formulation. 
 
To summarise, hydroxyethyl cellulose polymers of higher chain length produce 
xerogels with as well improved hydration properties as mechanical properties. The 
low residual moisture values are constant in all polymer qualities. Therefore, the 
quality 100.000 appears as best choice for further development. 
 
3.4.1.2.2  Excipients in hydroxyethyl cellulose xerogels 
After the polymers as main ingredients for xerogels have been characterised the 
effects of excipients in xerogel matrices are evaluated. Xerogels are prepared as 
above but the underlying hydrogels contain the additives to be tested. The 
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excipients are substances supporting the stability of the protein drug to be loaded 
on the one hand, i.e. electrolytes including buffer salts and various groups of 
protein stabilisers. On the other hand, substances useful for technical and 
mechanical reasons, especially improvement of swelling capacities are tested. 
Among these are soluble polymers as hydrophilisers and tablet disintegrants for 
improvement of swelling. So, the first group is tested for compatibility with the 
matrix and extent of disturbance of the xerogel formation and mechanical features. 
The second group is evaluated for the purpose of improvement of matrix 
formation and mechanics. Despite the slightly different objective, the influence of 
the particular excipients on the produced xerogels is evaluated in the same 
experimental setting, i.e. with regard to compatibility with the matrix, influence on 
hydration, influence on mechanical properties and residual moisture. The test series 
is conducted with the polymer HEC 100.000. 
 
Screening - for hydroxyethyl cellulose nearly all of the tested substances are 
compatible with the xerogel matrix (Tab. 3-13).  
 
From the group of stabilisers only sodium sulphate and glycine could not be 
incorporated. In detail, in these cases crystals are visible on the surface of the 
xerogel pads. Nevertheless, electrolytes and sugar-like structures tend to harden the 
matrix and decrease swelling. Surfactants and soluble polymers reduce the 
brittleness of the xerogels to some degree. The swellable polymers, crosslinked 
carboxymethyl cellulose, carboxymethyl starch, xanthan gum, and gellan gum, also 
harden the matrix. The hoped for increasing effect on swelling could not be 
verified. Unless, the addition of gellan gum showed the change in flow behaviour 
of the hydrated gel already discussed in the hydrogel section. Residual moistures are 
mainly between 0.5% and 1.5% and therefore suitable for protein stabilisation. 
 
After the screening, buffers, surfactants, and soluble polymers are further tested for 
their influence on swelling in dependence of their concentration. Also a mixture of 
components describing a formulation suitable for stabilisation of ACT is tested.  
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Excipient Concentration in hydrogel 
Elastic modulus 
[mN/mm2] 
Restoring 
energy 
[%] 
Swelling 
q 
Residual 
moisture 
[%] 
Control  22.0 28.2 66.26 0.5 
Potassium phosphate buffer 
pH 7.2 50 mM 39.2 12.8 50.8 0.6 
Potassium citrate buffer pH 
7.2 50 mM 41.1 15.0 33.5 0.6 
Tris HCl buffer pH 7.2 50 mM 20.3 42.3 34.4 0.5 
Sodium chloride 0.9% 35.3 15.6 32.4 0.5 
Potassium chloride 0.9% 34.9 13.2 33.8 0.5 
Calcium chloride 0.5% 45.3 15.9 24.3 0.8 
Magnesium chloride 0.5% 40.8 22.3 28.7 0.7 
EDTA Na 0.5% 35.7 12.2 32.6 0.7 
Arginine 2% 29.9 13.5 45.8 1.0 
Tween® 80 0.2% 24.9 28.3 69.7 0.9 
Poloxamer® 188 0.2% 25.2 25.1 67.0 0.8 
Sucrose 2% 48.7 40.8 22.3 1.8 
Mannitol 2% 46.3 43.2 25.8 1.5 
β-Cyclodextrin 1% 42.6 35.7 32.4 1.4 
Polyvinyl pyrrolidone 17PF 2% 19.6 45.3 52.8 0.9 
Polyvinyl pyrrolidone 90F 2% 18.6 48.7 38.6 0.8 
Polyethylenglycol 2.000 2% 17.8 52.8 36.1 0.8 
Polyethylenglycol 20.000 2% 19.2 59.3 55.2 0.9 
Polyvinyl alcohol 100.000 0.05% 22.3 31.2 34.1 0.5 
Crosslinked carboxymethyl 
cellulose sodium 5% 42.1 25.3 36.2 1.2 
Carboxymethyl starch 4% 25.3 30.2 31.1 1.4 
Xanthan gum  0.5% 23.2 32.1 36.1 1.1 
Gellan gum 0.5% 29.2 48.3 50.6 0.9 
 
Tab. 3-13 Excipients in hydroxyethyl cellulose matrices; xerogels are formed from 2.5% HEC 
100.000 hydrogels with named excipients and concentrations; given is the influence on dry 
mechanics by elastic modulus and restoring energy, the influence on swelling behaviour and 
on residual moisture after lyophilisation (n=2); 
 
Buffers – Both tested buffer types – potassium phosphate and Tris hydrochloride – 
decrease swelling in all tested concentrations. Except for very low contents there 
seems to be only minor dependence on the concentration of the buffer. The 
disturbance of swelling is far more pronounced with Tris hydrochloride than with 
the phosphate system (Fig. 3-39). 
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Fig. 3-39 Swelling behaviour of xerogels made from hydrogels containing 2.5% hydroxyethyl 
cellulose 100.000 and various phosphate buffer ( ) and TrisHCl buffer ( ) contents; 
 
Surfactants – Both candidates increase swelling at all concentration levels. But lower 
concentrations seem to be more effective. Also, with Tween® 80 this effect is more 
pronounced than with Poloxamer® 188 (Fig. 3-40). Further, not only the swelling 
value but also the speed of soaking with liquid and swelling is increased (data not 
shown).  
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Fig. 3-40 Swelling behaviour of xerogels made from hydrogels containing 2.5% hydroxyethyl 
cellulose 100.000 and various Tween® 80 ( ) and Poloxamer® 188 ( ) contents; 
 
Soluble Polymers – Depending on concentration these substances can do both an 
increase and decrease of xerogel swelling. Very low contents of less than 0.1% 
effect a high increase in swelling, whereas concentrations exceeding 0.1% lead to a 
decrease (Fig. 3-41). 
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Fig. 3-41 Swelling behaviour of xerogels made from hydrogels containing 2.5% hydroxyethyl 
cellulose 100.000 and various polyvinyl pyrrolidone 17 ( ) and polyethylene glycol 2.000 
( ) contents 
 
Formulation Mixture – Finally, formulations suitable for stabilisation of ACT are 
evaluated. The formulations are made from hydrogels consisting of 10mM buffer, 
10mM amino acid, 0.1% surfactant, 0.05% soluble polymer, and 2.5% hydroxyethyl 
cellulose 100.000. According to this pattern the substances potassium phosphate, 
Tris hydrochloride, potassium phosphate/citrate, arginine, Tween® 80, Poloxamer® 
188, polyvinyl pyrrolidone 17PF, and polyethylene glycol 2000 are combined in all 
possible variations. 
All prepared xerogel pads appear acceptable. Swelling is satisfactory in all cases 
with values gained exceeding 65.0. Residual moistures have been detected lower 
than 1%.  
The observed hardening of the xerogels with some excipients should be explained 
by a support of the porous polymer structure by substances with stronger 
intermolecular bindings, e.g. ionic bindings in the case of electrolytes and hydrogen 
bonds in the case of sugars. On the contrary, intermolecular bonds between gellant 
molecules should be plastisised by surfactants and other soluble polymers leading 
to a softening of the pad.  
For visualisation of the reconstitution of placebo xerogel formulations one example 
is displayed in Fig. 3-42. 
The xerogel pad is soft and has a favourable as well as homogeneous appearance. 
When put in contact with aqueous solution the pad soaks within seconds until 
completeness without air bubbles being entrapped. For the next two to three 
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minutes the pad keeps its shape before the gel forming process is finished and the 
gel starts flowing like it is typical for non-crosslinked gels (Fig. 3-42). So, from a 
practical point of view this provides enough time after external reconstitution for 
application into the wound site. 
 
 
 
Fig. 3-42 Swelling behaviour of xerogels made from hydrogels containing 2.5% hydroxyethyl 
cellulose 100.000, 10 mM potassium phosphate buffer pH 7.2, 10 mM arginine, 0.1% Tween® 
80, 0.05% polyvinyl pyrrolidone 17; left: dry pad, 2nd from left: pad is soaking when put in 
contact with water, 3rd from left and right: soaked pad stays in shape for 2-3 minutes before 
flowing starts 
 
To conclude, the development of hydroxyethyl cellulose xerogels with formulation 
ingredients suitable for delivery of ACT into open wounds has grown to an 
acceptable state. These patterns are used as starting points for the development of 
ACT loaded xerogels.  
 
3.4.1.2.3  Hydroxyethyl cellulose / gellan gum mixtures for xerogel formation 
For its convenient mechanics in the hydrogel state the mixture of hydroxyethyl 
cellulose 100.000 with gellan gum F is also investigated for xerogel formation. 
According to the rheological examinations the relation of gellant components in 
the mixture is tested. The concentration range thereby is between 1.5% and 3.0% 
for hydroxyethyl cellulose and between 0.7% and 1.5% for gellan gum. Due to the 
sensitivity of the rheology of gellan gum to ionic additives this examination is done 
both without any further excipients and with the addition of mixtures of 
formulation excipients, respectively. Moreover, swelling studies are conducted with 
water and isotonic sodium chloride solution, respectively, as reconstitution media.  
 
All the tested xerogels show an acceptable optical appearance. Moreover, they do 
not differ much in terms of mechanical properties, swelling, and residual moisture. 
So, instead of detailed datasets on all ingredient variations more generalised values 
are given.  
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The pads are harder than the pure hydroxyethyl cellulose pads. So, the elastic 
moduli are measured between 27.5 and 32.1, and restoring energies are found 
around 45%. Residual moistures are detected around 1%.  
Swelling is also hardly affected by gellant composition in the given range, i.e. q 
values of about 50 are found for the swelling without excipients. With formulation 
additives swelling decreases slightly to a q value of 35 to 45 but is still excellent. 
The reconstitution with water and isotonic sodium chloride solution, respectively, 
solely differs in the rheology of the resulting hydrogel. The resulting gel pads 
provide the same differences in rheological properties as the underlying hydrogels 
(Fig. 3-43). The reconstitution process itself seems unaffected.  
 
       
 
Fig. 3-43 Hydroxyethyl cellulose / gellan gum xerogel pad produced from a hydrogel 
containing a 2% / 1% mixture of hydroxyethyl cellulose 100.000 and gellan gum F swollen in 
water; left: dry pad before reconstitution; center: flowing gel pad 5 min after reconstitution 
with water; right: non flowing gel pad 5 min after reconstitution with isotonic sodium chloride 
solution; 
  
Therefore, it can be concluded that the mixture of hydroxyethyl cellulose and gellan 
gum is suitable for xerogel formation.  
Finally, for further studies the relation of the two gellants in the mixture is taken 
over from the hydrogel section. This is done because all tested relations are 
acceptable for xerogel formation but in the hydrated state an optimum has been 
found for a 2.0% / 1.0% mixture. This mixture, therefore, is acceptable for both 
the dry and hydrated state. In fact, further studies are conducted with a 2.0% / 
1.0% hydroxyethyl cellulose 100.000 / gellan gum mixture.  
 
3.4.1.2.4  Other polymers for xerogel formation 
Screening - next to hydroxyethyl cellulose further series of experiments were 
conducted on a variety of polymers. Xerogels were prepared from hydrogels 
consisting of the polymer swollen in water. Autoclavation was carried out where 
possible as outlined in the hydrogel section. The mechanical testing concerning 
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swelling and texture analysis as well as moisture measurement were performed as 
above (Tab. 3-14).  
 
Polymer Quality 
Concentration 
in hydrogel 
[%]l 
Elastic 
modulus 
[mN/mm2]
Restoring 
energy [%]
Swelling 
q 
Residual 
moisture 
[%] 
Alginate Sodium SF250 4.5 57.4 56.0 12.6 1.4 
Carboxymethyl 
cellulose sodium 1.000 6.0 58.7 32.8 11.2 0.9 
Carboxymethyl 
cellulose sodium 10.000 5.0 55.3 30.2 15.8 0.8 
Carboxymethyl 
cellulose sodium 30.000 10.5 51.0 31.8 36.9 0.9 
Carboxymethyl 
cellulose sodium crosslinked 11.5 12.1 9.5 67.4 0.4 
Hydroxypropyl 
cellulose 100.000 2.5 21.0 26.2 56.1 0.6 
Hydroxypropylmethyl 
cellulose 15.000 3.5 29.0 28.2 6.8 0.7 
Hydroxypropylmethyl 
cellulose 100.000 2.5 22.3 30.2 58.6 0.9 
Methyl cellulose 1.000 7.0 29.1 39.9 4.5 1.1 
Carboxymethyl starch 
sodium  8.5 35.0 41.7 27.3 1.3 
Gellan gum LT100 1.5 35.2 44.2 45.8 1.1 
Gellan gum F 1.5 34.4 41.6 56.1 0.9 
Xanthan gum  7.0 29.3 22.4 16.0 1.0 
Dextran 60 40 - - - - 
Gelatine A 10 53.5 45.8 2.97 2.0 
Polyacrylate Sodium Carbopol 940® 1.0 19.0 10.2 88.5 1.5 
Eudragit® L100 1.0 - - - - 
Lutrol® F127 15 25.0 36.1 6.2 2.5 
Polyvinyl pyrrolidone Kollidon
® 
90F 35 - - - - 
Polyvinyl pyrrolidone Kollidon
® 
17PF 45 - - - - 
Polyethylen glycol 20000 75 - - - - 
Polyethylen glycol 2000 75 - - - - 
 
Tab. 3-14 Screening of gelling agents for lyophilisation; xerogels are formed from named 
polymers in listed concentrations; given is the influence on dry mechanics by elastic modulus 
and restoring energy, the influence on swelling behaviour and on residual moisture after 
lyophilisation (n=2); 
 
Concerning optical appearance and residual moisture with most of the listed 
materials satisfactory xerogel formation is possible. However, with polyvinyl 
pyrrolidone, polyethylene glycol, and Eudragit® no acceptable xerogel formation 
was achieved. Therefore, these polymers were not further investgated. 
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Within the optically acceptable samples, though, swelling performance during 
hydration and texture properties are very diverted. The best performing polymers 
in this setting are the group of non-ionic cellulose ethers, i.e. hydroxypropyl 
cellulose, hydroxypropylmethyl cellulose, and methyl cellulose with properties 
similar to hydroxyethyl cellulose outlined above. Hereby, again the higher 
molecular weight turned out to be advantageous. More lipophilic derivatives 
provide reduced swelling properties. This is supposed to be related to reduced 
interactions with hydrophilic reconstitution media.  
Non-crosslinked carboxymethyl cellulose sodium, alginate sodium, and xanthan 
gum form harder and more slowly swelling matrices due to the strong ionic binding 
character of these polymers. The crosslinked carboxymethyl cellulose sodium and 
carboxymethyl starch that are commonly used as tablet disintegrants provide an 
amazing swelling behaviour. But, the crosslinked carboxymethyl cellulose matrix is 
not coherent and disintegrates into powdery snatches under slight mechanical 
stress. Carboxymethyl starch suffers from the hardness of the xerogel structure. A 
huge swelling capacity is also seen with pure gellan gum, but it as well suffers from 
hardness of the matrix. Polyacrylate sodium also swells to huge extend but on the 
contrary forms an only very weak structure due to the low content. Moreover, 
gelatine forms very hard and hardly swelling matrices. 
 
Excipients - excipient compatibility studies according to those with hydroxyethyl 
cellulose are conducted on carboxymethyl cellulose 10.000, hydroxypropylmethyl 
cellulose 15.000, hydroxypropylmethyl cellulose 100.000, and hydroxypropyl 
cellulose 100.000. Although experiments are performed as previously described 
results are given out in a short summary for reasons of lucidity. 
Concerning compatibility for all tested types of xerogels the influence of additives 
is similar as on hydroxyethyl cellulose xerogels. However, in all samples 
hydroxypropylmethyl cellulose and hydroxypropyl cellulose matrices still show a 
reduced swelling compared to those of hydroxyethyl cellulose. Experimental values 
are gained between 17 and 45 for both polymers. Furthermore, as carboxymethyl 
cellulose matrices generally are harder in texture due to higher density and the ionic 
structure the effects of additives are reduced. Also, an improvement of swelling 
behaviour by excipients is provoked only to a very limited extent. 
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3.4.2 Stability of ACT in xerogel formulations 
According to the results of the mechanical studies on xerogels most of the relevant 
protein stabilisers are compatible with the xerogels from that point of view and so 
can be used for further development of ACT stabilising formulations. Therefore, 
excipients are introduced in lyophilisation studies on ACT formulations that were 
tested positively in the prior stability studies on ACT concerning temperature and 
freeze/thaw stressing on the one hand, as well as in mechanical studies on xerogels 
on the other hand. The investigation of excipients in lyophilisation tests 
additionally to F/T stress – described in the hydrogel section - is necessary because 
denaturation can be induced by both freezing and subsequent drying179. First, the 
lyophilisation process itself as stress factor is investigated. Second, a three months 
stability study on xerogels is conducted. 
 
3.4.2.1  Stability of ACT during the lyophilisation process 
Due to the fact that most sugarlike substances demonstrated a destabilising effect 
on ACT in solution the polymers are used as bulking agents. Thereby, we have to 
accept that the known protective effect of disaccharides on proteins may not be 
mimicked by the polymers180.  
Sample gels are prepared in eppendorf caps to 0.1ml volume with 60µg/ml ACT 
and the excipients to be tested. In the further descriptions all concentrations of 
substances refer to the hydrated state of the particular gel. After swollen 
homogeneously the gels are freeze-dried using the procedure with annealing step 
described above whereby the xerogels are formed. These are reconstituted with 
40mM potassium phosphate buffer pH 7.2 immediately after lyophilisation adding 
up to 50mM buffer defined as standard in the solution stability testing. Due to the 
high resulting viscosities samples are diluted for analysis as before with 50mM 
potassium phosphate buffer pH 7.2 containing 0.1% Poloxamer® 188.  
Buffers - the first group of ingredients to be tested are the buffer components. Thus, 
10mM potassium phosphate, 5/5mM potassium citrate/phosphate mixture, 10mM 
Tris hydrochloride, 10mM arginine phosphate, and 5/5mM arginine 
citrate/phosphate mixture are tested in 2.5% hydroxyethyl cellulose matrices (Fig. 
3-44). 
In all buffer systems losses between 30% to 45% are detected. This indicates the 
necessity of further stabilisers. Although arginine seems to effectuate further 
reduction of recovered ACT activity compared to arginine free samples differences 
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are too marginal to lead to a decision over a favourite buffer system. This is to be 
evaluated during mid term stability tests.  
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Fig. 3-44 Relative activity of ACT in 2.5% hydroxyethyl cellulose 100.000 xerogels with 
10mM buffers after reconstitution with 40mM potassium phosphate buffer pH 7.2 measured 
by activity assay; 
 
Surfactants and soluble polymers - in the next series the influence of surfactants and 
soluble polymers is studied. Though, generally surfactants are not known to inhibit 
protein unfolding during dehydration181, they are tested for lyoprotection because 
they have been proven to be beneficial during freezing in the solution stability 
section. The soluble polymers are also known as lyoprotectants of proteins182,183. 
Samples with a basic matrix consisting of 2.5% hydroxypropylmethyl cellulose 
100.000 and 10mM potassium phosphate buffer are spiked with 0.1% Poloxamer® 
188, 0.1% Tween® 80, 0.5% PEG 2000, and 0.5% PVP 17, respectively. The 
control sample next to ACT solely contains gellant and buffer. Freeze drying, 
dilution and analysis is carried out as above. 
Surfactants clearly improve the stabilisation of ACT during lyophilisation, whereby 
Tween® 80 appears more effective than Poloxamer® 188. In accordance with 
literature, this may be explained by the protective activity of surfactants during 
freezing. PEG 2000 as well leads to higher recovered ACT activity. In contrast, the 
PVP 17 sample is comparable to the control, so PVP can be considered as inert 
(Fig. 3-45). It has been reported that soluble polymers like PEG184, PVP185 186, and 
PVA187 interact with proteins during freezing and drying e.g. by preferential steric 
exclusion. These interactions may lead to either stabilisation, destabilisation, or no 
change in protein stability depending on the particular protein and other factors, 
e.g. concentration. 
 
Chapter 3 – Results and Discussion 
- 114 - 
69,5
81,0
98,1
76,2
64,3
0 20 40 60 80 100
0.5 % Kollidon 17PF
0.5 % PEG 2000
0.1 % Tween 80
0.1 % Poloxamer 188
control
relative activity [%]
 
Fig. 3-45 Relative activity of ACT in 2.5% hydroxypropylmethyl cellulose xerogels with 
10mM potassium phosphate buffer pH 7.2 after reconstitution with 40mM potassium 
phosphate buffer pH 7.2 measured by activity assay; control without additional spiking, 
samples with surfactant and soluble polymer, respectively; 
 
Gelling agents and hydroxypropyl-β-cyclodextrin - the different gelling agents are tested in 
already improved formulations. Indeed, they contain 10mM potassium phosphate 
buffer pH 7.2, 0.1% Tween® 80, 0.05% PEG 2000, and variing polymers as gelling 
agents. These are hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and 
hydroxyethyl cellulose. Moreover, a gellan gum/hydroxyethyl cellulose mixture, 
carboxymethyl cellulose sodium, and alginate sodium are tested. A variation with 
hydroxypropyl-β-cyclodextrin added to each gellant was conducted in parallel. 
Without cyclodextrin the non-ionic polymers perform better than the ionic and 
sodium containing gelling agents. The gellan gum/HEC mixture surprisingly shows 
highest recovered ACT activities. It has been reported that this class of substances 
can provide stabilising capacity on proteins188. The ionic, sodium containing 
polymers may interact with the phosphate buffer system and lead to the well 
known pH shift during freezing. This may lead to the detected loss of activity. The 
series with cyclodextrin addition features generally lower activity values than 
without cyclodextrin. Most notably, the samples with the more lipophilic agents 
suffer from the cyclodextrin influence (Fig. 3-46). 
 
Chapter 3 – Results and Discussion 
- 115 - 
63,5
67,7
70,1
34,2
36,9
76,3
75,7
125,5
95,2
103,9
94,3
0 20 40 60 80 100 120
Alginate Na
Carboxymethyl
cellulose Na
Gellan Gum/HEC
Hydroxyethyl
cellulose
Hydroxypropylmethyl
cellulose
Hydroxypropyl
cellulose
relative activity [%]
*
 
Fig. 3-46 Relative activity of ACT in xerogels with 10mM potassium phosphate buffer, 0.1% 
Tween® 80, 0.05% PEG 2000 and gelling agent (above) and additional 0.0075% 
hydroxypropyl-β-cyclodextrin spike (below) after reconstitution with 40mM potassium 
phosphate buffer measured by activity assay; gellants are 2.5% hydroxypropylmethyl-, 
hydroxypropyl-, hydroxyethyl cellulose 100.000, gellan gum/hydroxyethyl cellulose 100.000 
1%/2% mixture, 3.0% carboxymethyl cellulose sodium 10.000, 5.0% alginate sodium; * 
sample not measured; 
 
To summarise, in this section the influence of the lyophilisation process for xerogel 
formation as stress factor on ACT stability is evaluated. It is found that xerogel 
formation with embedded active ACT is possible. Excipients can be chosen in 
concordance with results from studies on solution, hydrogel, and placebo xerogel. 
Buffer variations can be used as tested although arginine seems to be awkward. 
Surfactants and soluble polymers can be used without constraints. For the gelling 
agents non-ionic species are preferable. The gellan gum containing samples 
surprisingly turn out to provide the most effective stabilisation on ACT.  
 
3.4.2.2 Mid term stability of ACT in xerogel formulations 
Based on the previous results of the stabilisation in hydrogels and xerogels a three 
months stability test in xerogels was launched with a set of formulations. Variations 
are made in excipient composition. For the surfactant Tween® 80 and Poloxamer® 
188 are evaluated, for buffer systems phosphate, phosphate/citrate, and Tris 
hydrochloride are tested. As in the hydrogel tests, for gellants only hydroxyethyl 
cellulose and mixtures of hydroxyethyl cellulose with acylated (LT100) and 
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deacylated (F) derivatives of gellan gum are investigated. Despite other non-ionic 
cellulose ethers could also be considered according to the given results 
hydroxyethyl cellulose is chosen for its suitability for autoclavation. Additionally, 
the soluble polymers are varied between polyvinyl pyrrolidone and polyethylene 
glycol. 
Samples of ACT loaded gels were prepared under aseptic conditions as before. 
Packaging containers are glass vials that are sealed with a Teflon®-coated 
lyophilisation rubber stopper. The concentration of ACT in hydrated state was 60 
µg/ml, sample volume was 0.4 ml. After swollen homogeneously the gels are 
freeze-dried using the procedure with annealing step described above whereby the 
xerogels are formed. 
Xerogels are then stored at two temperature levels, 25°C and 40°C. After 4, 8, and 
12 weeks storage time samples are drawn and stored at –80°C until analysis. 
Xerogel samples then are reconstituted and prediluted as described above. Readout 
is again done by activity assay. For the samples stored for three months SDS-
PAGE is performed in addition. 
Calculations described in detail in the hydrogel section are conducted to estimate 
reaction kinetics and shelf lives under storage conditions. The 25°C level simulates 
real conditions for storage at room temperature, 40°C simulates temperature stress 
conditions. Other than in the hydrogel study the 6°C temperature level was omitted 
in this setting. This was done because the changes of measured values were 
estimated to be too small in comparison to the spreading of measured values 
delivered by the activity assay. In that case reasonable conclusions would be 
impossible. Moreover, a refrigerated storage of a lyophilised product at this 
temperature level would be hardly acceptable due to marketing concerns.  
The assessment of samples is done in pursuance with the suitability of the xerogel 
formulation as future storage form for stocking at room temperature. Therefore, 
the 25°C estimation has to exceed 18 months above the lower specification limit.  
 
3.4.2.2.1  Principles of data interpretation 
Generally, results are gained as a set of activity loss curves over time for every 
formulation and temperature level. An example is shown in Fig. 3-47. From a 
starting value of about 100% the activity declines over the 3 months of storage 
time.  
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Fig. 3-47 Recovered relative activities of a xerogel formulation consisting of 60µg/ml ACT, 
10mM arginine, 0.1% Poloxamer® 188, 0.05% PEG 2000, 2.5% hydroxyethyl cellulose 
100.000 in a 10mM potassium phosphate buffer pH 7.2 at 25°C ( ) and 40°C (□) in linear 
scale measured by activity assay;  
 
As in the mid-term stability study on hydrogels reaction kinetic functions are fitted 
to the modified curves and next to the equation parameters the correlation 
coefficient is determined and used for assessing the feasibility of the fitted reaction 
order. Fig. 3-48 shows an example for the fitting of the first order time law. 
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Fig. 3-48 Recovered relative activities of a xerogel formulation consisting of 60µg/ml ACT, 
10mM arginine, 0.1% Poloxamer® 188, 0.05% PEG 2000, 2.5% hydroxyethyl cellulose 
100.000 in a 10mM potassium phosphate buffer at 25°C ( ) and 40°C (□) in logarithmic 
concentration scale with fitted logarithmic functions resulting in evens in the one-sided 
logarithmic scale as predicted by first-order time law; measured by activity assay; 
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Results indicated that the best fittings given by correlation coefficients are gained 
for the first order equation, i.e. a logarithmic scale for relative activity results. In 
fact, the coefficients for 1st order are between 0.985 and 0.999, for zero order 
coefficients are between 0.950 and 0.992, and coefficients for 2nd order are below 
0.96. 
Like in the hydrogel section datasets are tested according to the guideline ICH-
QA1. Further, for an estimation of the shelf life the 95%-confidence intervals are 
calculated for the curves where appropriate. The intercept of the lower confidence 
limit with the lower specification limit – in our case 10 % loss of relative activity - 
indicates the end of the shelf life. Alternatively, the intercept of the extrapolated 
decay even with the lower specification limit is equated with the end of shelf life.  
 
3.4.2.2.2  Experimental results and discussion 
The kinetics of the decay curves follow most likely the first order time law (Fig. 3-
48) because correlation coefficients are best for the first order kinetics in most 
cases (data not shown).  
But, all datasets show change-over-time and additionally many are variable 
according to ICH-QA1 guideline (calculations not shown). Thus, confidence 
intervals of most datasets are too large to allow a sensible, statistically profound 
estimation of shelf life as described above.  
Instead, the described alternative is applied. The estimation is made by simple 
extrapolation of the fitted curve to the intercept with the 10% loss level as lower 
specification limit. For all formulations, consequently, first order reaction constants 
for every temperature level are calculated and corresponding shelf lives are 
estimated (Tab. 3-15). 
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60µg/ml α1-antichymotrypsin reaction constant k (24°C) 8.71·10-4 1/day 
10mM phosphate buffer reaction constant k (40°C) 3.08·10-3 1/day 
10mM arginine shelf life 25°C 121.0 days 
0.1% Poloxamer® 188 shelf life 40°C 34.3 days 
0.05% PVP 17   
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin reaction constant k (24°C) 1.48·10-4 1/day 
10mM phosphate buffer reaction constant k (40°C) 1.21·10-3 1/day 
10mM arginine shelf life 25°C 711.3 days 
0.1% Tween® 80 shelf life 40°C 87.3 days 
0.05% PVP 17   
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin reaction constant k (24°C) 1.17·10-3 1/day 
10mM phosphate buffer reaction constant k (40°C) 3.53·10-3 1/day 
10mM arginine shelf life 25°C 89.9 days 
0.1% Poloxamer® 188 shelf life 40°C 29.9 days 
0.05% PEG 2000   
2.5% HEC 100.000   
 
60 µg/ml α1-antichymotrypsin reaction constant k (24°C) 8.68·10-4 1/day 
10mM phosphate buffer reaction constant k (40°C) 3.47·10-3 1/day 
10mM arginine shelf life 25°C 121.4 days 
0.1% Poloxamer® 188 shelf life 40°C 30.4 days 
0.05% PVP 17   
2.0% HEC 100.000   
1.0% gellan gum LT100   
 
60µg/ml α1-antichymotrypsin reaction constant k (24°C) 1.92·10-4 1/day 
10mM phosphate buffer reaction constant k (40°C) 1.40·10-3 1/day 
10mM Arginine shelf life 25°C 547.7 days 
0.1% Poloxamer® 188 shelf life 40°C 75.5 days 
0.05% PVP 17   
2.0% HEC 100.000   
1.0% gellan gum F   
 
60µg/ml α1-antichymotrypsin reaction constant k (24°C) 4.06·10-4 1/day 
10mM Tris HCl buffer reaction constant k (40°C) 1.19·10-3 1/day 
10mM Arginine shelf life 25°C 259.3 days 
0.1% Poloxamer® 188 shelf life 40°C 88.4 days 
0.05% PVP 17   
2.0% HEC 100.000   
 
Tab. 3-15 Formulations of the mid term stability testing with ingredients (left column), first 
order reaction constants k at the experimental stress levels, and estimated shelf lives at the 
temperature levels (right column); 
 
Unless data show variation according to the ICH-QA1 guideline several 
conclusions can be made. For xerogels stored in glass vials the Tris hydrochloride 
system has greater stabilising potential than the phosphate buffer. This is 
manifested in shelf lives of formulation (1) in comparison with (6). The surfactant 
(1) 
 
 
 
 
 
(2) 
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(5) 
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Tween® 80 performs better than the Poloxamer® 188 alternative. See comparison 
of formulation (1) with (2). For the soluble polymers PVP is favourable over PEG 
as shelf lives of formulation (1) and (3) indicate. Moreover, the HEC / gellan gum 
F gellant system is favourable over pure hydroxyethyl cellulose and the HEC/gellan 
gum LT100 alternatives. This results from comparison of formulation (1) with (4) 
and (5).  
So, there are the two formulations – (2) and (5) - with shelf lives of about or greater 
550 days (18 months). Thus, these meet the stability requirements for a storage 
form for stocking at room temperature defined at the beginning of development.  
 
 
 
Fig. 3-49 Stability of ACT in formulations after a 3 months storage at 25 °C measured by 
SDS-PAGE:  
lane 1: formulation (1) with 9.4% 100kDa aggregate; lane 2: formulation (2) with 4.7% 
100kDa aggregate; lane 3: formulation (3) with 3.5% 100kDa aggregate; lane 4: formulation 
(4) with 1.7% 100kDa aggregate, 7.2% 40kDa, 10.7% 10kDa, and other fragments; lane 5: 
formulation (5) with 3.5% 100kDa aggregate; lane 6: formulation (6) with 0.7% 100kDa 
aggregate; lane 7: marker;  
control without degradation is visualised in Fig. 3-4 
 
The readout by SDS-PAGE for samples stored over three months at 25°C shows 
the dimer formation again as main instability. Again the addition of Tween® 80, 
Tris hydrochloride and the HEC/gellan gum F are favourable over particular 
alternatives. With gellan gum LT100 an extensive fragmentation is detected. Hence, 
the formulations (2) and (5) can be recommended for further development. 
However, the greatest stabilising potential of a xerogel formulation is to be 
estimated for a combination of Tween® 80 and HEC/gellan gum F maybe in a Tris 
hydrochloride buffer system. Although, this combination is not yet tested and 
therefore cannot be recommended for immediate further development. But, in 
future studies, e.g. adjustment of the formulation for market launch, this can be 
taken into account. 
 
100 kDa
 
60 kDa 
 
40 kDa 
 
 
10 kDa 1 2 3 4 5 6 7
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3.4.2.2.3  Summary 
Results indicate that reaction kinetics of activity decay of ACT in xerogels is highly 
likely to follow a first order equation. Main instability again is the loss of activity 
and dimer formation. Moreover, a commercial formulation of ACT in a xerogel is 
possible due to sufficient shelf life. Furthermore, the two suitable formulations 
after reconstitution can be applicated into the wound site as far as stability of ACT 
is concerned. As well, these formulations are applicative for the purpose of animal 
experiment or clinical trial. Results also indicate that a not yet tested excipient 
combination may be the most effective stabilising formulation. This can be 
evaluated within later studies, e.g. adjustment of the product for market launch. 
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3.4.3 Polymer films as drug delivery systems for wound 
healing 
To date, there are several non-swellable polymer film products used as drug free 
wound dressings in clinical practice. For example, OpSite® by Smith&Nephew 
consists of a polyurethane film with a polyacrylate adhesive. 
Besides, few patents have been applicated on swellable film dressing materials189. 
Some of these films also contain protein drugs190. But, like with xerogel matrices 
none of those developments has led to approval by authorities let alone to market 
launch, yet. 
In this section, the development of a production process for placebo swellable film 
carriers and investigations of their mechanical properties are described. Thereby, 
influence of the drying process, of the polymer composition, and of further 
formulation ingredients are highlighted.  
These studies are aiming at ensuring the suitability of the films as wound dressing 
and at investigating the compatibility with protein formulation ingredients. The 
development strategy, the used methods, and experimental design is similar to the 
xerogel development outlined in the previous chapter. For that reason, to avoid 
redundancy the description of methods and discussions is shortened with reference 
to the particular chapter of the xerogel studies. Moreover, the differences between 
xerogel and film development are stressed. 
So, one major difference is the swelling behaviour of films compared to that of 
xerogels. Films do not provide an open pore structure. Rather, they swell from 
outside to inside which is a much slower process than the soaking and swelling of 
xerogels. Thus, the swelling is not supposed to be completed when the film is 
applicated into the wound site. The wound will be confronted with a semi-
reconstituted state of the film. Therefore, the texture is the most important 
mechanical feature for polymer films. In fact, a certain robustness and a soft 
consistency is highly desirable for application and compliance reasons.  
 
3.4.3.1  Production process 
There are several methods in use for production of polymer films. In the field of 
oral dosage forms polymer films serve as coating material. There, the film is formed 
by spraying a polymer dispersion onto the tablet core followed by evaporation of 
the dispersion media. For self supportive films the most common method of film 
manufacture is blown film extrusion. The process involves extrusion of a plastic 
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melt through a circular die to form a thin walled tube, followed by bubble-like 
expansion by air being introduced via a hole in the centre of the die. The outcome 
of this process is a film tubing that is cooled and flattened to create a lay-flat tube 
of film. The regulation of film width and thickness is done by control of the 
volume of air in the bubble and the output of the extruder. Polyethylene is the 
most common polymer in use for blown film. Next to that, films can be formed by 
precipitation out of particular baths. But, the method mainly used for water 
swellable polymers is the dry-cast method. Thereby, a melt or a solution of the 
polymer is extruded through a die onto a roll. There, the mass cools down to form 
a film robust enough to be transferred onto a mesh for drying. The drying may be 
completed in a drying tunnel. This procedure is appropriate for many 
pharmaceutically relevant polymers such as gelatine and the cellulose ethers. A 
special application of this method is the production of transdermal therapeutic 
systems. Thereby, the polymer matrix is not directly cast onto the roll but onto a 
backing layer being placed between the roll and the matrix. Maybe, the mass is cast 
on a web before the backing is added. Further transportation is also supported by 
the backing layer.  
 
Although these procedures are widely used, they are not suitable for the minimal 
amounts of lab scale protein drug delivery. For that reason, two scale-down 
methods depending on the gel amount to be dried are investigated.  
 
For higher gel amounts a method involving a scraper is used. Thereby, the gel is 
filled in the scraper apparatus which consequently is drawn over a glass plate. By 
mild extrusion through the defined gap resulting from the movement over the plate 
a wet film of constant thickness is formed (Fig. 3-50). This film can be dried under 
laminar flow at room temperature or in a cabinet drier at any desired temperature. 
When dry, the self supportive film is removed from the plate (Fig. 3-50). When 
later preparing ACT loaded films in very low scale the appropriate amount of gel is 
placed on the bottom of an eppendorf cap or a vial. Consequently, the mass is 
dried under a flow of nitrogen in a special device controlling both gas and product 
temperature191. The film forms on the bottom and side walls of the container (Fig. 
3-50).  
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Fig. 3-50 Films made from 2.5% hydroxyethyl cellulose 100.000 hydrogels; left: 2R glass vial 
with dried film on the bottom an lower side walls; center: wet film being cast out with 
scraper; right: self supportive film after removal from plate; 
 
3.4.3.2 Gel composition for polymer film formation 
A variety of polymers is screened for eligibility for warm air drying and film 
formation. The concentration of the gellant in the hydrogel is chosen according to 
the results of the rheological studies during hydrogel development. After drying the 
films are examined concerning optical appearance, texture analysis, swelling 
behaviour, and residual moisture. Thereby, as during xerogel development 
optimised film compositions are to be developed concerning texture properties and 
embedding of protein stabilisers.  
Hence, films consisting of pure gelling agent are screened. In addition, texture 
properties of film compositions containing hydroxyethyl cellulose as gelling agent 
are optimised. Moreover, the formation of a film matrix made from two gellants – 
hydroxyethyl cellulose and gellan gum - is described. The compatibility of 
excipients with the particular film matrices is investigated subsequently. 
 
3.4.3.2.1  Gelling agents for film formation 
The screening of gelling agents is conducted in similar manner as during xerogel 
development described above.  
From the variety listed in Tab. 3-12 only the cellulose derivatives, alginate, xanthan 
gum, and gellan gum form acceptable films concerning their optical appearance 
after drying. However, the ionic polymers carboxymethyl cellulose sodium and 
alginate sodium form very hard and stiff films. Especially alginate films tend to 
break before drying is completed. These characteristics again should be related to 
the strong ionic intermolecular forces in these polymers. Besides, xanthan gum and 
Chapter 3 – Results and Discussion 
- 125 - 
gellan gum form softer but very brittle films. This implicates as well a tendency of 
breaking of the film in the later stages of drying. Finally, the non-ionic cellulose 
derivatives turn out as the most promising candidates. They form the softest and 
most elastic films in these experiments.  
The hardness and stiffness of films can be counteracted by a plasticiser. In the film 
structure solely consisting of gelling agent, the individual molecules of the polymer 
lack mobility because of their mutual interference which is much higher when ionic 
binding is involved. The use of a plasticiser implicates the introduction of a lower 
molecular weight substance into the structure that acts as a molecular lubricant, 
physically separating the chains and allowing them some mobility, thus giving 
flexibility. Obviously, the larger the volume of plasticiser is, the greater is the 
flexibility and softness. Common plasticisers in pharmaceutical products are esters 
of organic acids, e.g. citric acid and phthalic acid, polyalcohols and esters thereof, as 
well as polyethylene glycol derivatives. Although even very hard films should get 
softened by plasticiser addition, the film specimen already being softer without 
plasticiser, however, are taken as starting point for further development.  
Furthermore, generally, it is seen that the higher the concentration of the gelling 
agent in the hydrogel the more stiff appear the resulting films. That is obviously 
related to higher thickness of the film also resulting in a delayed swelling behaviour 
of these matrices. Unfortunately, this is hardly measurable in the swelling 
experiments but is noticeable by the degree and speed of softening of the films 
during hydration. Because a fast softening during hydration is desirable for a 
wound dressing, the focus of development concerning gelling agents is on high 
molecular weight polymer qualities. 
Although the film samples produced in this series from pure gelling agent are 
promising, none of those can be used as a wound dressing without further 
modifications. Because, the samples providing enough flexibility lack of a certain 
robustness required for proper handling. On the contrary, the more robust films 
fail to be flexible enough for a convenient application. Therefore, the use of 
plasticisers and strengtheners as additives on pure gelling agent with special focus 
on HEC and HEC/gellan gum is evaluated.  
 
3.4.3.2.2  Polymers as additives to hydroxyethyl cellulose films 
It has been pointed out that films solely consisting of a pure cellulose derivative 
cannot be recommended for use as a wound dressing. Therefore, the addition of 
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further excipients, namely polymers, is investigated to cope with the major weak 
points of the cellulose ethers in the formation of self supportive films.  
 
3.4.3.2.2.1 Swelling  
The films examined until this point of development offer a constantly low swelling 
rate at least compared to the xerogels. Therefore, the addition of tablet 
disintegrants – carboxymethyl starch and crosslinked carboxymethyl cellulose - to 
the film formulation is investigated to increase swelling of these matrices.  
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Fig. 3-51 Swelling of film matrices made from hydrogels containing 2.5% hydroxyethyl 
cellulose 100.000, 2.5% hydroxypropyl cellulose 100.000, 2.5% hydroxypropylmethyl 
cellulose 100.000, 3.5% hydroxypropylmethyl cellulose 15.000, and 5.0% carboxymethyl 
cellulose sodium 10.000, respectively (left bar); swelling with addition of 0.5% 
carboxymethyl starch to the basic hydrogels (center bar); swelling with addition of 0.5% 
crosslinked carboxymethyl cellulose to the basic hydrogels (right bar); 
 
Unfortunately, the hoped for effect of improvement of the swelling behaviour of 
the film matrices by adding disintegrants can not be verified. All swelling values are 
taken after three minutes exposure to water. Most of the values range between 5 
and 7 and therefore are 2 to 10-fold lower than the corresponding xerogel values 
(Fig. 3-51).  
Next to these experiments neither with surfactants nor with soluble polymers a 
major improvement of the swelling characteristics can be achieved.  
As a result, the application of films is supposed to be different from the application 
of xerogels. With the xerogels it is found that reconstitution is completed before or 
in the moment of application. In contrast, the films can not swell in that short 
period of time. Following, the film is to be wetted before placing onto the wound. 
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At that point reconstitution is started and will proceed in the wound with wound 
fluid or solution provided externally beneath and on top of the film. As a matter of 
fact, the wound will be confronted with a semi-reconstituted film not yet 
completely transformed into a hydrogel. For that reason, the texture properties of 
films play a very important role for the applicability of these matrices. 
Consequently, these are optimised by texture analysis outlined below. 
 
3.4.3.2.2.2 Texture 
For the optimisation of the mechanical characteristics a system consisting of three 
excipients is evaluated – the gelling agent, a strengthener, and a plasticiser. These 
studies are conducted on hydroxyethyl cellulose 100.000 as gellant, polyvinyl 
pyrrolidone 17 as strengthener, and polyethylene glycol 400 as plasticiser.  
However, due to extensive interaction the particular influences of these three 
substances on mechanics cannot be treated separately. Hence, all tested samples 
contain the three ingredients in varying concentrations. For evaluation of this 
complex system a simplex-lattice factorial design with the three factors on five 
levels is created. In detail, the concentration levels of HEC 100.000 are 1.13%, 
2.25%, 3.0%, 4.0%, and 5.0%. For PVP 17 and PEG 400, the levels are 0%, 1.0%, 
2.25%, 3.0%, and 4.5%. Response surfaces are calculated from average values of 
two measurements. 
Characterisation is done by texture analysis. Thereby, the tensile strength at rupture 
is gained from a tensile test method where the film is placed between two grips and 
is extended until rupture (Fig. 3-52).  
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Fig. 3-52 Measurement of tensile strength with texture analyser (left); force-distance diagram 
of tension experiments with rupture at 11.8 N (right); 
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The tensile strength value is calculated from applied force at rupture and the cross 
section area of the film specimen192 (Equ. 3-12).  
 
A
FTS =  
 
Equ. 3-12 Tensile strength TS [N/mm2]; F is applied force at rupture [N], A is cross-sectional 
area [mm2]; 
 
Moreover, the elastic modulus is tested in a puncture test where the sample is 
expanded and penetrated by a ball probe192 (Fig. 3-53).  
 
  
0
20
40
60
0 2 4 6 8 10 12
Elongation dL [mm]
Fo
rc
e 
F 
[N
]
 
 
Fig. 3-53 Measurement of elastic modulus with texture analyser (left); force-distance diagram 
of penetration experiments with rupture at 61.5 N (right); 
 
From the resulting load-displacement diagrams and the physical dimensions of the 
construction elastic moduli are calculated (Equ. 3-13).  
 
L
dL
A
F
strain
stressE ==  
 
Equ. 3-13 Young’s modulus of elasticity E [N/mm2]; F is applied force [N], A is cross-
sectional area [mm2], dL is change in length [mm], L is unstressed length [mm]; 
 
For visualisation of the different aspects of mechanical characterisation the 
response surfaces calculated by a 3rd order model with the Origin® Software are 
given describing the interaction of two particular factors. The third factor thereby is 
kept on a constant level. Like before, concentrations given in this section refer to 
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the hydrogel state before drying. Film specimen are gained by drying of a wet film 
of 2 mm height consisting of the particular hydrogel.  
 
Robustness - Surely, a certain robustness of the films is necessary to ensure a proper 
handling of the product by patients and medical personnel in practice. Thus, as a 
measure for robustness the tensile strength of the film specimen are investigated by 
texture analysis.  
Yet, the tensile strength of the system depends on all components of the ternary 
mixture. First of all, a set of gels is examined with a constant PEG content and 
varying HEC and PVP contents. As expected, the tensile strength of the film 
increases with rising HEC contents. But, tensile strength values of about 4.5 
N/mm2 gained for the practical concentrations of HEC between 2% to 3% are not 
satisfactory. But, with the addition of PVP an increase in tensile strength can be 
detected. Although values exceeding 10 N/mm2 can be achieved a reasonable 
content should be between 2.0% to 3.5% leading to strength values of 8.0 to 9.0 
N/mm2 (Fig. 3-54).  
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Fig. 3-54 Response surface calculated from tensile strength values of samples with 2.25% 
polyethylene glycol 400; hydroxyethyl cellulose 100.000 and polyvinyl pyrrolidone 17 
contents vary according to a simplex-lattice design; concentrations refer to the hydrated state 
before drying; 
 
Further, the effect of the plasticiser is clearly visible in Fig. 3-55. The content of 
PVP in this setting is kept at constant level - 2.25% in the hydrogel state. Variables 
are the HEC and PEG content. Here, a clear optimum for the PEG content is 
detected, i. e. from 0% until 2% PEG content an increase of strength values can be 
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seen. However, from 2% to higher concentrations of PEG a decrease of tensile 
strength is following. In fact, there is a clear maximum of tensile strength gained at 
1.5% to 2.25% polyethylene glycol content for all tested formulations.  
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Fig. 3-55 Response surface calculated from tensile strength values of samples with 2.25% 
polyvinyl pyrrolidone 17; polyethylene glycol 400 and hydroxyethyl cellulose 100.000 
contents vary according to a simplex-lattice design; concentrations refer to the hydrated state 
before drying; 
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Fig. 3-56 Response surface calculated from tensile strength values of samples with 2.25% 
hydroxyethyl cellulose 100.000; polyethylene glycol 400 and polyvinyl pyrrolidone 17 
contents vary according to a simplex-lattice design; concentrations refer to the hydrated state 
before drying; 
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The described maximum of tensile strength at an optimal PEG concentration is 
also visible in the third group of interacting partners. Because, for varying PVP 
contents and a constant HEC concentration the same maximum around 2% PEG 
content is obtained (Fig. 3-56).  
 
Flexibility - For a convenient and free of pain application as well as for provision of 
efficient contact to the wound ground a high flexibility of the film matrix is 
desirable. Thus, the elastic modulus E which is a measure for stiffness and a 
reciprocal measure for flexibility is calculated from texture analysis as given in Equ. 
3-13. 
Other than the tensile strength the elastic modulus is mainly dependent on the 
PEG content. Only at very low concentrations of PEG influences by the other 
components are noticeable in the tested concentration range. Indeed, at the PEG 
level detected as optimal for tensile strength – around 2% concentration in 
hydrogel state - the elastic moduli of the systems are at a constant low level nearly 
independent of the gellant (Fig. 3-57) and strengthener content (Fig. 3-58).  
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Fig. 3-57 Response surface calculated from elastic moduli of samples with 2.25% 
hydroxyethyl cellulose 100.000; polyethylene glycol 400 and polyvinyl pyrrolidone 17 
contents vary according to a simplex-lattice design; concentrations refer to the hydrated state 
before drying; 
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Fig. 3-58 Response surface calculated from elastic moduli of samples with 2.25% polyvinyl 
pyrrolidone 17; polyethylene glycol 400 and hydroxyethyl cellulose 100.000 contents vary 
according to a simplex-lattice design; concentrations refer to the hydrated state before drying; 
 
To sum up, by the addition of polymers the mechanics of swellable, self-supportive 
polymer films made from cellulose ethers as main ingredient can be influenced and 
optimised to a major extent. It has been shown that a film with favourable handling 
and applicative properties can be manufactured from formulations of the following 
pattern:  
 
2.0% – 2.5%  Hydroxyethyl cellulose 100.000 
2.0% - 3.5%  Polyvinyl pyrrolidone 17 
1.5% - 2.5%  Polyethylene glycol 400  
 
Concentrations given refer to the hydrogel state before drying. However, the low 
swelling rate of polymer films could not be improved by addition of polymers to 
hydroxyethyl cellulose films. 
 
3.4.3.2.3  Hydroxyethyl cellulose / gellan gum mixtures for film formation 
For its convenient rheology in the hydrogel state the mixture of hydroxyethyl 
cellulose 100.000 with gellan gum is also investigated for film formation. Thereby, 
the relation of gellant components in the mixture is tested with the concentration 
range being between 1.5% and 5.0% for hydroxyethyl cellulose and between 0% 
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and 1% for gellan gum. Each film additionally contains 2.25% PEG 400 and 2.25% 
PVP 17 according to the results with pure hydroxyethyl cellulose films outlined 
above. These films are tested by texture analysis and swelling studies that are 
conducted with water and isotonic sodium chloride solution, respectively, as 
reconstitution media.  
All the tested films show an acceptable optical appearance. Residual moistures of 
small scale samples dried under flowing nitrogen in glass vials are determined as 
between 1.5% and 2.0%. Moreover, swelling is hardly affected by gellant 
composition in the given range, i.e. values of about 8 to 10 are obtained. Like with 
the corresponding xerogels the reconstitution with water and isotonic sodium 
chloride solution, respectively, leads to differences in the rheology of the resulting 
hydrogels. 
Mechanical properties of the produced films are similar to those of the pure 
hydroxyethyl cellulose films discussed above. With higher hydroxyethyl cellulose 
contents tensile strength increases (Fig. 3-59). However, with the addition of gellan 
gum the tensile strength stays on a high level up to a gellan gum concentration of 
about 0.3%. For a gellan gum content exceeding 0.3% a clear decrease of strength 
values is found (Fig. 3-59). Macroscopically, this is manifested in a more brittle 
appearance of these film specimen. Though, these samples still appear acceptable 
for wound treatment. 
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Fig. 3-59 Response surface calculated from tensile strength values of film samples with 
variable hydroxyethyl cellulose 100.000 and gellan gum F contents according to a simplex-
lattice design; films also contain 2.25% polyethylene glycol 400 and 2.25% polyvinyl 
pyrrolidone 17; concentrations refer to the hydrated state before drying;  
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The elastic modulus of the system is also slightly increased with higher gellan gum 
contents. Despite, all measured values are in acceptable low range (Fig. 3-60). 
Besides, as found in the section above the main dependence should be on the 
plasticiser contents rather than on gellants which was not further tested. Therefore, 
as far as flexibility is concerned all tested formulations can be used. 
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Fig. 3-60 Response surface calculated from elastic moduli of film samples with variable 
hydroxyethyl cellulose 100.000 and gellan gum F contents according to a simplex-lattice 
design; films also contain 2.25% polyethylene glycol (PEG) 400 and 2.25% polyvinyl 
pyrrolidone (PVP) 17; concentrations refer to the hydrated state before drying; 
 
Therefore, it can be concluded that the mixture of hydroxyethyl cellulose and gellan 
gum is suitable for film formation. The relation of gellants found during the 
hydrogel studies can be taken as film composition as well. But, for a higher 
robustness a bisection or even further reduction of the gellan gum content maybe 
favourable. Although, further studies are conducted with a mixture of 2.0% 
hydroxyethyl cellulose 100.000 / 1.0% gellan gum mixture.  
 
3.4.3.2.4  Protein stabilisers in polymer films 
The effects of protein stabilizers added to films were found to solely regard optical 
appearance and homogeneity of the matrices. The swelling behaviour is hardly 
affected as well as mechanical properties. 
The effects again are described by means of hydroxyethyl cellulose matrices. These 
are made from hydrogels - 2.5% hydroxyethyl cellulose 100.000 with excipient to 
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be tested in water – that are cast out as wet films of 2 mm height. Contents given 
refer to the hydrogel state.  
Phosphate buffer is suitable up to a concentration of 5mM. However, higher 
contents lead to crystallisation on the film surface. Crystals on the film surface are 
also seen with the following substances given with their tested concentration: 
sodium chloride (1%), potassium chloride (1%), sodium sulphate (1%), mannitol 
(2%), and glycine (2%). Moreover, surfactants just combined with gellant provoke 
shrinking of the film during drying at room temperature in every tested 
concentration up to 0.2%. Therefore this class can be used only in combination 
with other excipients, e.g. the shrinking can be partly impeded by the use of Tris as 
buffer component. Shrinking is also seen with sucrose (2%), high molecular weight 
polyethylene glycol (2%), and crosslinked carboxymethyl cellulose (5%). 
Furthermore, Tris hydrochloride (50mM), arginine (2%), calcium and magnesium 
chloride (0.5%), EDTA sodium (0.5%), and β-cyclodextrin (1%) can be 
incorporated without noticeable disturbance.  
The tests described by means of hydroxyethyl cellulose as example are also 
conducted on other gallants. With carboxymethyl cellulose sodium, 
hydroxypropylmethyl cellulose, hydroxypropyl cellulose, and a hydroxyethyl 
cellulose/gellan gum mixture these effects basically are seen as well. Yet, the 
described negative effects of the tested stabilizers are more distinct with the more 
lipophilic matrices. This should be related to the hydrophilic character of most 
protein stabilizers and their reduced interaction with the lipophilic polymers.  
 
3.4.4 Stability of ACT in film formulations 
According to the results of the mechanical studies on polymer films most of the 
relevant protein stabilizers are compatible with the films from that point of view 
and so can be used for further development of ACT stabilising formulations. 
Therefore, excipients are introduced in film forming studies on ACT formulations 
that are tested positively in the prior stability studies on ACT concerning 
temperature stressing on the one hand, as well as in mechanical studies on polymer 
films on the other hand. First, the warm air drying process itself as stress factor is 
investigated. Second, a three months stability study on film formulations is 
conducted. 
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3.4.4.1  Stability of ACT during the film manufacturing process 
For the drying of the prepared hydrogel samples the warm air drying apparatus165 is 
used. Thereby, drying is carried out with flowing nitrogen for 12 hours, the gas 
stream and the gel containing eppendorf caps being tempered to 25°C. 
Reconstitution and dilution for analysis are conducted as described in the xerogel 
section. 
In this experimental set up the investigations on stabilising potency are conducted 
on formulation level. The formulations contain the substances according to Table. 
3-16 with ACT in a hydroxyethyl cellulose matrix. Hereby, the preferable excipients 
are detected by comparison of the recovered ACT activity in the different 
formulations.  
 
formulation    relative activity [%]±sd 
(1) phosphate Poloxamer® 188  94.5±3.49 
(2) phosphate Poloxamer® 188 PVP 17 104.5±10.17 
(3) phosphate Poloxamer® 188 PEG 400 98.1±1.49 
(4) arginine phosphate Poloxamer® 188  111.0±11.03 
(5) arginine phosphate Poloxamer® 188 PVP 17 119.1±21.07 
(6) arginine phosphate Poloxamer® 188 PEG 400 118.7±0.16 
(7) phosphate Tween® 80  106.3±1.21 
(8) phosphate Tween® 80 PVP 17 100.2±10.17 
(9) phosphate Tween® 80 PEG 400 102.4±5.3 
(10) arginine phosphate Tween® 80  120.5±0.75 
(11) arginine phosphate Tween® 80 PVP 17 125.2±0.02 
(12) arginine phosphate Tween® 80 PEG 400 112.2±10.26 
 
Tab. 3-16 Relative activity of ACT in films after reconstitution with 45mM potassium 
phosphate buffer with standard deviation measured by activity assay; underlying hydrogels 
contain 60µg/ml ACT, 5mM potassium phosphate buffer, 10mM arginine, 0.1% surfactant, 
1.5% soluble polymer, and 2.5% hydroxyethyl cellulose 100.000; 
 
Arginine – results indicate that arginine has a stabilising effect on ACT during film 
manufacture. This is gained by comparison of formulations (1)-(3) against (4)-(6) 
and (7)-(9) against (10)-(12), respectively. The stabilising potential of arginine on 
proteins during vacuum drying has been reported previously155 (Tab. 3-16).  
Surfactants – Tween® 80 is observed to be more effective than Poloxamer® 188 for 
ACT stabilisation during drying. This conclusion can be drawn from the 
comparison of formulation (1)-(6) with (7)-(12). There, most of the Tween® 80 
formulations show higher residual activity than the particular Poloxamer® 188 (Tab. 
3-16). This was also seen in hydrogel and xerogel formulations.  
Soluble polymers – polyvinyl pyrrolidone that is used as strengthener in the film 
matrix in most samples as well shows a stabilising effect. Comparing formulation 
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(1) with (2), (4) with (5), (7) with (8), and (10) with (11) indicates mostly higher 
recovered ACT activities. Polyethylene glycol is used as plasticiser in the film. In 
the Poloxamer® 188 containing samples an additional stabilisation on ACT is 
shown. This results from the comparison of formulation (1) with (3) and (4) with 
(8). On the contrary, comparing formulation (7) with (9) and (10) with (12) 
indicates that in the Tween® containing samples there is no additional stabilisation 
proven by polyethylene glycol (Tab. 3-16).  
 
Gelling agent – for evaluation of the gelling agents a standard formulation was 
chosen – 60 µg/ml ACT, 5mM potassium phosphate pH 7.2, 0.1% Tween® 80, 
1,5% PEG 400 - with variable polymer types as gellants. These are hydroxypropyl 
cellulose, hydroxypropylmethyl cellulose, and hydroxyethyl cellulose. Moreover, a 
gellan gum/hydroxyethyl cellulose mixture, carboxymethyl cellulose sodium, and 
alginate sodium are tested. Unlike with xerogels, the more hydrophilic and ionic 
polymers perform better than the more lipophilic gelling agents - HPC and HPMC. 
The gellan gum/HEC mixture again shows highest recovered ACT activities (Fig. 
3-61). 
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Fig. 3-61 Relative activity of ACT in films with 5mM potassium phosphate buffer, 0.1% 
Tween® 80, 1.5% PEG 400 and gelling agent after reconstitution with 45mM potassium 
phosphate buffer measured by activity assay; gellants are 2.5% hydroxypropylmethyl-, 
hydroxypropyl-, hydroxyethyl cellulose 100.000, gellan gum/hydroxyethyl cellulose 100.000 
1%/2% mixture, 3.0% carboxymethyl cellulose sodium 10.000, 5.0% alginate sodium; 
 
To summarize, in this section the influence of the drying process for polymer film 
formation as stress factor on ACT stability has been evaluated. It has been found 
that film formation with embedded active ACT is possible. Excipients can be 
chosen in concordance with results from studies on solution, hydrogel, and placebo 
films. Phosphate buffer can be used as tested. As well, arginine, surfactants and 
soluble polymers can be used without constraints. For the gelling agents 
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hydroxyethyl cellulose and the ionic species are preferable. The gellan gum 
containing samples again turned out to provide the most effective stabilisation on 
ACT.  
 
3.4.4.2 Mid term stability 
Based on the previous results of the stabilisation in hydrogels and films a three 
months stability test in polymer films is launched with a set of formulations. 
Excipient composition is varied by similar means as in the xerogel mid term 
stability setting. Additionally, the samples contain polyvinyl pyrrolidone and 
polyethylene glycol as evaluated in the texture studies. Gel samples are dried using 
the small scale drying apparatus as described above whereby the films are formed. 
Sample plans, reconstitution of samples, and analysis including preparations are 
again described in the xerogel section (see chapter 3.4.2.1).  
As expected, the data patterns gained from activity measurements by the activity 
assay correspond to those gained in the xerogel studies. Again, activity decrease 
over time is supposed to follow first order kinetics. Therefore, a linearisation is 
achieved in a one-sided logarithm plot. Moreover, a linear function can be fitted to 
the decrease (Fig. 3-62). The slope of the fitted curve delivers the negative reaction 
constant k. 
 
4,45
4,50
4,55
4,60
4,65
4,70
4,75
-1 0 1 2 3 4 5 6 7 8 9 10 11 12
time [weeks]
ln
 (r
el
at
iv
e 
ac
tiv
ity
 [%
])_
 
Fig. 3-62 Recovered relative activities of ACT measured by activity assay of a film 
formulation consisting of 60µg/ml ACT, 10mM arginine, 0.1% Tween® 80, 2.0% PVP 17, 
2.0% PEG 400, 2.5% HEC 100.000 in a 5mM potassium phosphate buffer at 25°C( , 
k=1.30·10-4 1/day) and 40°C( , k=7.43·10-4 1/day) in logarithmic concentration scale with 
fitted logarithmic functions resulting in evens in the one-sided logarithmic scale as predicted 
by first-order time law; 
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Further sample compositions and corresponding results after data processing like 
above are displayed in Tab. 3-17. 
 
60 µg/ml α1-antichymotrypsin reaction constant k (24°C) 7.90·10-4 1/day 
5 mM phosphate buffer reaction constant k (40°C) 8.76·10-4 1/day 
10 mM arginine shelf life 25°C 133.4 days 
0.1 % Poloxamer® 188 shelf life 40°C 120.3 days 
2.0 % PVP 17 residual moisture at start 1.5% 
2.0 % PEG 400 residual moisture after 3   
2.5 % HEC 100.000 months 2.0% 
 
60 µg/ml α1-antichymotrypsin reaction constant k (24°C) 1.22·10-3 1/day 
10 mM Tris HCl buffer reaction constant k (40°C) not evaluable 
10 mM arginine shelf life 25°C 86.3 days 
0.1 % Poloxamer® 188 shelf life 40°C not evaluable 
2.0 % PVP 17 residual moisture at start 2.0.% 
2.0 % PEG 400 residual moisture after 3   
2.5 % HEC 100.000 months 3.5% 
 
60 µg/ml α1-antichymotrypsin reaction constant k (24°C) 1.30·10-4 1/day 
5 mM phosphate buffer reaction constant k (40°C) 7.43·10-4 1/day 
10 mM arginine shelf life 25°C 810.5 days 
0.1 % Tween® 80 shelf life 40°C 141.8 days 
2.0 % PVP 17 residual moisture at start 1.9% 
2.0 % PEG 400 residual moisture after 3   
2.5 % HEC 100.000 months 2.8% 
 
60 µg/ml α1-antichymotrypsin reaction constant k (24°C) not evaluable 
5 mM phosphate buffer reaction constant k (40°C) 2.52·10-3 1/day 
10 mM arginine shelf life 25°C not evaluable 
0.1 % Poloxamer® 188 shelf life 40°C 41.9 days 
2.0 % PVP 17 residual moisture at start 2.1% 
2.0 % PEG 400 residual moisture after 3   
2.0 % HEC 100.000 months 3.5% 
1.0 % gellan gum LT100   
 
60 µg/ml α1-antichymotrypsin reaction constant k (24°C) 1.04·10-4 1/day 
5 mM phosphate buffer reaction constant k (40°C) 4.20·10-4 1/day 
10 mM arginine shelf life 25°C 1010.3 days 
0.1 % Poloxamer® 188 shelf life 40°C 250.9 days 
2.0 % PVP 17 residual moisture at start 1.2% 
2.0 % PEG 400 residual moisture after 3   
2.0 % HEC 100.000 months 2.1% 
1.0 % gellan gum F   
 
Tab. 3-17 Formulations of the mid term stability testing with ingredients (left column), 
reaction constants k at the experimental stress levels, estimated shelf lives at the required 
temperature levels, and residual moisture at start as well as after 3 months storage (right 
column); 
 
Generally, the stabilising potential of excipients in films is very similar to the results 
gained from xerogel mid-term stability studies. Nevertheless, for films stored in 
(1) 
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(4) 
 
 
 
 
 
 
(5) 
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glass vials the phosphate buffer has greater stabilising potential than Tris 
hydrochloride. This is manifested in shelf lives of formulation (1) in comparison 
with (2).  
As in xerogels, the surfactant Tween® 80 performs better than the Poloxamer® 188 
alternative. See comparison of formulation (1) with (3). Moreover, the HEC/gellan 
gum F gellant system is favourable over pure hydroxyethyl cellulose and the 
HEC/gellan gum LT100 alternatives. This results from comparison of formulation 
(1) with (4) and (5) (Tab. 3-17).  
So, there are the two formulations – (3) and (5) - with shelf lives of greater 550 days 
(18 months). Thus, these meet the stability requirements for a storage form for 
stocking at room temperature defined at the beginning of development.  
Moreover, studies on residual moisture by Karl-Fischer-titration produce values of 
1.5% to 2.1% for all formulations at the beginning of storage. After three months 
values of 2.0% to 3.5% residual moisture are detected on both temperature levels 
(Tab. 3-17). Thereby, gellan gum LT100 and Tris hydrochloride containing samples 
tend to show higher values. However, these values are good starting points, but 
further optimisation of e.g. the drying process to gain values less than 2.0% residual 
moisture may be appropriate. 
 
 
Fig. 3-63 Stability of ACT in formulations after a 3 months storage at 25 °C measured by 
SDS-PAGE:  
lane 1 formulation (1) with no aggregate detected; lane 2 formulation (2) with 0.7% 50kDa 
fragment; lane 3 formulation (3) with no aggregate detected; lane 4 formulation (5) with 0.9% 
100kDa aggregate; lane 5 marker;  
control without degradation is visualized in Fig. 3-4 
 
The readout by SDS-PAGE for samples stored over three months at 25°C 
surprisingly shows hardly any dimer formation (Fig. 3-63). Only formulation (4) is 
not evaluable. This specimen can not be filled properly in the electrophoresis gel 
100 kDa 
 
60 kDa 
50 kDa 
 
 1          2          3           4         5   
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due to its elastic rheology even when heated. However, this is a promising result for 
the formulations. Concerning choice of excipients no conclusions can be drawn out 
of these experiments, unfortunately.  
Hence, the formulations (3) and (5) can be recommended for further development. 
However, like with xerogels the greatest stabilising potential of a film formulation is 
to be estimated for a combination of Tween® 80 and HEC/gellan gum F. 
Although, this combination is as well not yet tested for the polymer films and 
therefore cannot be directly recommended supported by data for immediate further 
development. But, in future studies, e.g. adjustment of the formulation for market 
launch, this can be taken into account. 
 
3.4.4.3 Summary 
Results indicate that reaction kinetics of activity decay of ACT in films is highly 
likely to follow a first order equation. Main instability again is the loss of activity. In 
contrast to xerogel studies dimer formation is not found during film studies. 
Moreover, a commercial formulation of ACT in a swellable polymer film is possible 
due to sufficient shelf life. Furthermore, the two suitable formulations after 
reconstitution can be applicated into the wound site as far as stability of ACT is 
concerned. As well, these formulations are applicative for the purpose of animal 
experiment or clinical trial. Results also indicate that a not yet tested excipient 
combination may be the most effective stabilising formulation. This can be 
evaluated within later studies, e.g. adjustment of the product for market launch. 
 
3.4.5 Summary for dry matrices as ACT delivery systems for 
wound healing 
During the ACT stability studies in solution and hydrogels it has turned out that 
the shelf life of such formulations is very limited. Therefore, formulations with 
higher stabilising potential had to be developed that also have to fit the 
requirements of modern wound care. So, a dry form appears the best choice for 
improvement of drug stability, and hydrogels still are the state-of-the-art 
application form on wounds.  
As a result, dry forms had to be developed that form hydrogels after reconstitution. 
Based on the hydrogels reported in the prior chapter two alternatives were 
investigated to meet these aims - the xerogels and the polymer films. 
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For both forms carrier development was carried out by establishing production 
procedures, optimising ingredient composition for both mechanical properties of 
the products and stabilising ACT in the matrices. Characterisation thereby is done 
by examination of texture properties, swelling behaviour, residual moisture, ACT 
stability during drying, and during storage.  
Two xerogel formulations are identified that meet all the requirements. They have a 
homogeneous and soft appearance, they swell spontaneously when hydrated to a 
hydrogel, and they deliver shelf lives for ACT exceeding 18 months.  
For the films as well two formulations turn out to fulfil the aims. These matrices 
offer very convenient texture properties, as well form suitable hydrogels after 
hydration, and also provide shelf lives greater 18 months for ACT.  
Thus, development of stabilising formulations for ACT suitable for application into 
wound sites is finished successfully. In the following, the release of ACT from the 
preparations is studied in vitro. 
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3.5  Release of ACT from dry delivery systems 
In this chapter the release behaviour of ACT from the matrices reported in the 
prior sections is investigated. For that purpose an in vitro method for release 
studies is established.  
For the release period a time frame of one to five days is desirable from the medical 
point of view because a fast release and absorption of the drug is favourable. The 
common change of dressing intervals in clinical practice of wound care are between 
three to five days. Therefore, for highest effectiveness, the maximum release period 
preferably should not exceed five days. 
Moreover, the in vivo release site to be simulated is an open wound. Although a 
topical delivery is described, wounds are not supposed to provide a major diffusion 
barrier for a drug substance. Thus, there is no physiological diffusion barrier like 
skin to be mimicked in vitro. Rather, a system providing a very low resistance to 
diffusion of the drug out of the matrix is preferable. In addition, the release 
temperature is set to 32°C representing the USP specification for dermal release195. 
After the experimental setup the first studies on model substances are described. 
Following, release studies of ACT from xerogels and polymer films are reported. 
 
3.5.3 Experimental setup  
For the setup of this series of in vitro experiments the type of chamber model, a 
proper acceptor medium and a suitable membrane is discussed. The membrane is 
placed between the chambers to separate donor and acceptor and so is penetrated 
by the diffusing substance during release. 
 
3.5.3.1  Membrane 
To avoid dilution, erosion, and dissolution of the swellable donor gel with the 
liquid acceptor during the release experiment a separation of donor and acceptor 
chamber is obligatory. Therefore, a membrane is necessary that is not used for 
simulation of a physiological barrier, e.g. skin, rather it should mechanically 
separate the media. Thus, in preliminary tests a membrane is evaluated that allows 
an unimpeded diffusion of model substances but keeps the major part of the 
gelling agent on the donor side. In preliminary studies, it turns out that a cellulose 
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acetate filter membrane of 0.45µm pore size meets the named requirements at 
best196 (data not shown).  
It holds the gelling agent back in the donor chamber and provides one of the 
fastest release rates for FITC-Dextran 70kDa in a membrane testing series. 
Membranes with smaller pore sizes, e.g. 0.1µm and 0.22µm, show slower release 
and, therefore, seem to impede diffusion out of the gel. But, membranes with larger 
pores, e.g. 0.8µm and 1.2µm, do not provide further increased release rates 
compared to 0.45µm. Thus, diffusion of the drug is not affected by these 
membranes. However, the gelling agent can pass through the pores of 0.8µm and 
1.2µm diameter. This is detected by an increase in viscosity of the acceptor 
solution. Moreover, gel is found on the acceptor side of the membrane having 
penetrated through the pores.  
Cellulose acetate is non-lipophilic and water permeable. And, according to 
manufacturers` instructions this material has also a low protein adsorption 
tendency.  
 
3.5.3.2 Acceptor medium 
To simulate the conditions in a chronic wound site a solution similar to wound 
exudate would have been a reasonable choice. Unfortunately, the composition of 
wound exudate varies in very broad ranges197. Hence, an exact copy of a standard 
wound exudate is not possible. And more important, priorities are set on the 
second factor influencing the evaluation of the acceptor solution which is the 
stabilising potency on ACT. Release samples to be analysed are taken from the 
acceptor solution following a sample plan and are kept in frozen state until analysis 
and for later storage. Therefore, a degradation of the drug substance in the 
acceptor medium during the experiment and a degradation by freezing stress would 
adulterate the releasing profiles. This confines the composition of the medium, e.g. 
sodium is not suitable because of the pH shifting interaction with phosphate buffer 
during freezing. Further, a surfactant is desirable to minimize material loss due to 
adsorption to the membrane, the chamber and tubing walls. Thus, an ACT 
stabilising solution consisting of 10mM potassium phosphate buffer pH 7.2 and 
0.1% Poloxamer® 188 is chosen as acceptor. This solution is proven to be suitable 
for stabilisation in solution state during the release experiment as well as for 
stabilisation during storage of samples as frozen solution (section 3.2.2).  
Furthermore, the release medium has to provide sink conditions for the diffusion 
of the drug substance. That means a sufficient amount of acceptor medium has to 
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be offered in relation to the amounts of drug substance and donor medium. In 
detail, according to common definitions, sink conditions for a substance are 
provided if its concentration at the end of the experiment does not exceed 10% of 
its saturation solubility in the medium. Thus, for the low amounts of model drugs 
and ACT, sink is provided even with rather low acceptor volumes. Therefore, the 
minimum of acceptor medium is determined by the sample volume to be taken out 
of the reservoir until the experiment is finished.  
 
3.5.3.3 Chamber model 
For evaluation of methods it turned out to be important that the donor gel is 
mechanically fixed in the chamber. Because, by using a water permeable membrane 
slight differences in pressure between donor and acceptor might lead to an 
unwanted transport of water from one chamber into the other. This is to be 
avoided because both a dilution or shrinking of the gel and a change of acceptor 
volume would produce non-evaluable results. Therefore, the release tests are 
performed in a modified Loth model134.  
 
Membrane
Seal Acceptor 
Chamber
 
 
Fig. 3-64 Modified Loth chamber made of acrylic glass for release studies; the donor chamber 
(left and above) keeps 1.25ml of donor medium at a layer thickness of 4mm; the acceptor 
chamber (right and top) provided with a ripple plate supporting the membrane is filled with 
acceptor medium and is connected to the medium reservoir (not shown); chambers are 
separated by a cellulose acetate filter membrane with 0.45µm pore size; the system is sealed 
by a polyurethane rubber o-ring; 
 
There, the gel containing chamber is mechanically fixed. Due to the higher 
osmolarity of the donor medium a slight permanent pressure results in the donor 
chamber that is absorbed mechanically by the bending membrane and the chamber 
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body. Moreover, the model is modified in size that the donor sample cavity is 
circular in shape with 2.0cm in diameter and has a height of 0.4cm, resulting donor 
volume is only 1.25ml. The acceptor, moreover, provides a ripple plate supporting 
the membrane and providing contact between acceptor solution and the 
membrane. Particular drill holes in the body enables the acceptor medium to be 
pumped through the chamber (Fig. 3-64). The whole apparatus is tempered to 
32°C for measurement in a cabinet heater. 
 
For the provision of the acceptor medium to the chamber two alternative systems 
are evaluated. In the first system – the dynamic model - the acceptor medium is 
pumped in closed circuit by a hose pump with a flow rate of 10ml/min. The total 
volume is 20ml. Samples are taken from the reservoir without replacement 
according to a sample plan. In the alternative system – the static model – two 
syringes are connected to the acceptor chamber (Fig. 3-65). A 2ml portion of 
acceptor medium is filled in the syringes and provided to the diffusion site. 
Following a sample plan, sample collection is done by complete exchange of the 
portion against fresh medium.  
 
 
 
Fig. 3-65 Modified Loth chamber for release studies equipped as static model with two 
syringes providing the acceptor solution;  
 
3.5.4 Theoretical background and data interpretation 
For the interpretation of release kinetics the theoretical background given by 
Higuchi is used. These equations are solutions to Fick’s second law. So, they 
describe the diffusion process of a dissolved substance from a semi-solid base into 
a sink. Thereby, the diffusion within the donor to the releasing interface is the rate-
limiting step in the overall process. Equation 3-14 describes the whole process. But, 
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due to its complexity a simplified form (Equ. 3-15) of this relation is used for 
calculations199.  
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Equ. 3-14&3-15 Model functions after Higuchi describing the diffusion of a substance totally 
in solution out of a semi-solid matrix into a sink; equ. 3-14 describes the correlation more 
exactly; equ. 3-15 is a simplification strictly valid in the first third of the process; hereby, is  
cA = concentration in acceptor at time t [mol/l]; c0 = starting concentration in donor at time 
t=0 [mol/l]; t = time t [min]; D = diffusion coefficient [m/min]; h = thickness of diffusion 
layer [m]; 
 
For data interpretation the released amounts of substance are drawn against 
releasing time. The resulting curves describe a square root function. Therefore, this 
chart can be Linearised when drawn against the square root of time. Consequently, 
a linear function is fitted to the resulting even delivering the slope as a measure for 
the release rate. Further, the amounts released at a certain time point are read from 
this chart.  
 
3.5.5 Release of model substances from gel based matrices 
In a first series of experiments the release of model drugs of different molecular 
weight from standard hydrogel matrices are examined using the dynamic model. 
Thereby, hydrogels consisting of 2.5% hydroxyethyl cellulose 100.000 in water are 
used as standard. The hydrogels, moreover, contain Fluorescein sodium, FITC-
Dextran 19kDa, and FITC-Dextran 70kDa, respectively, as model drugs. 
Quantification is carried out spectrofluorimetrically in microwell plates at λex = 493 
nm and λin = 515 nm. The released amounts of the particular model drugs - given 
in percentage of total content - are drawn against the diffusion time (Fig. 3-66).  
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Fig. 3-66 Release diagram of Fluorescein Na ( ), FITC-Dextran 19kDa ( ), FITC-Dextran 
70kDa ( ), respectively, from hydrogels containing 2.5% hydroxyethyl cellulose 100.000 in 
water; release medium is a 10mM potassium phosphate buffer pH 7.2, 0.1% Poloxamer® 188; 
 
With all tested substances the model tests follow the theoretical predictions of a 
square root of time function and so can be Linearised in a square root of time chart 
(Fig. 3-67). It is seen that the release rate of the substance is clearly dependent on 
its molecular weight.  
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Fig. 3-67 Release diagram of Fluorescein Na ( , slope=34.4, R2=0.98), FITC-Dextran 19kDa 
( , slope=12.3, R2=0.99), FITC-Dextran 70kDa ( , slope=7.2, R2=0.99), respectively, from 
hydrogels containing 2.5% hydroxyethyl cellulose 100.000 in water drawn against the square 
root of time; release medium is a 10mM potassium phosphate buffer pH 7.2, 0.1% 
Poloxamer® 188; 
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Bearing in mind that the diffusion coefficient of a substance is also related to its 
molecular weight, the relation of the release rate to the diffusion coefficient 
becomes apparent. This also is predicted by theory (Equ. 3-15). Thus, the model 
can be used for release studies of molecules of the size of proteins, especially ACT 
with 68kDa molecular weight. 
One may doubt that the different release rates detected in Fig. 3-67 are determined 
by the different diffusional behaviour of the molecules in the gel matrix rather than 
by a restricted passage through the membrane due to the pore structure. To 
support our view about that topic, an estimation of molecule sizes is given in Fig. 
3-68. The molecule diameters of FITC-Dextran derivatives are given as Stokes 
diameters200. The diameter of ACT is calculated by an approximation according to 
Equ. 3-16201. 
 
moleculeproteinmoleculeprotein MV ⋅= 21.1  
 
Equ. 3-16 Approximation of the volume of a protein molecule Vprotein molecule [10-3nm3] by its 
molecular weight Mprotein molecule [Da]; the correction factor is related to the average partial 
specific volume of proteins being 0.73 cm3/g201; 
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Fig. 3-68 Visualisation of molecule sizes in comparison to membrane pore size; FITC-
Dextran molecule sizes are stokes diameters - 6.6nm for 19kDa derivative, 12.0nm for 70kDa 
derivative200; membrane pore size is given as 450nm, and ACT diameter is estimated as 
5.4nm; 
 
From the relation of diameters it can be stated that it is highly unlikely that 
differences in the diffusional behaviour of substances of different molecular weight 
displayed in Fig. 3-67 are related to different degrees of restriction for the diffusion 
of the given substances through the membrane. 
Nevertheless, a certain restriction for the diffusion is provided by the membrane 
because the pore structure effects a reduction of the diffusional area in the system 
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compared to e.g. an in vivo situation where the gel has direct and intimate contact 
with the wound ground. Therefore, the release in vivo is supposed to be faster to 
some degree compared to in vitro studies due to the lack of the membrane. 
 
In the following, the different application forms under development during this 
work are tested with a standard load of FITC-Dextran 70kDa. Xerogel and film 
samples are prepared as described for the ACT loaded specimen (section 3.3.2.2.). 
Samples are reconstituted with water for one minute before the release test in the 
dynamic model is started. The release curves are again linearised and displayed in 
Fig. 3-69.  
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Fig. 3-69 Release diagram of FITC-Dextran 70kDa from hydrogel ( , slope=7.2, R2=0.99), 
film ( , slope=10.0, R2=0.98), xerogel ( , slope=6.9, R2=0.99), respectively, from 
compositions containing 2.5% hydroxyethyl cellulose 100.000 against the square root of time; 
release medium is a 10mM phosphate buffer pH 7.2, 0.1% Poloxamer® 188; 
 
The release rates from xerogels and hydrogels are very similar. As a result, no 
differences are seen between xerogels after reconstitution and the underlying 
hydrogels as far as release characteristics are concerned. 
From films, the release rate slightly exceeds the rate from the corresponding wet 
hydrogel. This should be rooted in a higher concentration gradient of the drug in 
the film experiment. Unlike gels, films start the diffusion with a very low volume. 
Though it of course increases during the hydration period, at least in the first part 
the concentration in the film is higher than in the gel. That results in a higher 
driving force for the diffusion and with that in a higher release rate from films. 
Nevertheless, the release from the dry matrices is still in comparable range with 
that from the underlying hydrogels. Further, it can be estimated that a protein like 
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ACT with around 68kDa molecular weight will be released to 90% within 
approximately five days. The slope of the Linearised release curve of ACT is 
expected to be in the range of 6.5 to 10.5. However, the differences in chemistry 
and molecular weight of the molecules might influence the kinetics to a major 
degree. 
To sum up, the model studies indicate that the present system is suitable for in 
vitro release studies of drugs with the required molecular weight from wet or 
reconstituted gel preparations.  
 
3.5.6 Release of ACT from formulations 
In this section the release of ACT from the developed dry matrices is investigated. 
The formulations are taken over from the mid term stability studies reported in 
chapter 3.4. After the model evaluation the experiments on xerogels and films are 
reported. 
 
3.5.6.1  Dynamic model 
Based on the convincing results of the liberation of the model compound the first 
release studies on ACT are also performed in the dynamic system. Unfortunately, 
the read out methods of ELISA and activity assay deliver different results on the 
release curves. According to ELISA results, ACT is liberated from the preparations, 
and the release curves follow the expected kinetics very closely. Thereby, a 
maximium of 90% total content released is gained after 55 hours which means a 
slightly faster release rate than the rate gained with FITC-Dextran. Indeed, the 
active amount of ACT liberated increases in the first few hours as well. But in 
contrast to total content, after reaching a maximum at around 50 hours of releasing 
time the measured ACT activity declines rapidly to zero level.  
However, in the release phase before the activity decline starts slopes can be read 
that are higher than those gained in control experiments with FITC-Dextran 70kDa 
(Fig. 3-70). 
The reason for the decline of activity in the acceptor medium is found in the 
system of the dynamic release model. The medium is pumped through plastic 
tubing during the entire testing time by a hose pump. Moreover, the medium in the 
supply is homogenised by a magnetic stirrer.  
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Fig. 3-70 Linearised release diagram of ACT from a xerogel formulation in the dynamic 
model; release profiles are given as active ACT gained by activity assay ( , slope=10.8, 
R2=0.98) and total ACT content measured by ELISA ( ,slope=12.8, R2=0.98); underlying 
hydrogel contains 60µg/ml ACT, 10mM potassium phosphate buffer pH 7.2, 10mM arginine, 
0.1% Poloxamer® 188, and 2.5% hydroxyethyl cellulose 100.000 in water; release medium is 
a 10mM phosphate buffer pH 7.2 with 0.1% Poloxamer® 188;  
 
In control experiments an ACT solution similar to the acceptor medium is stressed 
by stirring and stirring in combination with pumping, respectively. Both factors put 
shear stress on the ACT molecule that leads to deactivation. Thereby, the pumping 
is more harmful than the stirring alone (Fig. 3-71).   
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Fig. 3-71 Decrease of relative activity of a 60µg/ml ACT solution (10mM potassium 
phosphate buffer pH 7.2, 0.1% Poloxamer® 188) during stirring in the acceptor surplus ( ) 
and during pumping through the tubes and stirring in the surplus ( ); 
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Therefore, it can be concluded that the dynamic system is unfavourable for the 
release studies on ACT. The sensitivity of ACT against shear stress also detected 
during experiments with static mixers (section 3.3.2.2) impedes the use of hose 
pumps. In the following, the static model is used for further investigations. 
 
3.5.6.2 Static model 
3.5.6.2.1  Evaluation of the model 
Before the actual release tests in the static model, control experiments are 
performed to evaluate the loss of activity and total content during the actual release 
tests. 
Therefore, a solution of 60µg/ml ACT formulated in a 50mM potassium 
phosphate buffer pH 7.2 with 0.1% Poloxamer® 188 is exposed to the tubing 
material, the chamber material, and the membrane, respectively. A control is kept 
in a glass vial. For analysis by activity assay and ELISA, samples are drawn after 18 
hours and 75 hours. 
The loss of activity is minimal in the glass vials. But, in the samples exposed to 
tubing, chamber, and membrane loss of activity is observed between 10% to 25% 
after 75 hours (Fig. 3-72).  
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Fig. 3-72 Residual activity of a 60µg/ml ACT solution formulated in a 50mM potassium 
phosphate buffer pH 7.2 with 0.1% Poloxamer® 188 during exposure to tubing material, 
chamber material, membrane material, and glass, respectively, measured by activity assay; 
left: control before exposure; centre: exposure for 18 hours, right: exposure for 75 hours;  
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The total content measured by ELISA shows a decrease over time as well, but to 
much lower extent. In detail, glass again shows almost no loss, but in the other 
samples only 90% to 95% of total content are recovered (Fig. 3-73). 
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Fig. 3-73 Residual total content of a 60µg/ml ACT solution formulated in a 50mM potassium 
phosphate buffer pH 7.2 with 0.1% Poloxamer® 188 during exposure to tubing material, 
chamber material, membrane material, and glass, respectively, measured by ELISA; left: 
control before exposure; centre: exposure for 18 hours, right: exposure for 75 hours;  
 
Therefore, it can be concluded that during the release experiments in the static 
model ACT activity and total content is lost as well but to much lower extent 
compared to the dynamic model. Moreover, the loss of ACT seems to follow two 
mechanisms. The loss of total content is supposed to be rooted in absorption 
phenomena which result in ACT molecules remaining in the system. Besides, this 
mechanism also leads to reduced recovered activity values. However, the 2-fold 
higher values of lost activity compared to total content loss can solely be explained 
by an additional deactivation of non-absorbed ACT molecules. 
Indeed, based on the results it is to be expected that during release experiments 
with ideally releasing formulations 75% to 90% of relative activity can be recovered 
at best. As well, a maximum of 90% of total content is likely to be recovered at 
most. 
A further improvement of the release system, e.g. by using glass instead of plastic 
materials for the chamber or pre-treatment of the membrane, would have been a 
promising possibility to improve ACT recovery results but was not possible for 
technical reasons. As well, a simple mathematical adjustment with a correction 
factor is problematic because of the measurement uncertainty of the analytical 
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methods being amplified in such an operation. Thus, a result gained after 
correction would imply an unsatisfactory inaccuracy.  
Moreover, the control experiments most notably on the tubing material have to be 
understood as worst case conditions because the surface of tubing presented to the 
protein containing medium is very low in the release model (Fig 3-65) compared to 
control experiments. For the latter, of course, a certain amount of solution (0.5ml) 
had to be filled in the tubing for technical and analytical reasons which also requires 
a certain tubing volume that naturally is correlated with a higher surface area 
compared to the small pieces of tubing used for the release chamber. This 
difference in the relation of solution amount and exposed tubing surface in control 
and actual release situation leads to an exaggerated impression about the influence 
of the tubing material. To conclude, a simple multiplication of the particular 
recovered activities and amounts, respectively, of Fig. 3-72 and Fig. 3-73 will not 
result in a correct overall value for the maximum recovered amount of ACT to be 
expected in release tests.  
For those reasons, the uncorrected values are used for the comparison of the 
release results of the different formulations.  
 
0
20
40
60
80
0 20 40 60 80 100 120
time [h]
re
le
as
ed
 a
m
ou
nt
 o
f A
CT
 [%
]_
 
Fig. 3-74 Release diagram of ACT from a xerogel formulation in the static model; release 
profiles are given as active ACT gained by activity assay ( ) and total ACT content 
measured by ELISA ( ); underlying hydrogel contains 60µg/ml ACT, 10mM potassium 
phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 188, 0.05% PVP 17, and 2.5% 
hydroxyethyl cellulose 100.000 in water – xerogel formulation (1) of Tab. 3-18; release 
medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% Poloxamer® 188;  
 
Fortunately, for the estimation of future in vivo experiments the situation is 
different. The constant recovered amounts in the glass samples for both analytical 
methods (Fig. 3-72, 3-73) indicate that the release system with its plastic 
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components is responsible for the losses. In an in vivo situation, however, these 
materials and surfaces are not present in the application site why it can be stated 
that the here detected losses are unlikely to occur. 
After the control experiments actual release tests on ACT xerogel formulations are 
performed. In fact, in release tests of ACT in the static model the complete loss of 
activity detected in the dynamic model is not observed. However, the curves 
measured by activity assay flattens after about 50 hours of testing time in 
comparison to the total content curve obtained from ELISA measurements (Fig. 3-
74). 
This corresponds to the control experiments predicting a higher loss of active ACT 
compared to total ACT content. As well, the magnitude of recovered contents in 
the release test concur with the results gained from control experiments. 
Nevertheless, when drawn in the square root of time plot both curves are linear up 
to 50 hours releasing time. In that period, a linear fitting can be conducted 
delivering slopes for measuring release rates (Fig. 3-75).  
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Fig. 3-75 Linearised release diagram of ACT from a xerogel formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=6.6, R2=0.98) and 
total ACT content measured by ELISA ( , slope 7.8, R2=0.99); underlying hydrogel contains 
60µg/ml ACT, 10mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 0.05% PVP 17, and 2.5% hydroxyethyl cellulose 100.000 in water – xerogel formulation 
(1) of Tab. 3-18; release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% 
Poloxamer® 188;  
 
For interpretation in the following, next to the slopes of the linearised release 
curves two values are presented: first, the total amount of ACT released within 120 
hours is gained from ELISA. Second, the amount of bioactive ACT is delivered by 
activity assay in the same release period. Additionally, the bioactive fraction of 
liberated ACT calculated by division of the two latter values is used. The amount 
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values are read after 120 hours of releasing time because this represents the 
common change of dressing interval in clinical practice. 
 
One may notice that slopes of release curves are lower in the static method – 6.6 
vs. 10.8 for activity assay readout and 7.8 vs. 12.8 in the ELISA readout - and 
therefore the release is delayed in comparison with the studies on the dynamic 
model. 
 
3.5.6.2.2  Release of ACT from xerogel formulations 
For the release studies of ACT from xerogels a set of formulations taken over from 
the xerogel stability studies (section 3.4.2.2) is tested using the static model. 
Experiments are conducted over a releasing time of 120 hours (5 days) which 
corresponds to the usual change of dressing interval in clinical practice. 
Approximately every 12 hours, 24 hours in later phases of the release, a sample is 
taken and analysed by both activity assay and ELISA. Interpretation is carried out 
as given above. Below, the linearised release curves for each formulations are 
presented (Fig. 3-75 to 3-80), a summary of calculations is given in Tab. 3-18. 
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Fig. 3-76 Linearised release diagram of ACT from a xerogel formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=6.5, R2=0.99) and 
total ACT content measured by ELISA ( , slope 7.8, R2=0.98); underlying hydrogel contains 
60µg/ml ACT, 10mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Tween® 80, 
0.05% PVP 17, and 2.5% hydroxyethyl cellulose 100.000 in water – formulation (2); release 
medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% Poloxamer® 188;  
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Fig. 3-77 Linearised release diagram of ACT from a xerogel formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=8.6, R2=0.98) and 
total ACT content measured by ELISA ( , slope 10.2, R2=0.99); underlying hydrogel 
contains 60µg/ml ACT, 10mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% 
Poloxamer® 188, 0.05% PEG 2000, and 2.5% hydroxyethyl cellulose 100.000 in water – 
formulation (3); release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% 
Poloxamer® 188;  
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Fig. 3-78 Linearised release diagram of ACT from a xerogel formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=7.0, R2=0.99) and 
total ACT content measured by ELISA ( , slope 8.5, R2=0.99); underlying hydrogel contains 
60µg/ml ACT, 10mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 0.05% PVP 17, 2.0% hydroxyethyl cellulose 100.000, and 1.0% gellan gum LT100 in 
water - formulation (4); release medium is a 10mM potassium phosphate buffer pH 7.2 with 
0.1% Poloxamer® 188;  
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Fig. 3-79 Linearised release diagram of ACT from a xerogel formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=7.2, R2=0.98) and 
total ACT content measured by ELISA ( , slope 7.4, R2=0.98); underlying hydrogel contains 
60µg/ml ACT, 10mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 0.05% PVP 17, 2.0% hydroxyethyl cellulose 100.000, and 1.0% gellan gum F in water - 
formulation (5); release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% 
Poloxamer® 188;  
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Fig. 3-80 Linearised release diagram of ACT from a xerogel formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=6.1, R2=0.99) and 
total ACT content measured by ELISA ( , slope 9.5, R2=0.99); underlying hydrogel contains 
60µg/ml ACT, 10mM Tris hydrochloride buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 0.05% PVP 17, and 2.5% hydroxyethyl cellulose 100.000 in water – formulation (6); 
release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% Poloxamer® 188;  
 
Generally, the release kinetics of ACT from xerogels follow the theoretical 
predictions of the square root of time function (Equ. 3-15 , Figs. 3-75 to 3-80).  
The total released amount of ACT values of all tested formulations vary in the 
range of 70% to 96%. Thereby, the lower values, also correlated with lower release 
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rates, are detected in Tween® 80 – formulation (2), Fig. 3-76 - and gellan gum 
containing samples – formulations (3), Fig. 3-77 and formulation (5), Fig. 3-79.  
However, a conclusion about specific influence of particular excipients is not 
significant because the released amount of bioactive ACT ranges only between 55% 
to 60%. Solely, the Tris hydrochloride containing samples – formulation (6), Fig. 3-
80 - show a lower value. Slopes and released amounts of all formulations are 
summarised in Tab. 3-18.  
 
The detected loss of activity and total amount exceed the predictions of the control 
experiments for the influence of the release system. Therefore, a certain amount of 
ACT should be lost by other means, e.g. due to an incomplete release or further 
degradation maybe within the matrix impeding the detection by both assays. 
Unfortunately, only minimal residual amount of ACT is detected in the donor gel 
so no data are available to support the speculations about missing ACT. As well, 
efforts to detect the absorbed amount of ACT by desorption with sodium dodecyl 
sulfate lead to no result due to incompatibility with assay methods.  
 
Moreover, the bioactive fraction of the total released amount, being a quotient of 
the bioactive and total amount, varies in reciprocal means of the total amount. The 
highest bioactive fraction is found in the Tween® 80 samples – formulation (2), Fig. 
3-76 – and in the gellan gum F sample – formulation (5), Fig. 3-79.  
 
Furthermore, although slopes of ACT release curves tend to be slightly higher than 
in the curves of the model studies on FITC-Dextran70kDa, the differences are still 
too small to draw sound conclusions referring to interactions between diffusing 
substances and excipients (Tab. 3-18).  
 
To conclude, although they do not provide the fastest release, formulation (2) and 
formulation (5) are to be assessed as best candidates because they offer the highest 
bioactive fraction released with acceptable release rates and sufficient total amounts 
liberated.  
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60µg/ml α1-antichymotrypsin slope of ELISA curve 7.8 
10mM phosphate buffer slope of activity curve 6.6 
10mM arginine total amount released 85% 
0.1% Poloxamer® 188 bioactive amount released 59% 
0.05% PVP 17 bioactive fraction 62% 
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 7.8 
10mM phosphate buffer slope of activity curve 6.5 
10mM arginine total amount released 72% 
0.1% Tween® 80 bioactive amount released 59% 
0.05% PVP 17 bioactive fraction 82% 
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 10.2 
10mM phosphate buffer slope of activity curve 8.6 
10mM arginine total amount released 94% 
0.1% Poloxamer® 188 bioactive amount released 55% 
0.05% PEG 2000 bioactive fraction 58% 
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 8.5 
10mM phosphate buffer slope of activity curve 7.0 
10mM arginine total amount released 76% 
0.1% Poloxamer® 188 bioactive amount released 57% 
0.05% PVP 17  bioactive fraction 75% 
2.0% HEC 100.000   
1.0% gellan gum LT100   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 7.4 
10mM phosphate buffer slope of activity curve 7.2 
10mM arginine total amount released 70% 
0.1% Poloxamer® 188 bioactive amount released 59% 
0.05% PVP 17  bioactive fraction 84% 
2.0% HEC 100.000   
1.0% gellan gum F   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 9.5 
10mM Tris HCl buffer slope of activity curve 6.1 
10mM arginine total amount released 96% 
0.1% Poloxamer® 188 bioactive amount released 47% 
0.05% PVP 17  bioactive fraction 49% 
2.5% HEC 100.000   
 
Tab. 3-18 Formulations of the release studies on xerogels; ingredients (left column), slopes of 
Linearised release curves for ELISA and activity assay detection, respectively, and content 
values after 120 hours release time; total released amount measured by ELISA, bioactive 
amount measured by activity assay, and the bioactive fraction released calculated by the 
quotient of bioactive amount and total amount; 
 
3.5.6.2.3  Release of ACT from film formulations 
For the release studies of ACT from films a set of formulations taken over from 
the film stability studies (section 3.4.4.2) is tested using the static model. As given in 
the previous chapter dealing with the release from xerogels, experiments are 
(1) 
 
 
 
(2) 
 
 
 
 
(3) 
 
 
 
 
(4) 
 
 
 
 
 
(5) 
 
 
 
 
 
(6) 
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conducted over a releasing time of 120 hours (5 days) which corresponds to the 
usual change of dressing interval in clinical practice. Approximately every 12 hours, 
24 hours in later phases of the release, a sample is taken and is analysed by both 
activity assay and ELISA. Interpretation is carried out as given above. Below, the 
linearised release curves for each formulations are presented (Fig. 3-81 to 3-85), a 
summary of calculations is given in Tab. 3-19. 
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Fig. 3-81 Linearised release diagram of ACT from a film formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=6.7, R2=0.99) and 
total ACT content measured by ELISA ( , slope 7.8, R2=0.98); underlying hydrogel contains 
60µg/ml ACT, 5mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 2.0% PVP 17, 2.0% PEG 400, and 2.5% hydroxyethyl cellulose 100.000 in water – 
formulation (1); release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% 
Poloxamer® 188;  
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Fig. 3-82 Linearised release diagram of ACT from a film formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=6.6, R2=0.99) and 
total ACT content measured by ELISA ( , slope 6.8, R2=0.98); underlying hydrogel contains 
60µg/ml ACT, 5mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Tween® 80, 
2.0% PVP 17, 2.0% PEG 400, and 2.5% hydroxyethyl cellulose 100.000 in water – 
formulation (2); release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% 
Poloxamer® 188;  
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Fig. 3-83 Linearised release diagram of ACT from a film formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=6.9, R2=0.99) and 
total ACT content measured by ELISA ( , slope 7.9, R2=0.98); underlying hydrogel contains 
60µg/ml ACT, 5mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 2.0% PVP 17, 2.0% PEG 400, 2.0% hydroxyethyl cellulose 100.000, and 1.0% gellan 
gum LT100 in water – formulation (3); release medium is a 10mM potassium phosphate 
buffer pH 7.2 with 0.1% Poloxamer® 188;  
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Fig. 3-84 Linearised release diagram of ACT from a film formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=5.1, R2=0.98) and 
total ACT content measured by ELISA ( , slope 5.5, R2=0.99); underlying hydrogel contains 
60µg/ml ACT, 5mM potassium phosphate buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 2.0% PVP 17, 2.0% PEG 400, 2.0% hydroxyethyl cellulose 100.000, and 1.0% gellan 
gum F in water – formulation (4); release medium is a 10mM potassium phosphate buffer pH 
7.2 with 0.1% Poloxamer® 188;  
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Fig. 3-85 Linearised release diagram of ACT from a film formulation in the static model; 
release profiles are given as active ACT gained by activity assay ( , slope=5.7, R2=0.98) and 
total ACT content measured by ELISA ( , slope 7.2, R2=0.98); underlying hydrogel contains 
60µg/ml ACT, 10mM Tris hydrochloride buffer pH 7.2, 10mM arginine, 0.1% Poloxamer® 
188, 2.0% PVP 17, 2.0% PEG 400, and 2.5% hydroxyethyl cellulose 100.000 in water – 
formulation (5); release medium is a 10mM potassium phosphate buffer pH 7.2 with 0.1% 
Poloxamer® 188;  
 
In all experiments films liberate about 55% of bioactive ACT within the given 
period. And, most of the corresponding total amounts of liberated ACT are 
detected between 77% and 87%.  
But, differences between the particular film formulations can be seen in the 
different values for the bioactive fraction of released ACT. So, 73% of ACT 
molecules released by the Tween® 80 containing samples – film formulation (2), 
Fig. 3-82 – are active. Similar cases are seen with the gellan gum samples – film 
formulation (3), Fig. 3-83 and film formulation (4), Fig. 3-84 – which show 
bioactive fractions of 71% and 91%, respectively. Moreover, the Tris containing 
sample – film formulation (5), Fig. 3-85 – indeed releases a high amount of ACT in 
the given period, but only a fraction of 51% is bioactive.  
Generally, these results correspond to the behaviour of particular xerogel 
formulations with similar excipient compositions. Besides, the amounts of non-
recovered ACT are in the same range as in the xerogel experiments (Tab. 3-19).  
The observation for films providing a faster release during model studies with 
FITC-Dextran can not be confirmed. This might be due to specific interactions of 
the protein structure with formulation excipients or experimental hardware 
superposing the small difference. Moreover, the uncertainty of results created by 
spreading of analytical read outs is also supposed to contribute to that.  
 
Chapter 3 – Results and Discussion 
- 165 - 
60µg/ml α1-antichymotrypsin slope of ELISA curve 7.5 
5mM phosphate buffer slope of activity curve 6.7 
10mM arginine total amount released 87% 
0.1% Poloxamer® 188 bioactive amount released 55% 
2.0% PVP 17 bioactive fraction 63% 
2.0% PEG 400   
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 6.8 
5mM phosphate buffer slope of activity curve 6.6 
10mM arginine total amount released 77% 
0.1% Tween® 80 bioactive amount released 56% 
2.0% PVP 17 bioactive fraction 73% 
2.0% PEG 400   
2.5% HEC 100.000   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 7.9. 
5mM phosphate buffer slope of activity curve 6.9 
10mM arginine total amount released 85% 
0.1% Poloxamer® 188 bioactive amount released 60% 
2.0% PVP 17 bioactive fraction 71% 
2.0% PEG 400   
2.0% HEC 100.000   
1.0% gellan gum LT100   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 5.5 
5mM phosphate buffer slope of activity curve 5.1 
10mM arginine total amount released 55% 
0.1% Poloxamer® 188 bioactive amount released 50% 
2.0% PVP 17 bioactive fraction 91% 
2.0% PEG 400   
2.0% HEC 100.000   
1.0% gellan gum F   
 
60µg/ml α1-antichymotrypsin slope of ELISA curve 7.0 
10mM Tris HCl buffer slope of activity curve 5.7 
10mM arginine total amount released 88% 
0.1% Poloxamer® 188 bioactive amount released 45% 
2.0% PVP 17 bioactive fraction 51% 
2.0% PEG 400   
2.5% HEC 100.000   
 
Tab. 3-19 Formulations of the release studies on film formulations; ingredients (left column), 
slopes of Linearised release curves for ELISA and activity assay detection, respectively, and 
content values after 120 hours release time: total released amount measured by ELISA, 
bioactive amount measured by activity assay, and the bioactive fraction released calculated by 
the quotient of bioactive amount and total amount; 
 
(1) 
 
 
 
 
(2) 
 
 
 
 
 
(3) 
 
 
 
 
 
(4) 
 
 
 
 
 
(5) 
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3.5.6.2.4  Summary 
Generally, the release characteristics of ACT from gel matrices follow the 
theoretical predictions of a square root of time function. Moreover, both dried 
delivery systems – the xerogels and the films - are proven to be suitable for delivery 
of ACT in chronic wounds. In general, within five days 50% to 60% of initial ACT 
load is liberated in bioactive form. The total released content differs in broader 
range – 70% to 96% - within the different formulations. Thereby, the composition 
of ingredients has greater influence than the type of matrix. For instance, Tween® 
80 and gellan gum F addition leads to lower total released amounts but provide 
high bioactive fractions in both xerogel and film matrices. The loss of activity is 
partly accredited to the influence of the release apparatus and therefore can be 
expected to be lower in an in vivo situation. However, a higher bioactive fraction 
released form a formulation in vitro is a measure for favourable properties of this 
particular formulation. 
Though the non-liberated substance is not detected properly, speculations about it 
remaining in the gel seem appropriate since the phenomenon of incomplete release 
of protein drugs from gels has been described earlier202. 
As a result, for xerogels the formulations (2) and (5) appear as best choices, as is 
the case with formulations (2) and (4) for polymer films. The ingredients 
advantageous for release behaviour are as well found to be favourable for 
stabilisation in the hydrogel state (section 3.3.2.4.2). However, like with stability 
studies the most promising formulation is to be estimated for a combination of 
Tween® 80 and HEC/gellan gum F. But, this combination is as well not yet tested 
for its release behaviour and therefore cannot be directly recommended supported 
by data. But, in future studies, e.g. adjustment of the formulation for market 
launch, this can be taken into account. As well, due to the reduced amount of 
liberated and bioactive ACT an adaptation of the drug load in the carriers may be 
necessary to ensure the delivery of a sufficient dose of ACT into its site of action. 
However, the difficulty of in vitro in vivo correlation has to be kept in mind, 
especially against the background of the observed differences between the two 
release models as far as the release rate is concerned. 
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4 General summary, conclusions, and 
perspective 
 
Despite wound treatment has gone through great revolutions during the last 
decades, the chronic cases, especially those associated with diabetes, are still 
difficult to treat. Indeed, about 25% of diabetes patients frequently develop chronic 
wounds with about half of them requiring very patient and persistent treatment. 
Therefore, there is strong desire for improved methods of therapy.  
Besides, enormous progress was achieved in recombinant DNA techniques and 
methodology during the last decade. Hence, a multitude of biosynthetic, 
pharmaceutically relevant polypeptides and proteins have become available for a 
broad variety of diseases including chronic wounds and partly have been employed 
in pharmaceutical products already.  
Yet, due to the proneness of proteins to degradation affecting pharmaceutical 
relevant features such as biological activity and immunogenicity, appropriate 
pharmaceutical formulation development of peptides and protein drugs is of 
utmost importance. Because, only in a well developed formulation the optimal 
therapeutic effects, harmlessness, and shelf life necessary for commercial success 
can be achieved and granted. 
 
The delivery of α1-antichymotrypsin (ACT) was identified as one approach for new 
ways of chronic wound treatment by SWITCH BIOTECH AG, Neuried, 
Germany. Hence, to take the next step in development of ACT as drug candidate a 
collaboration between SWITCH and the Department Pharmaceutical Technology 
and Biopharmaceutics of the LMU Munich was contracted in terms of this Ph. D. 
study at the Department under the supervision of Prof. Dr. Winter.  
So, it was the aim of this study to create formulations and drug carriers that 
stabilise and deliver ACT in bioactive state into the wound site.  
 
The theoretical introduction encompasses the sections of Chapter 1, where first an 
overview over the physiology and pathophysiology of wound healing is described. 
This represents the medicinal context of this work and highlights the scientific 
rationale behind the delivery of ACT in chronic wounds. Moreover, the established 
methods for treatment of wounds including dressings and carriers are discussed. 
Hereby, the methodical context of a treatment with ACT as drug product with the 
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indication wound treatment is given. Subsequently, several aspects of protein 
delivery from hydrogels as application form are presented.  
 
Chapter 2 outlines materials and methods used during the studies.  
 
In Chapter 3 the results of this research work are presented and discussed.  
In the course of the first section the stabilisation of ACT in solution is evaluated. 
Therefore, buffer systems at various pH levels and a multitude of stabilising 
ingredients were screened under temperature stress as well as freeze-thaw stress. By 
testing buffer conditions it turned out that a pH of 7.2 is the optimal value. 
However, the optimal range of pH values is very narrow. Especially, low pH levels 
can harmfully damage, fragment and inactivate ACT. So, for application on a 
wound site which can provide an acidic pH, a buffer system is recommended in the 
delivery device to guarantee suitable pH for non-liberated protein. For a phosphate 
buffer system the optimal content and relating osmolarity were examined. 
Moreover, from screened additives especially surfactants, cyclodextrins, and amino 
acids proved stabilising potential on ACT. 
Except for acidic conditions, the main degradation pathways for ACT seem to be 
deactivation presumably by refolding and dimer formation and maybe later higher 
order aggregation.  
Indeed, depending on the stress type two patterns for ingredients of stabilising 
solutions were identified relating to solutions to be kept in liquid state and frozen 
solutions, respectively. All ingredients are already approved for parenteral use by 
the FDA. 
The following section is dealing with the formulation of ACT as hydrogel. After 
the evaluation of sterilisation and rheological properties of the gel carriers the 
stability studies on ACT were continued on the semi-solid hydrogel matrices. In a 
first approach the placebo hydrogel carriers were evaluated with regard to ability 
for sterilisation and rheological properties. After short term studies on the 
influence of polymers on ACT solution stability, consequently, ACT stabilising 
hydrogel formulations were created containing excipients being suggested by short 
term studies. Following, drug loading procedures into hydrogels were evaluated. 
After that, the named formulations were introduced in mid term stability studies 
and F/T studies. It turned out that a commercial formulation of ACT in a wet 
hydrogel is not possible due to insufficient shelf life. In contrast, all formulations 
can be applicated into the wound site as far as stability of ACT is concerned. As 
well, several formulations are applicative as early refrigerated formulation for the 
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purpose of animal experiment or early clinical trial where only limited shelf life is 
required. 
 
For the inappropriateness of aqueous hydrogel and liquid formulations for long 
term stability of ACT, formulations with higher stabilising potential had to be 
developed that also have to fit the requirements of modern wound care. So, a dry 
form appears the best choice for improvement of drug stability, and hydrogels still 
are the state-of-the-art application form on wounds. As a result, dry forms had to 
be developed that form hydrogels after reconstitution. Based on the hydrogels 
reported in the prior chapter two alternatives were investigated to meet these aims - 
xerogels and polymer films. 
For both forms carrier development was carried out by establishing production 
procedures concerning gel technology and drying techniques. Further, ingredient 
composition was optimised for both mechanical properties of the products and 
stabilising ACT in the matrices. To characterise these products their texture 
properties, swelling behaviour, residual moisture, ACT stability during drying, and 
during storage were examined.  
Two xerogel formulations - based on hydroxyethyl cellulose and a mixture of 
hydroxyethyl cellulose and gellan gum, respectively - are identified that meet all the 
requirements. In fact, these matrices have a homogeneous and soft appearance, 
they swell spontaneously when hydrated to a hydrogel, and they deliver shelf lives 
for ACT exceeding 18 months.  
For the films, as well, two formulations based on the same polymer components 
turned out to fulfil the aims. These matrices offer very convenient texture 
properties, as well form suitable hydrogels after hydration, and also provide shelf 
lives greater 18 months for ACT.  
Thus, development of stabilising formulations for ACT suitable for application into 
wound sites was finished successfully.  
In the following, the release of ACT from the preparations was studied in vitro. 
Generally, the release characteristics of ACT from gel matrices follow the 
theoretical predictions of square root of time functions. Moreover, both dried 
delivery systems – the xerogels and the films - are proven to be suitable for delivery 
of ACT in chronic wounds. In general, within five days about 60% of initial ACT 
load is liberated in bioactive form thereby being influenced to a higher degree by 
the composition of ingredients rather than the type of matrix. 
Due to the reduced amount of liberated bioactive ACT an adaptation of the drug 
load in the carriers may be necessary to ensure the delivery of a sufficient dose of 
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ACT into its site of action. However, the difficulty of in vitro in vivo correlation 
has to be considered.  
 
This thesis has shown that formulation of ACT for the topical delivery into 
wounds is possible. Thereby, two dry application systems – xerogels and films – 
that form hydrogels after reconstitution with aqueous solution have been identified 
being suitable for stabilisation and release of ACT. 
Concerning stability the goal of a minimum shelf life of 18 months has been 
reached. Furthermore, the release period of ACT from the preparations is 
consistent with the common change of dressing intervals in clinical practice 
enabling an effective delivery. 
It has also been shown that the tested dry gel based carriers are suitable for protein 
stabilisation and delivery which could be a kick off for further proteins to be 
developed on the basis of these systems.  
During the whole development process great emphasis has been placed on the 
mechanical properties of the matrices to be suitable for wound treatment. Also, 
manufacturing procedures have always been evaluated with prospect of a future 
larger scale process for aseptic manufacture of a commercialised product. 
Concomitantly, ingredients have been reviewed for their status of approval to avoid 
unnecessary obstacles in a later process of approval by authorities. 
 
But, it also has to be mentioned that the difficulties created by analytical tools used 
for characterisation of ACT have not been completely overcome. Hence, for a 
further development of this project another evaluation and validation of analytical 
tools might be appropriate. Moreover, the discussed results are exclusively based 
on in vitro research which might not be correlated with in vivo situations in an 
unconfined way. 
 
The future milestones of this project should be the verification of these promising 
in vitro results in an animal experiment. Therefore, a study on excision wounds on 
diabetic rats has been evaluated. Furthermore, provided that these animal studies 
are finished successfully, Phase I clinical trials in man represent the next milestones 
to be aspired. 
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